The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

8-2019

Oxidative Phosphorylation: A Critical Feature and Novel
Therapeutic Target in Melanoma Brain Metastases
Grant Fischer

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Neoplasms Commons,
Neurology Commons, and the Oncology Commons

Recommended Citation
Fischer, Grant, "Oxidative Phosphorylation: A Critical Feature and Novel Therapeutic Target in Melanoma
Brain Metastases" (2019). The University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences Dissertations and Theses (Open Access). 953.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/953

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

OXIDATIVE PHOSPHORYLATION: A CRITICAL FEATURE AND NOVEL
THERAPEUTIC TARGET IN MELANOMA BRAIN METASTASES

By
Grant Matthew Fischer, B.S.

APPROVED:

______________________________
Michael A. Davies, M.D., Ph.D.
Advisory Professor
______________________________
Philip Lorenzi, Ph.D.

______________________________
John De Groot, M.D.

______________________________
Russell Broaddus, M.D., Ph.D.

______________________________
Dihua Yu, M.D., Ph.D.

APPROVED:

______________________________
Dean, The University of Texas
MD Anderson Cancer Center and UTHealth Graduate School of Biomedical Sciences

OXIDATIVE PHOSPHORYLATION: A CRITICAL FEATURE AND NOVEL
THERAPEUTIC TARGET IN MELANOMA BRAIN METASTASES

Presented to the Faculty of the
The University of Texas
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
Doctor of Philosophy

By

Grant Matthew Fischer, B.S.
Houston, Texas
Date of Graduation: August 2019

iii

DEDICATION

I dedicate this work to the family members that I have gained (Sloane Josephine) and lost
(John Cionko and Mary Ann Fischer) during this journey.

iv
ACKNOWLEDGEMENTS

I would like to start by saying “thank you” to Michael Davies. As my advisor for the past
4 years, you have taught me how to conduct meaningful research and run an effective lab. I came
to you when I found out that I couldn’t join the lab that I was originally planning on joining. You
displayed a great deal of patience with me as I worked to create my project from scratch after
completing an emergency tutorial with you. Taking on the amount of responsibility that I did as
a graduate student wasn’t easy but you always believed in me. In the end, you helped me to
accomplish everything that I set out to accomplish when I started graduate school. I hope that I
have made you proud and continue to do so in the future.
I must also thank my committee members. You have played a vital role in getting me to
this point. You have offered me meaningful guidance about my project and about my career. I am
grateful for everything you have done to help me become the best researcher possible.
I would like to thank my colleagues and collaborators. Our Cancer Discovery paper was
the result of effective team science. Thank you again for your input and assistance.
I am also grateful for the support of the MD/PhD program, Cancer Biology graduate
program, and UT-GSBS. Numerous individuals from these programs have helped me in countless
ways over the years, and I could not have succeeded without them.
I would like to thank my parents Gary and Rhonda Fischer. I could not have made it this
far without you. You instilled in me the work ethic that I needed to complete such a rigorous
program. More importantly, you have supported me in countless ways and made it possible to
cross the finish line. To the rest of my family, thank you for all of your love and support. It has
meant the world to me during my training.

v
Thank you to all of my friends. I appreciate your patience as there were many times I had
to work instead of spending time with you. For what it’s worth, the times we could do something
together made these years tolerable.
Finally, thank you to my loving wife Darci. You are the light of my life. Your patience
and belief in me have been unwavering. I could not have gotten to this point without you. Coming
home to you has been the highlight of my day since I started on this path. We have come a long
way since our first date at Olive Garden back in high school, and I can’t wait to see what the
future holds for us (hopefully more seasons of Temptation Island).

vi
OXIDATIVE PHOSPHORYLATION: A CRITICAL FEATURE AND NOVEL
THERAPEUTIC TARGET IN MELANOMA BRAIN METASTASES

Grant Matthew Fischer, B.S.

Advisory Professor: Michael A. Davies, M.D., Ph.D.

We recently showed via RNA-sequencing (RNA-seq) analysis of clinical samples that
melanoma brain metastases (MBMs) have higher expression of oxidative phosphorylation
(OXPHOS) genes (including PPARGC1A or PGC1α) than patient-matched extracranial
metastases (ECMs). Thus, the central hypothesis of this dissertation is that OXPHOS plays
a critical role in the pathogenesis of MBMs.
RNA-seq analysis identified increased expression of OXPHOS genes in intracranial (ICr)
vs. subcutaneous (SQ) xenografts of 4 different human melanoma cell lines. Increased OXPHOS
in the ICr xenografts was confirmed by direct metabolite analysis and [U-13C]-glucose tracing
analysis. Together, these studies indicate that the brain TME mediates OXPHOS enrichment in
MBMs.
The functional significance of OXPHOS in MBM pathogenesis was tested using IACS010759, a potent OXPHOS inhibitor currently in phase I clinical trials. IACS-010759 treatment
of an RCAS-TVA mouse model of spontaneous MBM and lung metastasis significantly decreased
the incidence of detectable MBMs but did not affect primary tumor growth or the incidence of
lung metastases. To clarify if OXPHOS promotes the formation of MBMs or the outgrowth of
micrometastases, we used an imageable experimental MBM model to demonstrate that IACS-

vii
010759 treatment prevented the growth of MBMs but did not prevent their formation, and had no
effect on the formation or growth of lung metastases. Likewise, knockdown of PGC1α
significantly extended the survival of mice challenged by intracranial injection of melanoma cell
lines but had no effect on subcutaneous tumor growth.
Hierarchical clustering analysis of surgically resected MBMs by OXPHOS genes
identified subsets of MBMs particularly enriched (High-OXPHOS) and depleted (LowOXPHOS) in OXPHOS. High-OXPHOS MBMs were characterized by mTORC1 pathway
activation, immunosuppression, and enhanced glutamine metabolism. IACS-010759 treatment
and treatment with the novel glutaminase inhibitor CB839 significantly improved the survival of
mice bearing High-OXPHOS, MAPKi-resistant ICr xenografts.
Together these studies indicate that the brain TME mediates OXPHOS enrichment in
MBMs. Further, while OXPHOS is not a critical determinant of brain metastasis formation, it
plays a crucial role in intracranial tumor growth. These findings suggest that targeting this
metabolic pathway and/or its dependencies may be an effective strategy for MBM treatment.
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1.1 - METABOLISM OF MELANOMAS

1.1.1 - Overview

Cutaneous melanoma is the most aggressive form of skin cancer, accounting for >80% of
skin-cancer related deaths (1). Characteristically resistant to conventional chemotherapy and
radiation, significant advances in metastatic melanoma treatments and outcomes have been made
in the last several years due to improved understanding of the features and drivers of this disease.
The Melanoma Cancer Genome Atlas (TCGA) effort and other studies have shown that the
mitogen-activated protein kinase (MAPK) pathway is ubiquitously activated in cutaneous
melanoma as a result of somatic mutations in multiple genes, including point mutations in the vRaf murine sarcoma viral oncogene homolog (BRAF) (35%–50% of melanomas) and
Neuroblastoma RAS viral oncogene homolog (NRAS) (10%–25%), and loss of function mutations
affecting Neurofibromin 1 (NF1) (~15%). Efforts to target this pathway therapeutically
culminated in the Food and Drug Administration (FDA) approval of the BRAF inhibitors
vemurafenib and dabrafenib; the mitogen-activated protein kinase (MEK) inhibitor trametinib;
and the combination regimens of dabrafenib + trametinib, vemurafenib + cobimetinib, and
encorafenib + binimetinib (2). All of these agents were approved specifically for melanoma
patients with mutations that cause substitution of the V600 residue of the BRAF protein (2).
While the BRAF inhibitors, alone and in combination with MEK inhibitors, reduce tumor burden
in almost all patients with a BRAFV600 mutation, most patients will eventually develop resistance
(3). In addition to these targeted therapies, several immune therapies have also been approved for
patients with metastatic melanoma in recent years, including the checkpoint inhibitors
ipilimumab, nivolumab, and pembrolizumab, and the combination of ipilimumab with nivolumab
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(2). Clinical responses and benefit with these immunotherapies can last for several years, and
may even be curative. However, the response rates with these immune therapies are lower than
for the targeted therapies (i.e. 10-15% for ipilimumab; 35-45% for nivolumab and
pembrolizumab; ~55% for ipilimumab + nivolumab) (2). Thus, while there has been tremendous
progress, there remains a need for additional effective therapeutic strategies for this disease.
There is a growing appreciation and supporting data regarding the frequency and
significance of metabolic reprogramming in cancer initiation, maintenance, and progression (4).
However, tumor metabolism is complex, and metabolic phenotypes may reflect both intrinsic
properties of tumor cells and interactions between tumor cells and the tumor microenvironment
(TME). Efforts to improve our understanding of this hallmark of cancer have produced
encouraging results that deserve further investigation.

1.1.2 - An Overview of Central Carbon Metabolic Pathways

Central carbon metabolism consists of glycolysis, the pentose phosphate pathway (PPP),
and tricarboxylic acid (TCA) cycle (5, 6) (Figure 1). In normoxic, nonmalignant cells, a molecule
of glucose undergoes the process of glycolysis in the cytosol to produce pyruvate, adenosine
triphosphate

(ATP),

and

reduced

nicotinamide

adenine

dinucleotide

(NADH)

(7).

Decarboxylation of pyruvate by mitochondrial pyruvate dehydrogenase (PDH) initiates the highly
efficient process of mitochondrial oxidative phosphorylation (OXPHOS) by feeding acetyl
coenzyme A (acetyl-CoA) into the TCA cycle (8). NADH and reduced flavin adenine dinucleotide
(FADH2) molecules transfer electrons to the electron transport chain (ETC), which responds by
transporting protons across the mitochondrial membrane (8). The resulting electrochemical
gradient then drives ATP synthesis, with oxygen serving as the final electron acceptor, producing
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water as a byproduct (8) (Figure 1). As oxygen is necessary for the coupling of glycolysis and
OXPHOS to occur, hypoxic cells rely more on glycolysis to meet their energy needs (9). In a
process known as lactic acid fermentation, lactate dehydrogenase (LDH) transfers electrons from
NADH to pyruvate, producing lactate and replenishing the supply of NAD+ in the cytosol to allow
further glycolysis to continue (9). Melanoma cells take advantage of these available metabolic
pathways, and others, by using them to meet their needs in a wide variety of contexts.

1.1.3 - Utilization and Regulation of Metabolic Pathways in Melanoma

1.1.3a - Glycolysis: An Essential Source of ATP and Molecular Precursors

Like many other cancer types, the majority of rapidly proliferating melanoma cells
metabolize glucose into lactate regardless of oxygen levels, a process known as aerobic
glycolysis, or the “Warburg effect,” in honor of Otto Warburg, who first described the
propensity of tumor cells to utilize glycolysis (10). When glycolysis is utilized at high
rates in proliferating tumor cells, it can supply the ATP necessary for survival while also
supplying materials required for proliferation. (11). Scott et al. found that in normoxic
conditions, only 25% of pyruvate enters the mitochondria of melanoma cells exhibiting
the Warburg phenotype, where it is converted to acetyl-CoA by PDH (10). Instead of fully
circulating in the TCA cycle, the citrate is transported to the cytosol, where ATP citrate
lyase (ACL) cleaves it into acetyl-CoA and oxaloacetate. Acetyl-CoA either enters the
fatty acid synthesis pathway, which is critical for the proliferation of melanoma cells, or
fuels acetylation of histones in epigenetic regulation reactions while oxaloacetate is
converted to malate, which produces pyruvate via malic enzyme and subsequently lactate
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via LDH (12, 13). The malic enzyme serves as a source of reduced nicotinamide adenine
dinucleotide phosphate (NADPH), necessary for detoxifying melanoma cells of reactive
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oxygen species (ROS), and LDH mitigates the surplus of NADH present from high
glycolytic rates. Consistent with the role of glycolysis as a source of citrate, treatment of
glycolytic B16-F10 melanoma cells with the PDH cofactor α-lipoic acid and the ACL
competitive inhibitor hydroxycitrate results in significant growth inhibition (14, 15).
Glycolysis also supports the PPP and serine/glycine synthetic pathway in
melanoma cells. Glucose-6-phosphate dehydrogenase (G6PD) oxidizes glucose-6phosphate (G6P), a glycolytic intermediate, in the rate-limiting step of the PPP (7). After
numerous additional reactions, the PPP produces a net gain of the reducing equivalent
NADPH and 5-carbon sugars used in nucleotide synthesis. G6PD is highly expressed in
melanomas, and inhibition of G6PD in A375 cells results in G1/S phase cell cycle arrest
due to ROS-mediated inhibition of signal transducer and activator of transcription
3 (STAT3) (16). Phosphoglycerate dehydrogenase (PHGDH) catalyzes the initial step of
the serine/glycine synthesis pathway, oxidizing the glycolytic intermediate 3phosphoglycerate (3-PG). Serine plays a critical role in the biosynthesis of purines and
pyrimidines, and it is the precursor of glycine. A bioinformatics analysis of 3131 human
cancer samples found recurring copy number gains in PHGDH at a frequency of 40% in
melanomas, and melanomas with PHGDH copy number gains were particularly sensitive
to PHGDH inhibition (17, 18).
The utilization of the Warburg phenotype by melanomas is driven in part by
activation of intrinsic signaling pathways, particularly the MAPK pathway (Figure 1 and
Table 1). Activation of the MAPK pathway increases the transcription of the hypoxia
inducible factor 1α (HIF1α) and v-MYC avian myelocytomatosis viral oncogene homolog
(MYC) (19, 20). Additionally, the MAPK pathway stabilizes HIF1α, allowing it to partner
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with HIF1β to become active and promote glycolysis via transcription of LDH, aldolase
(ALDOA), and enolase 1 (ENO1) (21). Furthermore, HIF1α activates pyruvate

Table 1: Impact of oncogenic signaling pathways on melanoma metabolism
Pathway

Alterations in Melanoma

Metabolic Effects

MAPK

 Constitutive activity due to point
mutations in BRAF (35%–50%) and NRAS
(10%–25%) and deletions in NF1 (~15%)

 Suppresses MITF and PGC1α signaling
to inhibit OXPHOS
 Stimulates MYC and HIF1α signaling to
promote glycolysis
 Also promotes fatty acid synthesis

PI3K-AKT






Loss of function of PTEN (30%–50%)
Point mutations in PI3K (<3%)
Point mutations in AKT (<3%)
Point mutations in NRAS (10%–25%)

 Stimulates MYC and HIF1α signaling to
promote aerobic glycolysis
 Promotes aerobic glycolysis and fatty
acid synthesis
 Stimulates mTOR to promote OXPHOS
in a subset of melanomas

mTOR

 mTORC1 and 2 activated by PI3K/AKT
pathway
 mTORC1 stimulated in response to amino
acids
 mTORC1 suppressed by AMPK in
response to ↑AMP/ATP

HIF1α

 Degradation inhibited by hypoxia and
ROS
 Transcription/translation promoted by
MAPK pathway signaling, and translation
promoted by PI3K pathway signaling

MYC

 Activated by P-ERK
 Copy number gains (~30% of metastatic
melanomas)

 Drives transcription of HIF1α and MYC,
promoting aerobic glycolysis
 Promotes fatty acid synthesis, protein
synthesis, and nucleotide synthesis
 Promotes translocation of MITF to the
nucleus, promoting PGC1α expression
and OXPHOS in a subset of melanomas
 Stimulates aldolase, ENO1, and LDH,
which directly promote glycolytic flux
 Activates PDK, preventing the flow of
pyruvate into the TCA cycle
 Promotes DEC1 activity, indirectly
inhibiting OXPHOS
 Drives GLUT1, HK2, and LDH
transcription, promoting aerobic
glycolysis
 Promotes glutaminase transcription,
stimulating glutamine metabolism

MITF

 MITF inhibited by P-ERK
 MITF transcription suppressed by HIF1α
and DEC1
 MITF transcription promoted by PGC1α
 PGC1α transcription promoted by LKB1AMPK axis
 LKB1 responds to ↑AMP/ATP ratio by
activating AMPK

LKB1-AMPK

 Promotes OXPHOS

 AMPK inhibits mTOR activity and
biosynthetic reactions
 Promotes PGC1α transcription and
OXPHOS

Used with permission from John Wiley & Sons Ltd. (Fischer, G. M., Y. N. Vashisht Gopal, J. L. McQuade, W. Peng,
R. J. DeBerardinis, and M. A. Davies. 2018. Metabolic strategies of melanoma cells: Mechanisms, interactions with
the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res 31: 11-30).
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dehydrogenase kinase (PDK), which inhibits PDH, preventing pyruvate from entering the
TCA cycle for use in OXPHOS (22). Besides HIF1α, MYC also promotes increased
glycolytic activity, either as a downstream effector of a constitutively active MAPK
pathway or due to copy number gains, which Kraehn et al. identified in 4/8 primary
melanomas and 11/33 metastatic melanomas (23). The MYC transcription factor activates
LDH, glucose transporter 1 (GLUT1), and hexokinase 2 (HK2), thereby promoting
glucose uptake and glycolytic activity (24, 25). The MAPK pathway also promotes the
Warburg phenotype through its inhibition of the microphthalmia-associated transcription
factor (MITF), a critical regulator and promoter of OXPHOS in tumor cells (26).
The phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin
(PI3K/AKT/mTOR) signaling pathway is activated multiple ways in melanoma, including
by loss of function of the PTEN tumor suppressor, activating mutations in AKT and
PIK3CA, and compensatory signaling through growth factor receptors (27-31). Activation
of this pathway promotes glycolytic metabolism in melanoma (Figure 1 and Table 1).
Phosphorylation and activation of AKT drives mTOR signaling, which can promote
HIF1α transcription and activity, thereby driving the synthesis of glycolytic machinery
(32, 33). Additionally, Zundel et al. demonstrated that restoring wild-type PTEN
expression in glioblastoma cells lacking functional PTEN corrected the deregulation of
cellular AKT and suppressed the transcription of numerous HIF1α-regulated genes,
highlighting the interplay between the PI3K/AKT/mTOR pathway and HIF1α
signaling (34).
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1.1.3b - Oxidative Phosphorylation (OXPHOS): A Driver of Growth and Progression in
a Subset of Human Melanomas

While many melanomas are characterized by the Warburg phenotype, OXPHOS
also plays a critical role in melanoma. OXPHOS is significantly more efficient at
generating ATP than glycolysis. While only 7% of pyruvate accesses the TCA cycle in
hypoxic cells, OXPHOS still contributes a significant portion of ATP to these cells as
large quantities of ATP are produced from a few molecules of pyruvate (10). Furthermore,
a subset of melanomas rely extensively on OXPHOS to meet their bioenergetic needs. Our
lab and others have identified that between 35-50% of BRAF-mutant and wild-type cell
lines and patient samples can be characterized as “High-OXPHOS” (3, 26, 35). This
phenotype is predominantly driven by peroxisome proliferator-activated receptor γ 1-α
(PPARGC1A or PGC1α), a transcriptional co-factor that regulates multiple mitochondrial
genes. Examination of PGC1α gene expression in the Broad Cancer Cell Line
Encyclopedia (CCLE) database revealed that melanomas have the highest expression of
PGC1α among >900 cell lines representing 23 cancer types (3). Melanomas highly
expressing PGC1α also express numerous nuclear respiratory factors, mitochondrial
transcriptional factors, mitochondrial DNA replication factors, mitochondrial fission
mediators, and mitochondrial fusion mediators (35).
PGC1α expression is regulated by MITF in melanoma cells (26). HIF1α prevents
the transcription of MITF in glycolytic melanomas through deleted in esophageal cancer
1 (DEC1) (36, 37). In High-OXPHOS melanomas, however, this regulation fails to occur
(Figure 1). Instead, mTOR promotes the nuclear translocation of MITF, which drives the
transcription of PGC1α and, subsequently, OXPHOS genes (Table 1 and Figure 2) (3,
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38). mTOR is the core component of two distinct complexes: mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2) (39). The PI3K-AKT pathway activates
both complexes by suppressing inhibitory inputs from tuberous sclerosis complexes 1/2
(TSC1/2) (39). mTORC1 also becomes active in the presence of amino acids. Once active,
mTORC1 phosphorylates ribosomal protein S6 kinase (p70S6K) and eukaryotic
translation initiation factor 4E-binding protein 1 (4EBP1), promoting protein synthesis,
including the translation of MYC and HIF1α (39). Active mTORC2 primarily functions
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to phosphorylate AKT at serine 473, resulting in further activation of AKT (39). These
interactions have been shown to promote protein synthesis, lipid synthesis, nucleotide
synthesis, and glycolysis (39). mTOR is also known to increase mitochondrial activity and
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OXPHOS via activation of YYI-PGC1α transcriptional complex (40). How mTORC1/2
signaling selects between promoting glycolysis or OXPHOS remains unclear.
AMP-activated protein kinase (AMPK) expression also positively correlates with
PGC1α expression (41). In low cellular energy states, designated by a high ratio of
AMP/ATP, liver kinase B1 (LKB1) activates AMPK, which inhibits anabolic reactions by
suppressing mTORC1 and promotes mitochondrial gene expression, likely through
PGC1α (41, 42). While the mechanism by which AMPK acts through PGC1α remains
unclear, one possibility is that AMPK directly drives PGC1α expression (42).
Alternatively, AMPK could promote PGC1α activation by either direct phosphorylation
or indirectly through sirtuin-1 (SIRT1)-mediated deacetylation (42, 43). In glycolytic
tumors, phosphorylated ERK (P-ERK) suppresses the activation of LKB1, inhibiting the
typical response to energy deficiency (44). These cells are less responsive to high
AMP/ATP ratios and less dependent on OXPHOS to meet their bioenergetic needs. It is
likely that suppression of LKB1 also inhibits PGC1α expression, though this has not been
tested.

1.1.3c - TCA Cycle Metabolism: A Supplier of Cellular Building Blocks

While mitochondria serve as the primary bioenergetic source for a subset of
melanomas, functional mitochondria are critical for all melanoma cells by providing
intermediates utilized by biosynthetic and redox reactions (45). In addition to producing
the fatty acid precursor citrate via condensation with acetyl-CoA, oxaloacetate produced
from the TCA cycle is converted to aspartate via transamination reactions involving
glutamate. This aspartate cooperates with malate, another TCA intermediate, to power the
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malate-aspartate shuttle, which moves NADH from glycolysis to the mitochondria (7).
Furthermore, aspartate transported into the cytosol by the shuttle contributes to the
synthesis of nucleic acids (12) (Figure 1). Rabinovich et al. demonstrated the role of
cytoplasmic aspartate in promoting melanoma progression by suppressing arginosuccinate
synthetase 1 (ASS1), which utilizes aspartate to produce arginosuccinate in the urea cycle.
As a result, cytoplasmic levels of aspartate increased, activating carbamoyl phosphate
synthetase II (CAD), the rate-limiting enzyme in pyrimidine synthesis, thereby facilitating
the synthesis of nucleotides and promoting melanoma cell proliferation (46).
To continue utilizing citrate and oxaloacetate as biosynthetic precursors,
melanoma cells must replenish TCA intermediates in a process called anaplerosis (47).
While some cancers replenish oxaloacetate from pyruvate via pyruvate carboxylase, the
contribution of pyruvate carboxylase to the TCA cycle is minimal in cultured melanoma
cells characterized by the Warburg phenotype (10, 48, 49). Instead, these cells utilize
glutamine as the primary source of carbon entering the TCA cycle (10). Upon transport
into the cell via the glutamine receptor SLC1A5, glutamine is converted to glutamate via
cytosolic glutaminase (50). Glutamate enters the TCA cycle as α-ketoglutarate via
reactions catalyzed by either glutamate dehydrogenase 1 (GDH) or mitochondrial alanine
and aspartate aminotransferase (GOT2 and GPT2, respectively) (50). Reactions catalyzed
by GDH generate free ammonia, which can promote autophagy, while the
aminotransferases transfer nitrogen to α-keto acids to form α-ketoglutarate and amino
acids. Ratkinov et al. labeled Lu1205 melanoma cells with 13C-glutamine to demonstrate
that GDH and aminotransferases interchangeably catalyze this anaplerotic reaction and
can maintain anaplerosis upon suppression of the alternative route (50). However, in vitro
studies of SF188 glioblastoma cells demonstrated induction of GDH upon deprivation of
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glucose and that GDH mediated survival in glucose-deprived conditions (51). In
glioblastoma cells cultured in glucose-rich conditions, transamination reactions play a
greater role in converting the glutamate to α-ketoglutarate (51, 52). Additional studies are
required to further determine the contexts in which GDH and aminotransferase-catalyzed
reactions predominate in melanoma cells and whether or not these findings can be verified
in vivo.
Like other cancers, melanoma cells can reverse the flow of the TCA cycle via
reductive carboxylation of α-ketoglutarate. This process increases the mitochondrial
supply of citrate for use in fatty acid synthesis. For hypoxic melanoma cells, reductive
carboxylation of glutamine-derived α-ketoglutarate provides over one-third of citrate
necessary for fatty acid synthesis (10). In hypoxic WM35 and LU1205 melanoma cells,
cytosolic isocitrate dehydrogenase 1 (IDH1) and mitochondrial isocitrate 2 (IDH2), 2 of 3
isoforms of IDH, are necessary and sufficient for the production of reductive
carboxylation in hypoxic conditions (53) (Figure 1). Likewise, Mullen et al. demonstrated
that IDH1 and IDH2 mediate reductive carboxylation in 143B human osteosarcoma cells
with mitochondrial defects (54). In contrast, Metallo et al. utilized cells from multiple
cancer types to demonstrate that IDH1 predominates in hypoxic conditions (55).
Furthermore, IDH1 also predominates in monolayer detachment of multiple lung
adenocarcinoma cell lines (56). With melanoma-specific findings limited to work
performed on only two cell lines, additional work remains to fully understand the relative
contributions of IDH1 and IDH2 to reductive carboxylation in melanoma and if these
findings can be replicated in in vivo experiments.
A great deal of attention has been placed on IDH1 and IDH2 in recent years as
heterozygous mutations have been identified at R132 in the cytosolic IDH1 and at R172
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in mitochondrial IDH2 in glioblastoma and acute myeloid leukemia (53, 57-59). These
mutated enzymes produce 2-hydroxyglutarate (2-HG) from alpha-ketoglutarate. 2-HG
acts as an oncometabolite by inducing a variety of epigenetic changes in the tumor cells
(60, 61). Mutations in IDH1/2 are rare in melanoma and typically affect IDH1 (53, 62).
These mutations have shown to provide a growth advantage to melanoma cell lines with
concurrent BRAF mutations (63). While succinate dehydrogenase and fumarate hydratase
mutations have also been identified in a variety of cancers, they have not been identified
in melanomas (12).

1.1.3d - Protein/Amino Acid Metabolism: Arginine, Proline, and Proteasomal
Degradation in Human Melanomas

In addition to glutamine and aspartate, a considerable amount of amino acid
research in melanoma has focused on arginine and proline. Interestingly, melanomas
cannot synthesize their own arginine, as they lack expression of arginine synthetase (64).
Thus, they are solely dependent on external sources of arginine in the TME for protein
synthesis (65). While efforts have been made to starve melanoma cells by depleting them
of arginine, this strategy has been complicated by resistance mechanisms in which
arginine synthetase is stimulated following arginine depletion (66).
The limited supply of arginine directly impacts the synthesis of proline in
melanoma cells, as it makes the cells largely dependent on glutamine for the synthesis of
proline as opposed to using both arginine and glutamine to synthesize proline (60).
Melanoma cells synthesize proline to a significantly greater extent than melanocytes (10,
67). Three isoforms of pyrroline-5-carboxylate reductase (PYCR) catalyze the rate-

17
limiting reaction of proline synthesis (67). PYCR1 and 2 are localized to the mitochondria
and utilize glutamate and NADH to produce proline, while PYCRL is localized to the
cytoplasm and utilizes NADPH and arginine-derived ornithine to produce proline (67).
Only PYCR1 and 2 are overexpressed in melanoma cells compared to melanocytes,
suggesting that only glutamate-derived proline synthesis provides melanoma cells with a
survival advantage (67). Given NADPH’s critical role in maintaining redox balance in
melanoma cells, it has been proposed that cells select against PYCRL expression in order
to preserve NADPH levels, though this explanation remains to be explored further (13,
60). The potential role of proline in redox balance is further supported by the fact that
melanoma cells synthesize proline regardless of the concentration of proline in the
surrounding environment, suggesting that the act of synthesizing proline is significantly
more important than proline itself (13). It is possible that melanoma cells synthesize
proline via PYCR1 and PYCR2 to replenish the cellular supply of NAD+ for use in
glycolysis while preserving NADPH necessary for anabolic reactions and for managing
oxidative stress.
While physiological proteasomal degradation of proteins is essential for the health
of normal cells, melanoma cells take advantage of this existing machinery to rid
themselves of various tumor suppressor proteins. For example, Healey et al. utilized
Tyr/Tet-Ras INK4a−/− transgenic mice, and R545 melanoma cells isolated from their
tumors, to demonstrate that Ras-mediated melanomas target the Inducible cAMP early
repressor (ICER) for proteasomal degradation (68). Without functional ICER protein, the
tumor cells upregulated the transcription of cyclin D1, an essential mediator of cell cycle
progression (68). Likewise, p53 mutations are relatively uncommon (~20%) in melanoma
(69-73). However, Mouse double minute 2 homolog (MDM2) can still freely suppress the
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transcriptional activity of p53 and target p53 for proteasomal degradation (74). Anwar et
al. derived 8B20 cells from a genetically engineered mouse model (GEMM) of melanoma
to demonstrate that low levels of p53 protein in the cells resulted from increased ubiquitinmediated proteasomal degradation (75). Their attempts at disrupting this uncontrolled
degradation of p53 protein triggered G1 cell cycle arrest in the 8B20 cells (75). Similarly,
nutlins are a class of compounds that disrupt the interactions between MDM2 and p53. By
preventing the unregulated degradation of p53, nutlin-3 restores p53 levels in human
melanoma cell lines, regardless of p53 mutational status (76, 77). However, nutlin-3
selectively decreases the viability of cells with wild-type p53 (76, 77). Interestingly,
nutlin-3 treatment increases cellular levels of MDM2, resulting in ubiquination and
degradation of Insulin-like growth factor type 1 receptor (IGF-1R) (77). The disruption of
the IGF-1R signaling axis causes an initial increase in melanoma cell proliferation but
ultimately suppresses proliferation and inhibits migration (77). These examples
demonstrate the tendency of melanoma cells to hijack common cellular machinery to
promote their own survival and how doing so makes them vulnerable to novel classes of
therapeutics.

1.1.3e - Lipid Metabolism:

Synthesis and Degradation of Fatty Acids Promotes

Melanoma Progression

Fatty acid synthase (FASN) catalyzes the rate-limiting step of the endogenous
synthesis of fatty acids (78). FASN is positively regulated in normal tissue by insulin and
hormones such as estrogen and progesterone and negatively regulated by leptin, which in
turn is stimulated by free fatty acids (FFAs) (78-80). Insulin, estrogen, and progesterone
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activate the transcription factor sterol regulatory element-binding protein 1c (SREBPC1c),
which is responsible for driving FASN transcription (78-80). In many tumor types,
including melanoma, SREBPC1c is constitutively driven by the MAPK and PI3K/AKT
pathways, which causes significant upregulation of FASN (78-80) (Figure 1 and Table
1). These signaling pathways promote the maturation of SREBP1c from its precursors and
its nuclear localization from the Golgi apparatus following its maturation (78). The
increased FASN is believed to provide a survival benefit to tumor cells by promoting a
“lipogenic phenotype.” Fatty acids form the structural foundation of cellular and organelle
membranes. Proliferating cells require a large supply of fatty acids to form these
structures. Constitutively active FASN ensures an adequate concentration of
phospholipids necessary for this rapid proliferation (78). Saab et al. demonstrated that
patient-derived metastatic melanomas test positive for FASN staining, as opposed to
benign intracapsular nodal nevi (81).
Additionally, melanomas overexpress numerous genes involved in synthesis of
sialylated glycosphingolipids known as gangliosides. For example, microarray analysis
performed by Sumantran et al. determined that UDP-glucose ceramide glucosyltransferase
(UGCG), hexosaminidase A (HEXA), ST3 β-galactoside α-2,3-sialyltransferase 5
(ST3GAL5), and ST8 α-N-acetyl-neuramide-α-2,8-sialyltransferaase 1 (ST8SIA1), all of
which are involved in ganglioside synthesis, are upregulated in melanomas between 3 and
9-fold, relative to benign nevi (82). Subclones of M4BE melanoma cells enriched in
gangliosides survive radiation treatment significantly better than parental cells (83).
Furthermore, ganglioside GD3- SK-MEL-28-N1 melanoma cells became significantly
more proliferative and invasive following transfection with GD3 via stimulation of
p130Cas and paxillin signaling (84). siRNA-mediated knockdown of p130Cas and
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paxillin subsequently inhibited ganglioside GD3 signaling in these cells, though the effects
remain to be validated in vivo (84).
In addition to the synthesis of fatty acids, fatty acid oxidation (FAO) appears to
play an important role in promoting melanoma progression. For example, carnitine
palmitoyltransferase 2 (CPT2), the enzyme critical for translocation of long-chain fatty
acids (LCFAs) in preparation for β-oxidation, is one of the most significantly upregulated
genes in melanomas, relative to benign nevi (82). Furthermore, Rodrigues et al. derived
metastatic 4C11+ cells from melan-a melanocytes after sequential detachment-re-adhesion
cycles, and FAO contributed significantly to the energy reserves of these 4C11+ cells,
relative to nonmetastatic controls (85). How FAO promotes melanoma progression
remains unclear. Studies in other tumor types have demonstrated that fatty acids can
provide an ATP boost for tumor cells when necessary under nutrient-depleted conditions
(86-88). Indeed, the process of metastasis is a highly demanding process. Highly efficient
β-oxidation could provide a survival advantage for cells away from the primary tumor site.
Furthermore, fatty acids can serve as a valuable source of acetyl-CoA that contributes to
citrate formation after entering the TCA cycle (87). As detailed earlier, this citrate can
enter metabolic reactions that produce NADPH via IDH1, thereby contributing to redox
balance in the tumor cells.
Numerous lipid-derived second messengers such as phospholipase D3 (PLD3),
inositol triphosphate protein kinase B (ITPKB), and inositol triphosphate receptor 3
(ITPR3) are significantly upregulated in melanomas, relative to benign nevi (82).
Furthermore, ITPKB is significantly upregulated in MALME_3M and UACC_257
melanoma cell lines of the National Cancer Institute (NCI) Cell Miner database (82).
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1.2 - MOLECULAR BIOLOGY AND IMMUNOLOGY OF MELANOMA BRAIN
METASTASES

1.2.1 - Signaling Pathways Implicated in Melanoma Brain Metastases

Focused studies have identified numerous signaling pathways that likely contribute to
melanoma brain metastasis (MBM) pathogenesis, including the MAPK, PI3K-AKT, Janus
kinase-signal transducer and activator of transcription (JAK-STAT), vascular endothelial growth
factor (VEGF), and endothelin pathways. Additional molecules and pathways have been
implicated in many of the steps that are critical to the establishment and maintenance of MBMs
(Table 2).

1.2.1a - MAPK Pathway

Point mutation analysis of patient-matched MBMs and extracranial metastases
(ECMs) demonstrated no significant differences in the prevalence of BRAF mutations
between anatomical sites (89). Data regarding NRAS mutation concordance between
anatomical sites differs depending on if the comparison occurs between MBMs and ECMs
or between MBMs and primary tumors. Analysis of patient-matched MBMs and ECMs
identified 100% concordance in NRAS mutations while significantly lower concordance
(80%) was observed between patient-matched MBMs and primary tumors (89, 90). While
no concordance data exist for NF1 mutations, it is clear that MAPK pathway
hyperactivation is highly prevalent in MBMs, which is consistent with the fact that
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activating BRAF and NRAS mutations occur early in melanoma progression and are likely
not selected against during the brain metastasis cascade (91, 92).
Table 2: Signaling pathways implicated in melanoma brain metastasis pathogenesis
Pathway
MAPK




PI3K-AKT

JAK-STAT






VEGF




Endothelin

BBB Penetration
Factors









Brain-Tropic
Factors




Alterations in Melanoma Brain Metastases
High concordance in BRAF/NRAS mutation status
in MBMs and patient-matched ECMs and primary
tumors
No information known about NF1 concordance
between MBMs and patient-matched ECMs and
primary tumors





Higher expression of numerous markers of PI3KAKT activation ± lower expression of PTEN in
MBM specimens compared to lung and liver
metastases



Significantly higher levels of P-STAT3 in MBMs
vs. primary tumor specimens
Significantly lower levels of SOCS1 (negative
regulator of P-STAT3) in MBMs vs. primary
tumor specimens
Expression correlates with brain-metastatic
capacity in melanoma cells in vivo
Forced expression promotes melanoma cell
metastasis to the brain in vivo



EDNRB expression correlates with brainmetastatic capacity in melanoma cells

VLA-4 expression present in 90% of MBMs
HPSE is expressed at higher levels in brainmetastatic melanoma cells
PLEKHA5 expression is significantly higher in
brain-metastatic melanoma cells and in melanoma
ECMs from patients that developed MBMs vs.
those that did not
S100A4 overexpression correlates with increased
brain metastatic capacity of melanoma cells in vivo
MMP2 expression is significantly higher in cells
able to cross in vitro BBB models
Melanoma cells that establish parenchymal
metastases express significantly more TGF-β than
those that establish leptomeningeal metastases
Brain-metastatic melanoma subclones express
significantly less CLDN1 than parental cells












Significance
Constitutive activation that parallels
ECMs
Fundamental driver of melanoma
pathogenesis
No evidence of selection against
MAPK pathway hyperactivation
during metastasis to the brain
Pathway hyperactivity is selected for
during the process of metastasis
and/or the product of interactions
with the brain TME
Precise mechanism by which
pathway activation promotes MBM
pathogenesis remains unclear
Drives transcription of pro-invasive
and angiogenic genes

Stimulates formation of new blood
vessels
Promotes co-option of existing
blood vessels
Facilitates MBM growth
EDNRB promotes a general
metastatic phenotype
Targeting EDNRB prevents visceral
metastasis and growth of brain
metastases
Promote invasion across the BBB
for access to the brain parenchyma

Promote the development of
parenchymal metastases exclusively,
as opposed to a general metastatic
phenotype
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1.2.1b - PI3K-AKT Pathway

PI3K-AKT pathway activation occurs frequently during tumorigenesis in multiple
cancer types and promotes the malignant phenotype through multiple effectors (93, 94).
The pathway can be activated via receptor tyrosine kinases (RTKs) following stimulation
by extracellular ligands [e.g. hepatocyte growth factor (HGF) activating tyrosinase kinase
protein Met (c-MET)], point mutations in RTKs [e.g. epidermal growth factor receptor
(EGFR) in non-small-cell lung cancers], and/or gene amplifications in RTKs [e.g. receptor
tyrosine-protein kinase erbB-2 (HER2/neu) in breast cancer]. The pathway can also be
activated by mutations in key effectors, including point mutations in PIK3CA (encodes
the catalytic subunit of PI3K), AKT1, and AKT3. Constitutive activation of the pathway
also results from loss of function of the tumor suppressor PTEN, which dephosphorylates
lipids to counteract the activity of PI3K.
In melanoma, point mutations rarely activate the pathway, affecting AKT1 and
AKT3 in 1-2% of cases and PIK3CA in 3% (70, 95, 96). Mutations more commonly affect
the NRAS gene, primarily at codons Q60/61 and G12/13, which results in constitutive
activation of both the MAPK and PI3K-AKT pathways. Additionally, complete loss of
PTEN has been detected in 10-30% of melanomas, generally in tumors with concurrent
BRAF mutations, and thus mutually exclusive with NRAS mutations (97, 98). Missense
mutations that inhibit the tumor suppressor function of PTEN have been recorded and
typically occur in exon 5 of the PTEN gene, which encodes the phosphatase domain of the
protein. Nonsense mutations are more common genetic causes of loss of PTEN function
in melanomas (99). Interestingly, genetic aberrations might not explain all instances of
loss of PTEN expression in melanomas. Epigenetic events including miRNA signaling
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and promoter methylation can silence PTEN expression and may facilitate PI3K-AKT
pathway hyperactivation in melanomas (100, 101). However, more recent genomic studies
of the melanoma TCGA database that employed optimized criteria for identifying copy
number alterations demonstrated that only point mutations or high-medium amplitude
focal deletions corresponded with complete loss of PTEN expression and significant
increases in P-AKT levels (102).
Unlike the MAPK pathway, a significant difference in PI3K-AKT pathway
activation has been observed in MBMs compared to metastases at other sites. Reverse
phase protein arrays (RPPA) analysis demonstrated significantly higher expression of
numerous markers of PI3K-AKT activation and lower expression of PTEN in MBM
specimens compared to lung and liver metastases (98). Subsequent RPPA analysis of
patient-matched MBMs and ECMs confirmed PI3K-AKT pathway hyperactivation in
MBMs, yet failed to demonstrate significant differences in PTEN protein levels (89).
Immunohistochemistry (IHC) of an independent cohort of patient-matched samples also
demonstrated PI3K-AKT pathway hyperactivation in MBMs, with some (but not all) of
the brain lesions demonstrating decreased PTEN expression compared to the patientmatched ECMs (103). Together, these findings suggest that PI3K-AKT pathway
hyperactivation plays an important role in MBM pathogenesis and that pathway activation
can occur independently of loss of PTEN expression.
PI3K-AKT hyperactivation plays multiple roles in MBM pathogenesis by
facilitating cell adhesion, extravasation, and angiogenesis. One study of patients with stage
III melanoma determined that loss of PTEN protein levels correlated with significantly
increased risk of MBM formation (97). Similarly, experiments by Cho et al. using a
genetically engineered mouse model showed that PI3K-AKT pathway activation
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promoted MBM formation. Loss of Pten in melanocytes with concurrent BrafV600E
mutations and cyclin-dependent kinase inhibitor 2A (Cdkn2a) deletions formed primary
melanomas in 100% of mice but infrequently caused distant metastases. However,
introduction of a constitutively active Akt1 protein promoted MBM formation in 80% of
mice (104). Together, these findings suggest that PI3K-AKT pathway hyperactivation
promotes MBM formation, and primary tumors and ECMs enriched in this pathway may
metastasize to the brain more frequently.
The TME also appears to play a critical role in mediating PI3K-AKT pathway
hyperactivation. Zhang et al. demonstrated that loss of PTEN expression occurred
following intracarotid injection of PTEN-intact cell lines from multiple tumor types,
including B16-F10 melanoma cells (101). Astrocytes in contact with the tumor cells
transferred miRNAs that suppressed expression of PTEN via exosomes. Interestingly, loss
of PTEN expression promoted secretion of the cytokine C-C motif chemokine ligand 2
(CCL2), which recruited Iba1+ myeloid cells that promoted growth of the tumor cells. In
contrast, the authors failed to observe differences in metastatic incidence between B16F10 cells expressing PTEN and those in which PTEN was silenced. Further, Seifert et al.
provided additional evidence that cerebrospinal fluid (CSF), which bathes the brain, can
promote PI3K-AKT pathway activation (105). Culturing melanoma cells in the presence
of CSF caused significant activation of the PI3K-AKT pathway and mediated resistance
to targeted therapies without causing a loss of PTEN expression.

1.2.1c - JAK-STAT Pathway
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The JAK-STAT pathway transduces signals from a variety of ligands – often
cytokines such as interleukins and interferons - from the cell surface to the nucleus of
tumor cells. Unlike RTKs, cytokine receptors typically lack intrinsic kinase activity.
Instead, ligand binding triggers dimerization of receptors, which recruits and activates
JAKs in the cytoplasm. In turn, JAKs phosphorylate the receptor, which facilitates binding
of STAT proteins to the receptor. JAKs then phosphorylate and activate the STATs, which
dimerize and move into the nucleus to drive transcription of genes (106).
STAT3 activity facilitates transcription of tumor cell survival, growth,
angiogenesis, and immunosuppressive genes such as B-cell lymphoma 2 (BCL2), c-MYC,
Cyclin D1 (CCND1), VEGF-A, and interleukin-10 (IL-10) (107). STAT3 has also been
implicated in MBM pathogenesis. Xie at al.’s analysis of MBMs demonstrated
significantly stronger staining for phosphorylated STAT3 (P-STAT3) in MBMs compared
to primary tumors. In addition, the introduction of a constitutively active form of P-STAT3
transformed nonmetastatic A375P cells into highly brain-metastatic cells but did not alter
the growth rates of cells implanted subcutaneously. Likewise, brain-metastatic TXM-18
melanoma cells lost their brain-metastatic capacity following suppression of P-STAT3
(108). Huang et al. demonstrated that overexpression of suppressor of cytokine signaling
1 (SOCS1), a negative regulator of JAK-STAT signaling, prevented brain-metastatic
melanoma cell lines from forming MBMs following intracarotid injections (109).
Mechanistic studies determined that JAK-STAT signaling promoted beneficial
angiogenesis and invasion signaling cascades by increasing transcription of VEGF-A and
matrix metalloprotease-2 (MMP-2) (108, 109). While these findings implicate JAK-STAT
signaling in MBM pathogenesis, enforced expression of P-STAT3 also promoted
melanoma cell metastasis to the lungs of mice, while suppression of P-STAT3 prevented
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lung metastasis formation (108). Together, these findings suggest that JAK-STAT
signaling may promote the general process of melanoma metastasis instead of metastasis
specifically to the brain.

1.2.1d - VEGF

The VEGF signaling cascade is mostly mediated through the binding of the VEGFA (VEGF) ligand to the VEGFR2 receptor on endothelial cells (110). Binding of the ligand
to the receptor triggers activation of the PI3K-AKT, phospholipase Cγ, and Src family
kinase signaling pathway to promote angiogenesis and vascular permeability (111, 112).
Yano et al. used a panel of cell lines from multiple tumor types – including melanoma –
to demonstrate that VEGF expression correlates with brain metastatic capacity in vivo.
Cells expressing high levels of VEGF formed large, rapidly growing metastases while
cells lacking VEGF expression formed small, poorly growing metastases (113).
Additionally, forced overexpression of VEGF facilitated growth of MBMs formed by
MEL57 cells following intracarotid injection. Interestingly, VEGF expression did not
induce the formation of new vessels but rather caused beneficial co-option of existing
blood vessels (114). This propensity for vascular co-option agrees with pathological
assessments of human brain metastases that determined vascular co-option occurs more
often in MBMs relative to metastases of other tumor types (115).

1.2.1e - Endothelins
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Endothelin signaling appears to facilitate spread of melanomas to the brain. CruzMunoz et al. established a mouse model of spontaneous melanoma metastasis and
determined via microarray analysis that brain-metastatic WM239 variants significantly
overexpressed endothelin receptor B (EDNRB) compared to visceral metastatic variants.
However, the visceral variants did not overexpress EDNRB compared to nonmetastatic
variants. Forced overexpression of EDNRB in the visceral metastatic variants increased
overall metastatic incidence and promoted metastasis to the brain. Pharmacological
inhibition of EDNRB inhibited lung metastasis formation and brain metastasis growth.
Together, these findings suggest that EDNRB promotes a general metastatic phenotype
but plays a critical role in the formation of MBMs (116).

1.2.2 - Factors That Promote Penetration of the Blood Brain Barrier (BBB)

The BBB is a network designed to protect the brain by restricting free access of blood
products to the brain parenchyma. Brain capillary walls are composed of endothelial cells
connected via tight junctions, end-foot process of astrocytes surrounding the capillaries, and
pericytes embedded in the basement membrane of the capillaries (117). Together, this BBB limits
free passage into the brain to small (<400 Da) lipophilic molecules (118). Circulating melanoma
cells must cross this BBB to access the brain parenchyma during a process known as
extravasation. As described below, a variety of factors appear capable of contributing to this
process (119, 120).Very late antigen 4 (VLA-4) mediates adhesion of melanoma cells to vascular
cell adhesion molecule 1 (VCAM-1) on the surface of endothelial cells, which facilitates arrest in
capillaries and successful extravasation. VLA-4 expression promoted melanoma cell migration
across several immortalized endothelial cell lines, and VLA-4 inhibition prevented the formation
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of melanoma lung metastases in vivo (121, 122). To assess the role of VLA-4 in MBM
pathogenesis, Garcia-Martin et al. utilized a tissue microarray and determined that over 90% of
MBMs express VLA-4. They subsequently constructed a mouse in vitro BBB model and observed
that inhibition of VLA-4 prevented melanoma cells from adhering to the endothelial cells and
migrating across the BBB (121). The exact route by which melanoma cells transverse the BBB
remains unclear. Melanoma cells might utilize the paracellular route by degrading tight junction
proteins via serine proteases such as seprase. Analyses of A2058 and B16-F10 melanoma cells
demonstrated that secretion of seprase allowed these cells to migrate across an in vitro model of
the BBB. Pharmacological and siRNA-mediated inhibition of seprase effectively prevented their
transmigration across the BBB (123). However, the role of seprase in mediating extravasation has
not been confirmed in vivo. Heparanase (HPSE) is an enzyme that degrades heparan sulfate
chains in endothelial cell layers and appears to mediate extravasation. Murine (B16B15b) and
human (70W) cells selected for their brain-metastatic capacity displayed significantly higher
HPSE production and activity compared to their parental cell lines (B16F1 and MEWO) (124).
Additionally, in vitro treatment of B16B15b cells with HPSE increased their ability to invade a
brain slide model. Pharmacological inhibition of HPSE mitigated this effect (125). Interestingly,
co-culturing brain-metastatic melanoma cells with syngeneic astrocytes or nerve growth factor
(NGF) – a growth factor secreted in the brain - significantly enhanced their secretion of HPSE
and invasiveness, indicating that normal brain tissue plays a role in facilitating the entrance of
metastatic melanoma cells into the parenchyma (126, 127). To date, in vivo studies assessing
HPSE’s role in BM pathogenesis have been limited to breast cancer. Zhang et al. determined that
breast cancer brain metastases lose expression of miRNA-1258, which is a key suppressor HPSE
production. Further, microRNA-1258 expression levels negatively correlated with the brain
metastatic capacity of breast cancer cells. Transfection of miRNA-1258 in breast cancer cells
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significantly inhibited brain metastasis formation in an experimental model of metastasis (128).
Interest in the role of pleckstrin homology domain containing A5 (PLEKHA5) in MBMs arose
following Jilaveanu et al.’s integrative comparative analysis of a brain metastatic A375P subclone
(A375Br) and the parental line and between ECMs from patients that did and did not develop
MBMs (129). Gene expression profiling determined that PLEKHA5 expression was significantly
higher in A375Br cells, and in ECMs from patients that developed MBMs. Interestingly,
PLEKHA5 expression correlated only with formation of metastases in the brain. PLEKHA5
suppression inhibited survival of A375Br cells and their ability to invade an in vitro BBB model.
However, these findings have not been confirmed in vivo.
Studies of the A375 cell line’s interactions with an in vitro BBB demonstrated that
secretion of S100A4 calcium-binding protein A4 (S100A4) mediated BBB invasion by
facilitating a loss of tight junction integrity (130). Binding of S100A4 to its receptor [receptor for
advanced glycation end products (RAGE)] suppressed expression of the tight junction proteins
occludin and VE-cadherin. These findings were confirmed in vivo where forced overexpression
of S100A4 increased brain metastasis formation of A375 cells following intracardiac injection.
However, S100A4 overexpression also stimulated metastasis to other anatomical sites, suggesting
that S100A4 promotes a generic pro-metastatic phenotype as opposed to a brain-metastatic
phenotype.
Studies across multiple tumor types have also implicated MMPs in tumor cell invasion
and metastasis through their ability to proteolytically degrade components of the extracellular
matrix (131). MMP-2 appears to mediate extravasation across the BBB. MMP-2 catalyzes the
breakdown of type IV collagen, which forms a critical component of the basement membrane of
endothelial cells in the BBB (131). Correlation studies determined that tumor MMP-2 expression
levels predict worse survival in patients (132). Gene expression studies established that MMP-2
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is expressed significantly higher in primary melanoma cultures able to invade an in vitro model
of the BBB compared to poorly invasive primary melanoma cultures (133). Interestingly,
astrocytes facilitate expression of MMP-2 in melanoma cells by secreting interleukin-23 (IL-23)
(134). Tang et al. determined that IL-23 stimulates secretion of IL-17 by γδ T cells. The IL-17
drives increased levels of P-STAT3 through interleukin-6 (IL-6) and is likely the means by which
this signaling axis promotes MMP-2 transcription (135).

1.2.3 - Homing to the Brain

Circulating melanoma cells arrest in brain capillaries once they exceed the capillary in
size (136). Additionally, they express numerous adhesion factors including integrins (including
VLA-4, as previously described) and selectins that promote the arrest of the cells within the
capillaries. Thus, mechanical factors promote the spread of melanoma cells to the brain.
Consistent with Stephen Paget’s “seed and soil” hypothesis, however, numerous additional factors
(including the PI3K-AKT pathway, as previously described) appear to promote metastasis
specifically to the brain.
Using miRNA expression profiling and three cohorts of clinical primary melanomas,
Hanniford et al. derived a miRNA signature (miR-150–5p, miR-15b-5p, miR-16–5p, and miR374b-3p) that predicted the likelihood of brain metastasis formation (137). Further, their signature
distinguished primary melanomas that initially metastasized to the brain from those that
metastasized to the brain along with other extracranial sites, suggesting that their signature might
predict brain tropism. Zhang et al. demonstrated that TGF-β signaling is necessary for metastasis
to the brain parenchyma (138). K1735 cells exclusively formed metastases in the brains of mice
following intracarotid injections while B16F10 cells formed metastases in the ventricles. K1735
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cells expressed high levels of TGF-β2 while B16F10 cells lacked expressed of TGF-β2. Forced
overexpression of TGF-β2 in B16F10 cells promoted metastasis to the parenchyma while
suppression of TGF-β2 in K1735 cells inhibited metastasis to the brain parenchyma. Gene
expression studies identified significantly higher levels of C-C chemokine receptor 4 (CCR4) in
cell lines from MBMs compared to cell lines from cutaneous tumors (139). Klein et al. confirmed
these findings by comparing flow cytometry results between YDFR.CB4, M12.CB3, and
M16.CB2 brain-metastatic variants and their parental cell lines (YDFR.C, M12.C, and M16.C).
They also determined that astrocytes and microglia secrete known CCR4 ligands and that
incubation of these glial cells in brain metastasizing melanoma cell-conditioned media
upregulates their secretion of CCR4 ligands. Further, incubation of YDFR.C cells overexpressing
CCR4 with CCR4 ligands facilitated transmigration across an in vitro BBB model, and
pharmacological inhibition of CCR4 prevented metastasis of these cells to the brain in vivo.
Together, these studies strongly implicate CCR4 in MBM pathogenesis (139). However, analysis
of clinical specimens determined that both MBMs and lymph node metastases expressed CCR4
at significantly higher levels than primary tumors, but CCR4 expression did not differ between
MBMs and lymph node metastases, suggesting that CCR4 might not mediate metastasis
exclusively to the brain (140). In contrast, brain-metastatic YDFR cells express significantly less
claudin-1 (CLDN1) than their parental cells (141). Forced overexpression of CLDN1 in brainmetastatic YDFR cells significantly inhibited the formation of MBMs in vivo but had no effect on
the formation of lung metastases, indicating that CLDN1 promotes melanoma metastasis
exclusively to the brain (142).

1.2.4 - Comprehensive Molecular Analyses of Melanoma Brain Metastases
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Global molecular characterization of MBMs was once quite limited. The studies that had
been performed demonstrated that MBMs possess unique molecular features compared to
metastases that form at other anatomical sites. Gene expression microarray studies identified
numerous differentially expressed genes between MBMs and ECMs (89, 143). However, the
microarray studies featured a relatively small number of samples, including very few patientmatched metastases, and overall failed to identify significantly enriched pathways. Whole exome
sequencing (WES) analysis of multiple tumor types has identified significant differences between
BMs and primary tumors, including three tumors from three melanoma patients (144). The
analyses demonstrated significantly divergent evolution of BMs following metastasis from the
primary tumors, yet minimal divergent evolution between multiple BMs from the same patient.
Gene expression microarray analyses of breast, lung, colorectal, and melanoma cell lines
suggest that the brain TME can trigger a fundamental reprogramming of cell lines grown in mouse
brains compared to those grown in subcutaneous tissue or orthotopic sites (145). Cells grown in
the brain overexpressed thousands of genes and acquired neuronal cell characteristics following
epigenetic changes induced by interactions with surrounding astrocytes. Interestingly, coculturing tumor cells with astrocytes replicated this reprogramming. These studies highlighted the
importance of the TME in regulating tumor cell biology.
Recently, we performed RNA-sequencing (RNA-seq) on the largest cohort of MBMs to
date, and the largest cohort of patient-matched brain metastases and ECMs from any tumor type,
and provided new insights into the pathogenesis of these tumors. Similar to melanoma regional
(70) and distant metastases (146), our analysis demonstrated significant heterogeneity of the
expression of immune related gene sets between MBMs from different patients. Immune
infiltration correlated with prolonged overall survival (OS), which corroborates findings from
previous studies (143, 147).
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Our analysis of MBMs and patient-matched ECMs identified suppression of multiple
components of the anti-tumor immune response in MBMs. Unsupervised hierarchical clustering
of RNA-seq data for the 500 most variable genes (those with the greatest variance across samples)
from 35 MBMs and 42 patient-matched ECMs (from 29 patients) showed that nearly all samples
clustered by patient ID rather than by tissue site, suggesting overall similar gene expression
patterns between MBMs and ECMs from individual patients (Figure 3A). However, further
analysis of patient-matched MBMs and ECMs identified 494 differentially expressed genes
(DEGs). Pathway analysis of numerous gene sets repeatedly indicated that MBMs are
characterized by (1) suppression of immune cell networks and (2) upregulation of nervous system
pathways. ImmuneScores – a 142 gene signature able to predict the extent of intratumoral immune
cell infiltration – were significantly lower in the MBMs compared to the patient-matched ECMs,
even after omitting lymph node (LN) ECMs from the analysis (Figure 3B). IHC staining
confirmed significantly lower CD3+ and CD8+ T cell infiltration in the MBMs vs. patient-matched
non-LN ECMs (Figure 3C-D), but no significant difference in PAX5+ B cells was detected
(Figure 3E). MCP-Counter analysis – a cell type quantification algorithm used to estimate
immune cell populations from gene expression data – of other immune cell classes identified
significantly fewer monocytic lineage cells and myeloid dendritic cells in MBMs; no significant
difference in natural killer (NK) cells; and significantly more neutrophils in MBMs. We examined
molecular features associated with immunosuppression and did not identify significant
differences in membranous or cytoplasmic β-catenin expression or PTEN loss between MBMs
and patient-matched ECMs. We also did not detect a significant difference in PD-L1 expression
between the MBMs and ECMs overall, but discordant PD-L1 expression (MBM+/ECM- or MBM/ECM+) was detected in 40% of patient-matched samples (Figure 3F). In addition, comparative
analysis of RNA-seq data from a cohort of unmatched primary melanomas (148) identified
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decreased ImmuneScores, myeloid dendritic cells, T cells, B lineage cells, and neutrophils in
MBMs.
To supplement our transcriptomic profiling, we performed WES on patient-matched
MBMs (n=21) and ECMs (n=23) from patients (n=17) with germline DNA and sufficient tissue
available. We observed no significant difference between the overall number of genes with
nonsynonymous somatic mutations between the patient-matched MBMs and ECMs, nor in the
mutation rate of 74 therapeutically targetable genes (149). TCR-seq was performed on patientmatched MBMs (n=11) and ECMs (n=16) with sufficient DNA from 10 patients. Mean clonality
did not differ between matched pairs (Figure 3G). Observed richness, however, was significantly
lower in the MBMs (Figure 3H). Together the results indicate that while T cells present in MBMs
are equally reactive as T cells in the ECMs, there is a significantly less diverse repertoire of T cell
clones in MBMs. To evaluate T cell repertoire heterogeneity, we calculated the Morisita Overlap
Index (MOI) (150), which identified minimal similarity in the T cell repertoires between MBMs
and patient-matched ECMs (Figure 3I). This suggests divergent tumor immunogenicity
associated with metastasis to the brain.
As previous studies have shown that CD8+ T cell and other immune cell infiltrates
correlate positively with responsiveness to anti-PD-1 immunotherapy in melanoma (151, 152),
this result provides a potential explanation for the relatively disappointing intracranial response
rates (ICRR) observed with pembrolizumab (18%) (153) and nivolumab (20%) (154). Notably,
the ICRR for combined immunotherapy with ipilimumab and nivolumab appears to be more
promising (154, 155), perhaps consistent with studies suggesting that the baseline T cell infiltrate
is less critical to the efficacy of this regimen (156).
The cause for MBM immunosuppression remains unclear. While it might be tempting to
blame the BBB for physically impeding immune cells from accessing MBMs, several lines of

36
evidence challenge this conclusion. BBB disruption occurs in numerous neurological diseases
such as multiple sclerosis, stroke, and epilepsy. In each case, the BBB is unable to restrict the
entry of immune cells into the brain parenchyma and prevent an inflammatory state as it typically
does in a normal, healthy brain (157). MBMs induce significant leakage in the BBB during the
processes of extravasation and angiogenesis. The previously described factors HPSE, MMP-2,
and S100A4 damage the integrity of the BBB to promote extravasation into the parenchyma, and
VEGF causes vessels to leak as it stimulates angiogenesis. Clinical imaging findings confirm
MBM-induced BBB leakage. For example, MBMs take up gadolinium contrast agent during MRI
imaging while normal brain parenchyma fails to do so. Additionally, immunotherapy with antiCTLA4 and anti-PD1 antibodies achieve clinical responses in patients with MBMs (158, 159).
Both of these treatments depend on T cells crossing the BBB and accessing the tumor. Clinical
responses to these agents indicate that the BBB is not able to prevent the entry of T cells into the
brain parenchyma. Together, these findings indicate that physical barriers cannot explain the
immunosuppression observed in MBMs.
Several key signaling pathways mediate immunosuppression in melanoma ECMs and play
critical roles in MBM pathogenesis. For example, Peng et al. observed that loss of PTEN
stimulates PI3K-AKT pathway activation and secretion of VEGF in melanomas (160). Expression
levels of VEGF inversely correlated with intratumoral T cell infiltrate and response to adoptive T
cell therapy. Further, treatment of PTEN-null melanomas with the selective PI3KB inhibitor
GSK2636771 overcame the immunosuppression and promoted response to immunotherapy.
However, we did not detect differences in PTEN expression between the matched MBMs and
ECMs, although this does not preclude the possibility that PI3K-AKT pathway activation in the
MBMs by other mechanisms could contribute to the differences in immune cell infiltrate. We also
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did not detect significant differences in either β-catenin expression or nonsynonymous somatic
mutation frequency that would explain the observed immune suppression in MBMs (161, 162).
The immunosuppressive effects of TGF-β signaling have been extensively characterized
(163, 164). Additionally, Walentynowicz et al. demonstrated that TGF-β2 polarizes gliomaassociated macrophages into tumor-supporting cells (165). It is possible that the TGF-β2 signaling
axis which is necessary for formation of parenchymal brain metastases also mediates MBM
immunosuppression. Further studies would be necessary to confirm this possibility and to
elucidate whether or not the mechanisms of TGF-β2-mediated immunosuppression are the same
in MBMs as in ECMs. It is also possible that stromal cells may cause immunosuppression in
MBMs via STAT3 signaling. Priego et al. performed IHC on 91 BMs, including 2 MBMs, and
identified positive P-STAT3 staining in the peritumoral reactive astrocytes of 89% of the BMs.
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Further, strong P-STAT3 staining in reactive astrocytes significantly correlated with patient
survival. Mechanistic studies determined that the BMs induced P-STAT3 signaling in the
astrocytes, which in turn inhibited the activation of CD8+ T cells and promoted the activity of protumor macrophages/microglia expressing cluster of differentiation 74 (CD74). Importantly,
inhibition of P-STAT3 signaling in reactive astrocytes inhibited the intracranial growth of the
B16/F10-BrM melanoma cell line in vivo, suggesting that targeting this signaling axis in reactive
astrocytes could be beneficial for patients with MBMs (166).

1.3 - METABOLISM OF MELANOMA BRAIN METASTASES

While there is a growing appreciation for the metabolism of melanomas and molecular
features of MBMs, little is known about the metabolism of MBMs. As a first step towards
addressing this gap in knowledge, we selected 70 MSigDB KEGG metabolism-specific gene
sets and performed a preranked Gene Set Enrichment Analysis (GSEA-P) on the RNA-seq data
from our patient-matched MBMs and ECMs. This analysis demonstrated greater enrichment of
the KEGG OXPHOS gene set than any other metabolism gene set in the MBMs (Figure 4A-B).
We used a panel of 15 melanoma cell lines with gene expression and Seahorse Extracellular Flux
(XF) Assay data to derive an OXPHOS-Index (OP-Index), a transcriptional signature that
correlates with OXPHOS in vitro. We found that the majority of MBMs had a higher OP-Index
than their patient-matched ECMs, and the average OP-Index of MBMs was significantly higher
than the OP-Index of patient-matched ECMs (Figure 4C). We confirmed OXPHOS enrichment
in unmatched treatment-naïve MBMs (n=29) vs. ECMs (n=33), as well as in the patient-matched
treatment-naïve MBMs (n=10) vs. ECMs (n=12) in that subset, excluding the possibility that
enrichment of OXPHOS in MBMs was due to differences in prior treatments. The KEGG
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OXPHOS gene set was also enriched in treatment-naïve MBMs (n=29) vs. a cohort of primary
melanomas with available RNA-seq data (n=54) (Figure 4D).

1.4 - CENTRAL HYPOTHESIS

1.4.1 - Rationale and Significance
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Melanoma is the deadliest type of skin cancer, accounting for over 80% of skin cancerrelated deaths (1). Many of these deaths result from brain metastases, a devastating complication
of melanoma diagnosed in up to 60% of patients with distant metastases (167). Surgery and
radiation are the predominant therapeutic modalities used to treat MBMs, but they have minimal
impact on the long-term survival of patients (167). As patients with MBMs traditionally have a
median survival of ~4 months, there is a critical unmet need to develop new, more effective
therapeutic strategies for this disease (167). Several phase II clinical trials meant to address this
need have tested agents previously validated in the treatment of non-central nervous system
(CNS) disease, though neither targeted therapies nor immunotherapies meet the pressing need for
adequate therapies (154, 168-171). To address the shortcomings of available therapies for the
treatment of MBMs, we must improve our understanding of the features, heterogeneity, and
functional drivers of MBMs.
A metabolic phenotype defined by elevated OXPHOS (High-OXPHOS) has been
identified in 30-50% of non-CNS melanomas and correlates with shorter patient survival (35,
172). Furthermore, OXPHOS mediates de novo and acquired resistance to FDA-approved MAPK
pathway inhibitors and anti-PD1 immunotherapy (3, 26, 35, 173). Recently, we found that MBMs
are significantly enriched in OXPHOS gene sets vs. ECMs from the same patients and that
OXPHOS levels vary significantly between MBMs from different patients. While these findings
represent the most comprehensive metabolic profiling of MBMs to date, they provided little
insight into the functional role of OXPHOS in MBM pathogenesis nor which step in the metastatic
cascade mediates the enrichment of OXPHOS in MBMs. Additionally, the molecular,
immunological, and metabolic associations of OXPHOS in MBMs remain unknown.
The purpose of this study was to understand the role of OXPHOS in MBM pathogenesis
to better prevent and treat this deadly disease complication. This dissertation demonstrates that
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the brain TME is responsible for OXPHOS enrichment in MBMs compared to ECMs.
Additionally, it provides new insight into the role of OXPHOS as a key mediator of MBM growth
and validates direct OXPHOS inhibition as a feasible therapeutic approach for MAPKi-resistant
MBMs. Finally, this work identifies multiple novel therapeutic targets that could improve the
prognosis of MBMs most enriched in OXPHOS and thus at highest risk of developing therapeutic
resistance to approved therapies.

1.4.2 - Hypothesis

The central hypothesis of this dissertation is that OXPHOS plays a critical role in the
pathogenesis of MBMs.
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2.1 - Patient Cohort/Sample Collection

For the MBM/ECM cohort, tumors resected from melanoma patients between 7/31/1991
and 10/15/2015 were obtained from the UT MD Anderson Cancer Center (MDACC) Central
Nervous System Tissue Bank and the Melanoma Informatics, Tissue Resource, and Procurement
Core facility (MelCore) under a protocol approved by the Institutional Review Board. Samples
were formalin-fixed, paraffin embedded (FFPE) tissue blocks (stored at room temperature). Due
to known differences in underlying biology between melanoma subtypes, only cutaneous
melanomas were included. Full clinical information is freely available online in (174).
For the primary tumor cohort, sample selection and acquisition have been previously
described (148). Briefly, patients between 1998 and 2010 were included if they had (1) a single,
invasive, primary melanoma with Breslow thickness greater than 1.5 mm, (2) FFPE primary
tumor tissue available for analysis, (3) no clinical evidence of regional metastasis at the time of
primary tumor diagnosis, and (4) a sentinel lymph node biopsy conducted within 1 year of the
primary tumor diagnosis. The pilot 35 patients were divided into two groups: (1) patients that
relapsed with a non-CNS metastasis within 3-18 months after initial diagnosis (N=16) and (2)
patients that did not recur with a minimum of 60 months of follow-up from initial diagnosis
(N=19). Since this initial characterization, an additional 19 primary tumors that recurred with
metastasis to the brain within 3-18 months after initial diagnosis were identified for molecular
characterization and processed identically as the other tumors. Full clinical information is freely
available online in (174).

2.2 - Cell Lines
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All cell lines were grown at 37°C under 5% CO2. Luciferase-tagged A375, MEWO, CHL1,
MEL624, and WM1361A cells [provided by Guo Chen, MDACC], A375-R1 cells [developed by
Y.N. Vashisht Gopal (3) and provided by Guo Chen, MDACC], and SKMEL5 cells [provided by
the Center for Co-Clinical Trials, MDACC] were grown in RPMI-1640 media supplemented with
glutamine and heat-inactivated 5% fetal bovine serum (FBS) (all from Gibco). Duel Luciferase
and Green Fluorescent Protein (GFP)-tagged YUMM5.2 cell lines [developed by Marcus
Bosenberg (175), Yale University, and provided by Guo Chen, MDACC] were grown in
DMEM/F12 (50:50) media supplemented with 1% non-essential amino acids (NEAA) (both from
Corning, Inc.) and 10% heat-inactivated FBS. Luciferase-tagged B16-F10 cells [developed and
provided by Willem Overwijk, MDACC], A375Br3/A375P cells [developed and provided by
Suyun Huang (108), MDACC], and YDFR.CB3/YDFR.C cells [developed and provided by Isaac
Witz (176), Tel Aviv Institute] were grown in RPMI-1640 media supplemented with glutamine
and 10% heat-inactivated FBS. A375P and G361 cells stably transfected with shRNA against
PGC1α (shPGC1α) and a scrambled control vector (shScr) [developed and provided by Pere
Puigserver (172), Dana-Farber Cancer Institute] were grown in high glucose DMEM (Gibco)
containing 10% heat-inactivated FBS. Identity of the human cell lines was verified by shorttandem repeat (STR) fingerprinting at least every 6 months (177). All cell lines were confirmed
negative for mycoplasma prior to the study using the MycoAlert Mycoplasma Detection Kit
(Lonza) according to the manufacturer’s specifications.

2.3 - Compounds

IACS-010759 is a proprietary compound of the Institute for Applied Cancer Science
(IACS) at MDACC and synthesized as previously described (178). Compound used for in vitro
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treatments was prepared in dimethylsulfoxide (DMSO; Sigma) and stored at -20°C until further
use. For in vivo treatments, clear suspensions of the compound were prepared in 0.5%
methylcellulose (0.5% MC) by IACS every 14 days. Compound was stored at 4°C in the absence
of light and constantly stirred.
Metformin (Cayman Chemical) was prepared in phosphate buffered saline (PBS; Corning,
Inc.) and filter-sterilized immediately before each in vivo treatment.
Isotype rat IgG control antibody (BioXCell, Clone: 2A3, #BE0089) and anti-mouse PD1
antibody (BioXCell, Clone: RMP1-14, #BE0146) were prepared in filter-sterilized PBS under
sterile conditions immediately before each in vivo treatment.
Pimonidazole hydrochloride (Hypoxyprobe, Inc.) was prepared in normal saline (VWR
International) and filter-sterilized. Compound was stored at 4°C in the absence of light and
constantly stirred for up to 3 months for in vivo injections.
AZD2014 (Selleck Chemical) was formulated as a suspension in sterilized 0.5%
hydroxypropyl methylcellulose (HPMC; Sigma)/0.1% Tween 80 (Sigma) under sterile
conditions. Compound was stored at 4°C in the absence of light and constantly stirred for up to
14 days for in vivo treatments.
CB839 (Selleck Chemical) used for in vitro treatments was prepared in DMSO and stored
at -20°C until further use. For in vivo studies, CB839 was prepared in 25% (w/v) hydroxypropylβ-cyclodextrin (HPBCD; Roquette) in 10 mmol/L citrate, pH 2. Compound was stored at 4°C in
the absence of light and constantly stirred for up to 14 days.

2.4 - Mice
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All mouse experiments were approved by the Institutional Animal Care and Use
Committees of MDACC and University of Utah Health Sciences Center. Female C57BL/6 and
CD-1 nude mice were purchased from the Jackson Laboratory and Charles River Laboratories,
respectively. C57BL/6 and CD-1 nude mice were used at 8 weeks of age, and experiments using
these mice were performed at the MDACC South Campus Animal Vivarium and housed in
specific pathogen-free conditions. All experiments using the RCAS-TVA model were conducted
at the University of Utah Health Sciences Center.

2.5 - Stereotaxic Intracranial Injection

On the day of injection, cells between 80-90% confluent were trypsinized (Corning,
Inc. 0.25% Trypsin, 0.1% EDTA in HBSS without Calcium, Magnesium and Sodium
Bicarbonate) and resuspended in Hank’s Balanced Salt Solution (HBSS; Corning, Inc.).
Specifically, media was aspirated and tissue culture plates were rinsed with 10 ml of PBS per 100
mm plate. PBS was aspirated and 1 ml of trypsin was added to each 100 mm plate and incubated
at 37°C for 1 minute. Trypsin was inactivated with addition of 5 ml of media (RPMI, DMEM/F12
50:50, or DMEM) + 5-10% FBS per 100 mm plate. Cells were pelleted via centrifugation at 500
x g for 3 minutes and resuspended in 5 ml ice-cold HBSS per 100 mm plate. Viable cells were
counted using Trypan Blue (Gibco) and an automated cell counter. Only harvested cells with a
mean viability of at least 90% were used in each injection. The live cell density was adjusted as
necessary with ice-cold HBSS. The cell suspension was kept on ice until injection.
Mice were anesthetized with an intraperitoneal (i.p.) injection of ketamine/xylazine
cocktail (80 mg/kg ketamine and 12 mg/kg xylazine). Once sufficiently deep anesthesia was
confirmed via toe pinch, the scalp was sterilized via chlorhexidine scrub. Ophthalmic ointment
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was applied. Using a sterile scalpel, a ~1 cm incision was made longitudinally along the midline
of the scalp beginning at the level of the eyes and extending caudally. A sterile 23-gauge needle
was used to pierce the bone at a position 1 mm posterior and 2 mm lateral to the bregma in the
right hemisphere. The mouse was placed in a stereotaxic frame (World Precision Instruments)
such that the head was in a level plane and immobilized to finger touch. 2.5 µl of the cell
suspension was taken up into a 10 µl Hamilton syringe (Hamilton Co.) held by the stereotaxic
frame. The Hamilton syringe needle was positioned at the entrance of the burr hole and then
lowered perpendicularly to the skull through the burr hole to a depth of 4 mm. The needle was
withdrawn slowly to a final depth of 3 mm. The cell suspension was delivered at a rate of 0.5
µl/min. After an additional 30 seconds, the needle was withdrawn over a period of 1 minute. A
cotton swab was used to dry the surface of the skull around the burr hole. Sterile bone wax was
applied to the burr hole. The incision was closed with sterile wound clips. This procedure was
repeated until all mice were injected. Mice were monitored on a heating pad until alert and
ambulatory and then transferred to a clean cage.

2.6 - Intracardiac Injection

On the day of injection, cells were prepared as described for intracranial injections. Live
cell density was adjusted as necessary. Fur was removed from the ventral surface of C57BL/6
mice via hair removal cream. Each mouse was anesthetized (2.5% isoflurane in 100% O2 in an
induction chamber) and maintained with isoflurane (2.5% in 100% O2) during the whole
procedure via a nose cone. Anesthesia was confirmed when no withdrawal reflex was observed
with toe pinch. The anesthetized mouse was taped to a heated imaging table in supine position.
VisualSonics Vevo 770 ultrasound system was activated and the transducer 704 (40 MHz) was
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initialized. Ultrasound gel was applied to the ventral surface of the mouse. The transducer was
mounted securely in the holder of a stereotaxic frame. The transducer was lowered until the
desired imaging depth was reached. The stage was then moved until the left ventricle was
identified with the ascending aorta used as the landmark. The stage was then locked. 100 µl of
cell mixture was drawn into a 1 ml syringe with a 27-gauge needle. The syringe was fixed on the
syringe mount of the stereotaxic frame. The syringe was advanced towards the mouse’s ventral
surface and carefully moved until the needle tip was in the imaging field of view. The needle
height and angle were adjusted to acquire direct access to the left ventricle upon penetration of
the chest wall. The syringe needle was then pushed through the intercostal space and into the left
ventricle under the guidance of ultrasound imaging. The needle was inspected for the reflux of
fresh arterial blood into the syringe to confirm proper placement of the needle. The cell mixture
was then injected over the course of 30 seconds. Upon completion, the needle was withdrawn and
the mouse was thoroughly cleaned with dampened gauze and removed from the imaging stage.
This procedure was repeated until all mice were injected. The mice were monitored on a heating
pad until alert and ambulatory and then transferred to a clean cage.

2.7 - In vivo Bioluminescence Imaging (BLI)

At selected time points, D-luciferin sodium salt (BioVision) was injected at 150 mg/kg
into the peritoneum of each mouse. After 10 minutes, the animal was placed into an IVIS100 in
vivo imager and scanned on default settings with the exception that exposure time was
automatically determined by the Living Image (v4.5.2) software. The bioluminescence image was
overlaid onto a photographic image for anatomical location of the signal. Signal intensities were
quantified using Living Image (v4.5.2) software. Briefly, regions of interest (ROIs) were
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automatically determined by the software. The minimum % of peak pixel intensity for inclusion
was set to 20%. Values were normalized against a black surface in the image and a nonluminescent surface of the animal. Total flux values were exported into Microsoft Excel 2013 and
Prism 7.0 (Graphpad) for downstream analysis.

2.8 - Subcutaneous Injection

On the day of injection, cells were prepared as described for intracranial injections. Live
cell density was adjusted as necessary. Each mouse was anesthetized (2.5% isoflurane in 100%
O2 in an induction chamber) and maintained with isoflurane (2.5% in 100% O2) during the whole
procedure via a nose cone. The injection site was cleaned with 70% ethanol. 100 µl of cell mixture
was drawn into a 1 ml syringe with a 30-gauge needle. The needle was inserted superficially
beneath the skin 5-10 mm into the subcutaneous tissue. The cell mixture was ejected from the
syringe. A positive injection was indicated by the appearance of a “bleb.” The needle was gently
withdrawn and the mouse was placed in a cage once alert and ambulatory. The procedure was
repeated until all mice were injected. Tumors were measured using a digital caliper (Fowler). The
greatest longitudinal diameter (length or “L”) and the greatest transverse diameter (width or “W”)
were recorded. Tumor volume was calculated as [(LxW2)/2].

2.9 - Intracranial (ICr) and Subcutaneous (SQ) Xenograft Implantation and Sample
Collection for Tumor Microenvironment Gene Expression Studies

3x103 luciferase-tagged A375 and A375-R1 cells and 1x104 MEWO and WM1361A cells
suspended in HBSS were directly implanted in the brain parenchyma of CD-1 nude mice (female,
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8-10 weeks of age). 3x106 luciferase-tagged A375, A375-R1, MEWO, and WM1361A cells
suspended in HBSS were subcutaneously implanted in the flanks of CD-1 nude mice of the same
cohort. Mice with ICr tumors were euthanized if they lost > 20% body weight, if they became
moribund, or if they displayed neurological symptoms (ataxia, seizures, circling behavior,
paralysis, or cranial doming). Mice with SQ tumors were euthanized once tumors reached 250
mm3. Tumors were harvested, rinsed briefly in ice-cold normal saline, embedded in optimal
cutting temperature (OCT) compound (Fisher Scientific), and flash-frozen via liquid nitrogen.

2.10 - RCAS-TVA Model Tumor Induction and Sample Collection

FFPE

specimens.

Primary

tumors

were

generated

in

Dct::TVA;BrafCA;Cdkn2alox/lox±Ptenlox/lox mice using RCAS:Cre ± RCAS:myrAkt1 retroviruses as
previously described (179). A full necropsy was performed on all mice following euthanasia.
Brain, lung, and primary tumor tissues were fixed in formalin overnight, dehydrated in 70% ethyl
alcohol, and paraffin embedded. Sections were stained with hematoxylin & eosin (H&E) for
review by a pathologist.
Frozen primary tumor specimens. RCAS-myrAKT1 was used as a template to generate
Akt1 mutant constructs. Mouse melanocyte cDNA and Akt2-specific primers (Dharmacon) were
used to amplify Akt2 via PCR reaction. The product was TOPO cloned into a gateway compatible
pCR8 TOPO vector and then subcloned into the RCAS destination vector. RCAS-myrAKT2 was
used as a template to generate Akt2 mutant constructs. Mouse myrAkt3 was amplified via PCR
reaction from Akt3 cDNA / ORF (Dharmacon) and Akt3-specific primers. The product was TOPO
cloned into a gateway compatible pCR8 TOPO vector and then subcloned into the RCAS
destination vector. RCAS-myrAKT3 used as a template to generate Akt3 mutant constructs. All
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mutants were engineered with an N-terminus HA-epitope tag. The E17K substitution was
engineered into the forward primer of oligonucleotides of each paralog. All viral vectors were
verified via Sanger Sequencing. Primer sequences and are available upon request. Viral
production and spread were initiated and monitored as previously described (179). Primary tumors
were

generated in

Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox mice using RCAS:Cre ±

RCAS:Akt1/2/3-E17K mutant retroviruses as previously described (179).

2.11 - RNA-Sequencing and Analysis

cDNA library construction for clinical FFPE specimens, A375, A375-R1, MEWO, and
WM1361A xenografts. Total RNA was assessed for quality using the Caliper LabChip GX2 at
the Broad Institute (Cambridge, MA). The percentage of fragments with a size greater than 200
nucleotides (DV200) was calculated using software. An aliquot of 200 ng of RNA was used as
the input for first strand cDNA synthesis using Illumina’s TruSeq RNA Access Library Prep
Kit. Synthesis of the second strand of cDNA was followed by indexed adapter ligation.
Subsequent PCR amplification enriched for adapted fragments. The amplified libraries were
quantified using an automated PicoGreen assay. 200 ng of each cDNA library, not including
controls, were combined into 4-plex pools. Capture probes that target the exome were added, and
hybridized for recommended time. Following hybridization, streptavidin magnetic beads were
used to capture the library-bound probes from the previous step. Two wash steps effectively
removed any non-specifically bound products. These same hybridization, capture, and wash steps
were repeated to assure high specificity. A second round of amplification enriched the captured
libraries. After enrichment, the libraries were quantified with qRT-PCR using the KAPA Library
Quantification Kit for Illumina Sequencing Platforms and then pooled equimolarly. The entire
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process was in 96-well format and all pipetting was done by either Agilent Bravo or Hamilton
Starlet.
Illumina sequencing for clinical FFPE specimens, A375, A375-R1, MEWO, and
WM1361A xenografts. Pooled libraries were normalized to 2 nM and denatured using 0.1 N
NaOH prior to sequencing at the Broad Institute. Flowcell cluster amplification and sequencing
were performed according to the manufacturer’s protocols using HiSeq 2500. Each run was a 76bp paired-end with an eight-base index barcode read. Data was analyzed using the Broad Picard
Pipeline which includes de-multiplexing and data aggregation.
cDNA library construction for RCAS-TVA model specimens. Total RNA samples (100500 ng) were hybridized with Ribo-Zero Gold at the University of Utah Health Sciences Center
to substantially deplete cytoplasmic and mitochondrial rRNA from the samples. Stranded RNA
sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Kit with RiboZero Gold (RS-122-2301 and RS-122-2302). Purified libraries were qualified on an Agilent
Technologies 2200 TapeStation using a D1000 ScreenTape assay (cat# 5067-5582 and 50675583). The molarity of adapter-modified molecules was defined by qRT-PCR using the Kapa
Biosystems Kapa Library Quant Kit (cat# KK4824). Individual libraries were normalized to 10
nM and equal volumes were pooled in preparation for Illumina sequencing and analysis.
Illumina sequencing for RCAS-TVA model specimens. Sequencing libraries (25 pM)
were chemically denatured and applied to an Illumina HiSeq v4 single read flow cell using an
Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers
with reagents from an Illumina HiSeq SR Cluster Kit v4-cBot (GD-401-4001). Following transfer
of the flowcell to an Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50 cycle
single-read sequence run was performed using HiSeq SBS Kit v4 sequencing reagents (FC-4014002). The reference murine genome sequence (FASTA file) and annotation file (GTF file) were
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downloaded from Ensembl release 92. A reference database was created using the
genomeGenerate option of STAR aligner (v2.5.4a) (180). The sjdbGTFfile option was used to
extract splice junctions from the GTF file with a maximum possible overhang of 49 bases (for the
50 bp read). The Illumina adapter sequences were trimmed using cutadapt (v1.16). The -O option
trimmed after 6 matching bases and -m option discarded trimmed reads shorter than 20 bases.
Following quality assessment via FastQC, the trimmed reads were aligned to the reference
genome using STAR (v2.5.4a) in two pass mode with default parameters to generate an RNA-seq
BAM file for each sequencing event. Picard CollectRnaSeqMetrics was used to calculate the
post-alignment mapping statistics.
Count matrix generation. HTSeq-count (v0.9.1) tool (181) was applied with its default
settings to aligned RNA-seq BAM files from the Broad Institute (except A375, A375-R1, MEWO,
and WM1361A xenografts) to count uniquely aligned reads overlapping features in the GTF file,
and featureCounts (v1.5.1) (182) was applied with its default settings to the aligned RNA-seq
BAM files generated at the University of Utah Health Sciences Center. Samples with less than 10
million uniquely mapped reads were excluded from further analyses. Only Entrez genes were
included in further analyses.
Xenome pipeline. RNA-seq data from A375, A375-R1, MEWO, and WM1361A ICr and
SQ xenografts were processed on the Seven Bridges Cancer Genomics Cloud platform
(https://cgc.sbgenomics.com/) with a workflow implemented using Common Workflow
Language. After initial data upload (24 samples), starting BAM files were converted to FASTQs
using the biobambam2 bamtofastq utility and processed with the Jackson Laboratory’s RNA-Seq
pipeline. Briefly, the transcriptome of hg38 and NOD (based on mm10 mouse genome) were used
to construct the Xenome (v1.0.0) (183) indices (k=25) and then all reads from engrafted samples
were classified into five types: human, mouse, both, neither and ambiguous at default parameters.
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Reference indices for alignment were built by rsem-prepare-reference using ENSEMBL
annotation (vGRCh38.91) for STAR aligner (v2.5.1b). Xenome-classified human-specific reads
were further mapped to reference indices using STAR and expression estimates were performed
using

rsem-calculate-expression

(v1.2.31)

at

default

parameters

(184).

Picard

CollectRnaSeqMetrics was used to calculate the post-alignment mapping statistics. Only Entrez
genes were included in further analyses.
Identification of differentially expressed genes (DEGs). Counts were normalized using
the TMM method and generalized linear models were used for differential expression analysis
(185). Comparisons of interest were performed using functions from the edgeR and limma/voom
Bioconductor packages in R (185). Blocking was performed to account for differences in cell line
identity during xenograft studies. Clinical samples with median transcript counts of 0 were
excluded from further analysis. Lowly expressed genes were filtered according to the following
criteria in the preclinical models: genes with an average log2-(CPM+0.5) < 0 (A375, A375R1,
MEWO, and WM1361A ICr and SQ xenografts) and genes with an average log2-(CPM+0.5) < 1
(RCAS-TVA model samples). DEGs were defined as those genes with a Benjamini-Hochberg
corrected p value less than 0.05.
Pathway analyses. Preranked GSEA (GSEA-P) was implemented using the GenePattern
module GSEAPreranked (v6.0.10). Gene sets were downloaded from the MSigDB database or
featured the 70 KEGG metabolic pathways from Table 3 included in a single .gmt file. Rank
metric was calculated as the sign of log2-FCs multiplied by the inverse of p-values calculated
using the EdgeR/limma/voom pipeline (186). Genes from murine samples were converted to their
human orthologs via mapping from Ensembl BioMart version 77. GSEA-P was performed on the
rank metric–sorted list of genes.
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Single sample GSEA (ssGSEA) and OXPHOS-Index (OP-Index) derivation. ssGSEA
was conducted on TMM-normalized, voom-transformed log2-(CPM+0.5) expression matrices
using the GenePattern module ssGSEAProjection (v9.0.10) with default settings. To derive the
OP-Index, we analyzed two datasets: 1) previously published gene expression data from MEL624
and SKMEL5 melanoma cells resistant to MEKi because of increased OXPHOS and MEKisensitive A375 and WM35 melanoma cells treated for 24 hours with 0.25 μM of the MEKi
selumetinib (3) and 2) publicly available gene expression data from A375P cells transfected with
two shRNAs targeting PGC1α and a scrambled control (GSE36879) (172). GSEA (v19.0.24) was
performed as previously described (187) with default settings except that the rank metric was set
to “log2 ratio of classes.” The 8 OXPHOS-related MSigDB Hallmarks and c2 gene sets most
enriched in both the MEKi-resistant cells and scrambled controls were identified as the basis of
the index (Figure 5). We then acquired publicly available gene expression data from 15 melanoma
cell lines (GSE101644) (188) with matching Seahorse Extracellular Flux (XF) Assay data.
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Table 3 - KEGG metabolism gene sets used in metabolomics pathway analyses
Pathway Name
Pathway Name
GLYCOLYSIS GLUCONEOGENESIS

GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE

CITRATE CYCLE TCA CYCLE

GLYCOSAMINOGLYCAN BIOSYNTHESIS KERATAN SULFATE

PENTOSE PHOSPHATE PATHWAY

GLYCOSAMINOGLYCAN BIOSYNTHESIS HEPARAN SULFATE

PENTOSE AND GLUCURONATE INTERCONVERSIONS

GLYCEROLIPID METABOLISM

FRUCTOSE AND MANNOSE METABOLISM

INOSITOL PHOSPHATE METABOLISM

GALACTOSE METABOLISM

GLYCOSYLPHOSPHATIDYLINOSITOL GPI ANCHOR BIOSYNTHESIS

ASCORBATE AND ALDARATE METABOLISM

GLYCEROPHOSPHOLIPID METABOLISM

FATTY ACID METABOLISM

ETHER LIPID METABOLISM

STEROID BIOSYNTHESIS

ARACHIDONIC ACID METABOLISM

PRIMARY BILE ACID BIOSYNTHESIS

LINOLEIC ACID METABOLISM

STEROID HORMONE BIOSYNTHESIS

ALPHA LINOLENIC ACID METABOLISM

OXIDATIVE PHOSPHORYLATION

SPHINGOLIPID METABOLISM

PURINE METABOLISM

GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO/NEOLACTO SERIES

PYRIMIDINE METABOLISM

GLYCOSPHINGOLIPID BIOSYNTHESIS GLOBO SERIES

ALANINE ASPARTATE AND GLUTAMATE METABOLISM

GLYCOSPHINGOLIPID BIOSYNTHESIS GANGLIO SERIES

GLYCINE SERINE AND THREONINE METABOLISM

PYRUVATE METABOLISM

CYSTEINE AND METHIONINE METABOLISM

GLYOXYLATE AND DICARBOXYLATE METABOLISM

VALINE LEUCINE AND ISOLEUCINE DEGRADATION

PROPANOATE METABOLISM

VALINE LEUCINE AND ISOLEUCINE BIOSYNTHESIS

BUTANOATE METABOLISM

LYSINE DEGRADATION

ONE CARBON POOL BY FOLATE

ARGININE AND PROLINE METABOLISM

RIBOFLAVIN METABOLISM

HISTIDINE METABOLISM

NICOTINATE AND NICOTINAMIDE METABOLISM

TYROSINE METABOLISM

PANTOTHENATE AND COA BIOSYNTHESIS

PHENYLALANINE METABOLISM

FOLATE BIOSYNTHESIS

TRYPTOPHAN METABOLISM

RETINOL METABOLISM

BETA ALANINE METABOLISM

PORPHYRIN AND CHLOROPHYLL METABOLISM

TAURINE AND HYPOTAURINE METABOLISM

TERPENOID BACKBONE BIOSYNTHESIS

SELENOAMINO ACID METABOLISM

LIMONENE AND PINENE DEGRADATION

GLUTATHIONE METABOLISM

NITROGEN METABOLISM

STARCH AND SUCROSE METABOLISM

SULFUR METABOLISM

N GLYCAN BIOSYNTHESIS

AMINOACYL TRNA BIOSYNTHESIS

OTHER GLYCAN DEGRADATION

METABOLISM OF XENOBIOTICS BY CYTOCHROME P450

O GLYCAN BIOSYNTHESIS

DRUG METABOLISM CYTOCHROME P450

AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM

DRUG METABOLISM OTHER ENZYMES

GLYCOSAMINOGLYCAN DEGRADATION

BIOSYNTHESIS OF UNSATURATED FATTY ACIDS
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ssGSEA was used to generate enrichment scores for each of the 8 OXPHOS-related gene sets in
the 15 melanoma cell lines. The OP-Index was calculated by taking the arithmetic mean of these
enrichment scores for each sample. The mean baseline oxygen consumption rate (OCR) of 3
readings was calculated from the XF Assay data. Z-scores were generated for the OP-Indices and
mean OCR values across the 15 samples to determine the correlation between OP-Index and OCR.
Clustering analyses and principal components analysis (PCA) of clinical FFPE
samples. Values from the 8 components of the OP-Indices of MBMs or primary tumors were
median centered. Hierarchical clustering was conducted with distances calculated using Euclidean
correlation metrics and clusters joined using complete linkage. PCA analysis was performed using
“SVD with imputation.” The heatmaps and PCA plots were generated via ClustVis
(https://biit.cs.ut.ee/clustvis/).
ESTIMATE analyses. The R package software ESTIMATE was applied as previously
described (189) to the TMM-normalized, voom-transformed log2(CPM+0.5) expression matrices
to produce the ImmuneScores for comparison.
MCP-Counter analyses. The R package software MCP-counter was applied as previously
described (190) to TMM-normalized, voom-transformed log2(CPM+0.5) expression matrices to
produce the abundance scores for T-cells, CD8+ T-cells, cytotoxic lymphocytes, NK cells, B
lymphocytes, monocytic lineage cells, myeloid dendritic cells, and neutrophils.

2.12 – In vivo Metabolic Tracing Studies

Tumor implantation and infusions. 3x103 luciferase-tagged A375 cells suspended in
HBSS were directly implanted in the brain parenchyma of CD-1 nude mice (female, 8 weeks of
age). 3x106 cells suspended in HBSS were subcutaneously injected into the flanks of CD-1 nude
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mice of the same cohort. Infusions occurred when mice bearing ICr xenografts lost 15% of body
weight or when SQ tumors reached 250 mm3 in size. Mice were fasted for 16 hours, and 27 gauge
catheters were placed in the lateral tail vein under anesthesia. Isotope infusions started
immediately after implantation of the catheter and continued for approximately 3 hours, also
under anesthesia, as previously described (191). The total dose of [U-13C]-glucose (Cambridge
Isotope Laboratories) was 2.48 g/kg dissolved in 750 ml normal saline. The glucose solution was
administered as a bolus of 125 mL/min (1 min) followed by a continuous rate of 2.5 mL/min for
3 hours. Animals were euthanized at the end of the infusion. Tumors were harvested, rinsed briefly
in cold saline, and frozen in liquid nitrogen. Samples were stored at -80°C until analysis at the
University of Texas Southwestern Metabolomics Facility.
Sample preparation and data acquisition. 15-25 mg of frozen tissue fragments were
homogenized in 1 mL of 80% methanol on ice by a polytron electronic homogenizer and then
centrifuged at 16,000xg for 15 min. to precipitate tissue debris. The supernatants were completely
dried down under air flow, re-suspended in 40 uL of anhydrous pyridine with 10 mg/mL
methoxyamine hydrochloride and subjected to a 70°C heatblock for 15 min. Samples were then
transferred to gas chromatography-mass spectrometry (GC-MS) autoinjector vials containing 80
uL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) derivatization reagent
and incubated at 70°C for 1 hour. 1 uL of each this sample was injected into an Agilent 7890 Gas
Chromatograph coupled with an Agilent 5975C Mass Selective Detector. The observed
distributions of mass isotopologues were corrected for natural abundance. Steady-state metabolic
fluxes were calculated by 13C mass isotopologue distributions (MIDs) for 3-phosphoglycerate,
phosphoenolpyruvate, pyruvate, lactate, citrate, malate, and fumarate using the INCA software
package with previously characterized assumptions (191).
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2.13 - Targeted Metabolomics

Tumor implantation and sample collection. 3x103 luciferase-tagged A375 cells and 1x104
luciferase-tagged CHL1 cells suspended in HBSS were directly implanted in the brain
parenchyma of CD-1 nude mice (female, 8 weeks of age). 3x106 luciferase-tagged A375 cells and
CHL1 cells suspended in HBSS were subcutaneously implanted in the flanks of CD-1 nude mice
of the same cohort. Mice with ICr tumors were euthanized once moribund. Mice with SQ tumors
were euthanized once tumors reached 250 mm3. Tumors were harvested, rinsed briefly in cold
saline, and frozen in liquid nitrogen.
Reagents and internal standards. High-performance liquid chromatography (HPLC)grade ammonium acetate, acetonitrile, methanol, chloroform, and water were procured from
Burdick & Jackson. Mass spectrometry-grade formic acid was purchased from Sigma-Aldrich.
Metabolites and internal standards were purchased from Sigma-Aldrich.
Sample preparation for mass spectrometry and metabolomics analysis. Tissues samples
were stored at -80°C until the analysis at the Baylor College of Medicine Metabolomics Core. 25
mg of tissue was homogenized in 1:4 ice cold water:methanol mixture containing equimolar
mixture of 2 standard compounds: Zeatine and [15N]-Tryptophan (mass difference from
endogenous Tryptophan = 1 Da). Ice-cold chloroform and water were added in a 3:1 ratio for a
final proportion of 1:4:3:1 water:methanol:chloroform:water. Both the organic and aqueous layers
were transferred into a new tube, dried, and resuspended with 50:50 methanol:water. The
resuspended sample was then deproteinized using a 3kDa molecular filter (Amicon ultracel-3K
Membrane; Millipore Corporation) and the filtrate was dried under vacuum (Genevac EZ-2plus;
Genevac). Prior to mass spectrometry, the dried extracts were re-suspended in 1:1 ratio of
methanol and water and were subjected to liquid chromatography-mass spectrometry (LC-MS).
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Separation of metabolites. Two different analytical methods were used for the separation
of targeted metabolomics to measure 46 metabolites. ESI positive mode was used for Method 1.
The HPLC column Waters X-bridge Amide 3.5 µm, 4.6 x 100 mm (PN: 186004868; Waters) was
used. Mobile phase A and B were 0.1% formic acid in water and acetonitrile, respectively.
Gradient: 0-3 min-85 % B; 3-12 min-30 % B, 12-15 min-2 % B, 16 min-95% B, followed by reequilibration at the end of the gradient 23 min to the initial starting condition 85% B. Flow rate:
0.3 mL/min. ESI negative mode was used for Method 2. The HPLC column used was Waters Xbridge Amide 3.5 µm, 4.6 x 100 mm (PN: 186004868; Waters). Mobile phase A and B were 20
mM ammonium acetate in water with pH 9.0 and 100% acetonitrile, respectively. Gradient: 0-3
min-85% B, 3-12 min-30% B, 12-15 min-2% B, 15-16 min-85% B followed by re-equilibration
at the end of the gradient 23 min to the initial starting condition of 85% B. Flow rate: 0.3 mL/min.
Data acquisition through LC-MS analysis. LC-MS was performed using a 6490 triple
quadrupole mass spectrometer coupled to an Agilent 1290 series HPLC system (Agilent
Technologies) with single reaction monitoring (SRM). This LC system is equipped with a
degasser, binary pump, thermostatted auto sampler, and column oven. This SRM-based
measurement of relative metabolite levels used normal phase chromatographic separation. 10 µL
of suspended samples were injected and analyzed using source parameters as follows: Gas
temperature - 250°C; Gas flow - 14 L/min; Nebulizer - 20 psi; Sheath gas temperature - 350°C;
Sheath gas flow - 12 L/min; Capillary - 3000 V positive and 3000 V negative; Nozzle voltage 1500 V positive and 1500 V negative. Approximately 8-11 data points were acquired per each
detected metabolite.
Data analysis. Agilent MassHunter Workstation Software - Quantitative Analysis was
used for manual review of chromatograms, and peak area integration was assessed based on the
retention time. The normalization of each metabolite peak area was done by the peak area of the
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spiked internal standard (L-zeatine for amino acids and L-tryptophan for fatty acids and TCA
cycle metabolites) and then the data was log2-transformed. For every metabolite in the normalized
dataset, paired Student’s t-tests were conducted to compare expression levels between ICr and SQ
tumors. Differential metabolites were identified by adjusting the p-values for multiple testing at a
False Discovery Rate (FDR) threshold of <0.25. All metabolites significantly upregulated in ICr
xenografts (log2FC>0 and FDR q-val<0.25) were uploaded into MetaboAnalyst 4.0
(http://www.metaboanalyst.ca/). The Pathway Analysis tool set to default settings was used to
perform overrepresentation analysis (ORA) of the significantly upregulated metabolites, as
previously described (192).

2.14 - Reverse Phase Protein Array (RPPA) Analysis

Protein extraction. Lysis buffer and 4x SDS sample buffer supplemented with βmercaptoethanol (Sigma) were prepared according to protocols established by the MD Anderson
Functional Proteomics Core. 15-25 mg of frozen tissue fragments were weighed and added to 2
ml tubes with ceramic beads in preparation for homogenization. Ice-cold lysis buffer was added
to samples at a volume of 1 ml/40 mg of tissue. A Procellys homogenizer housed in a 4°C cold
room was set to program 1 for sample homogenization. Lysates were centrifuged at 4°C for 15
minutes at 14,000 rpm. Supernatants were transferred to fresh microcentrifuge tubes kept on ice.
Protein concentration was determined via BCA reaction according to the instructions from Pierce
BCA Protein Assay Kit. Concentration was adjusted to 1.5 ug/ul with additional lysis buffer. Cell
lysate was mixed with 4x SDS + β-mercaptoethanol sample buffer at 3 parts lysate + 1 part sample
buffer. The samples were boiled at 95°C for 5 minutes and stored at -80°C until further processing.
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A detailed description of the RPPA method (including antibodies available for xenograft tissues)
and data normalization is available at the core facility’s web page.
Analysis. Normalized data provided by the core was utilized for all downstream analysis.
Generalized linear models were used for differential expression analysis (185). Blocking was
performed to account for differences in cell line identity. Comparisons of interest were performed
using functions from the limma Bioconductor packages in R (v3.3.3).

2.15 - Microarray Analyses

Datasets. Preprocessed and normalized Affymetrix Human Exon 1.0 ST Array
(GSE34970 and GSE44660), Illumina HumanHT-12 WG-DASL Array V4.0 (GSE60464), and
Agilent Human HEEBO 44K array (GSE23601) datasets were downloaded from GEO.
OP-Index calculations. OP-Indices were calculated as described for RNA-seq data using
normalized expression matrices as the initial input.
Pathway analysis. GSEA was performed on GSE34970, GSE44660, and GSE60464 using
the GenePattern modules GSEA (v19.0.25) and normalized expression matrices as the initial
input. Parameters used for the analyses were as follows. The MSigDB Hallmarks gene set
collection and the aforementioned 70-member KEGG metabolism gene set collection were used
for running GSEA. 1000 permutations were used to calculate statistical significance, and
permutation type was set to “gene_set” in analyses with less than 7 samples per group. All basic
and advanced fields were set to default for GSE44660 and GSE60464 samples while the “Metric
for ranking genes” was set to “log2_Ratio_of_Classes” for GSE34970 samples. GSEAPreranked
(v6.0.10) was used to perform pathway analysis for GSE23601. Rank metric was calculated as
the average log2-FCs of replicates included in each analysis.
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2.16 – Bioenergetics Stress Test

A Seahorse XFe96 Bioanalyzer (Agilent) was used according to the manufacturer’s
instructions. Briefly, cells were plated in a 96-well Seahorse XF Cell Culture Microplate at a
density of 25,000/well in 100 ul of the appropriate cell culture growth media ± inhibitor and
incubated for 12-16 hours at 37°C under 5% CO2. Media was then removed and replaced with
minimal, unbuffered DMEM media supplemented with 5 mM glucose, 1 mM pyruvate, and 2 mM
glutamine ± inhibitor for a 1-hour CO2-free incubation at 37°C. For Mito Stress Test, basal
oxygen consumption rate (OCR) was recorded prior to stimulation with 1.5 µM oligomycin, 0.5
µM FCCP, and 0.5 µM rotenone/antimycin A. 3 cycles of 2-min mixes, 2-min wait times, and 3min measure times were performed.

2.17 - In vivo Pharmacodynamics (PD) Studies

IACS-010759. CD-1 nude mice bearing human ICr xenograft tumors or RCAS-TVA
model mice bearing BrafV600E;Cdkn2a-/-;Pten-/-;myrAkt1 primary tumors were treated with vehicle
or IACS-010759 (5-7.5 mg/kg p.o. once daily). After 24 hours, 72 hours, or 7 days, the mice were
intraperitoneal-injected with 60 mg/kg of pimonidazole and given one final treatment. Three hours
after this treatment, tumors were harvested and fixed in 10% formalin. FFPE slides of these tumors
were generated and probed with a combination of the following: anti-pimonidazole (marker of
hypoxia), anti-P-S6 (marker of mTOR pathway activation), anti-ki67 (marker of proliferation), or
anti-cleaved caspase 3 (marker of apoptosis) antibody, as described previously (178).
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BRAFi and mTORC1/2i. CD-1 nude mice bearing human ICr xenograft tumors were
treated with vehicle, dabrafenib (30 mg/kg p.o. once daily), or AZD2014 (20 mg/kg p.o. once
daily). On day 3 (dabrafenib and vehicle) or day 7 (AZD2014 and vehicle), mice were given one
final treatment. Three hours after this treatment, tumors were harvested and fixed in 10% formalin.
FFPE slides of these tumors were generated and probed for P-ERK (marker of MAPK pathway
activation) and P-S6 (marker of mTOR pathway activation), as previously described (3).

2.18 - Metastasis Studies

RCAS-TVA

model

studies.

Primary

tumors

were

generated

in

Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox mice using RCAS:myrAkt1 and RCAS:Cre retroviruses
as previously described (179). Upon detection of a primary tumor, mice were gavaged once daily
with 0.5% methylcellulose vehicle control or IACS-010759 (7.5 mg/kg) until the experimental
endpoint. Body weights and tumor volumes were recorded every 3 days. A full necropsy was
performed on all mice following euthanasia. Brain, lung, and primary tumor tissues were fixed in
formalin overnight, dehydrated in 70% ethyl alcohol, and paraffin embedded. Sections were
stained with hematoxylin and eosin (H&E) for review by a pathologist. A rate-based
tumor/control (T/C) metric was used to compare growth in primary tumors treated with IACS010759 vs. those treated with vehicle control (193).
Experimental metastasis studies. 2.5x106 duel luciferase/GFP-tagged YUMM5.2 cells
were injected into the left cardiac ventricle of 5 C57BL/6 mice (female, 8 weeks of age). Brain
metastasis was confirmed by BLI. Animals were sacrificed once the mice were moribund. The
brain with the greatest BLI signal was dissociated with collagenase type I (200 units/ml) and
DNase (270 units/ml) to form single cell suspensions, as previously described (194). A purified
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population of cells was acquired via GFP+ cell sorting (performed on the FACSAria Fusion Cell
Sorter with assistance from the MDACC South Campus Flow Cytometry Facility). To increase
the brain‐seeking capacity of the brain‐metastasizing variants, cells were passaged in the brain for
three successive passages yielding brain metastasis variants (Br1, Br2, and Br3). All of these
variants were established as cell lines but only the YUMM5.2-Br3 cell line was used for
metastasis studies. To determine if inhibition of OXPHOS diminishes CNS metastatic potential,
YUMM5.2-Br3 cells were treated in vitro with IACS-010759 (100 nM) or with vehicle control
for 12 hours. 2.5x106 cells were then injected into the left cardiac ventricles of C57BL/6 mice
(female, 8 weeks of age). Mice injected with the cells treated in vitro with vehicle were
randomized to receive either 0.5% methylcellulose vehicle control (once daily) or IACS-010759
(7.5 mg/kg once daily) via oral gavage. In parallel, mice injected with cells treated in vitro with
IACS-010759 were randomized to receive either 0.5% methylcellulose vehicle control (once
daily) or IACS-010759 (7.5 mg/kg once daily) via oral gavage. In vivo treatments began 3 hours
after cardiac injections. After 14 days, mice were injected with 150 mg/kg D-luciferin salt and
euthanized 10 min later for ex vivo BLI analysis to evaluate organ involvement in detail. Brains
were fixed in formalin overnight, dehydrated in 70% ethyl alcohol, and paraffin embedded.
Sections were stained with H&E for review by a pathologist.
Effect of pharmacological OXPHOS inhibition on intracranial tumor growth. 1x103
luciferase-tagged A375-R1 cells suspended in HBSS were directly implanted in the brain
parenchyma of CD-1 nude mice (female, 8 weeks of age). Mice were immediately randomized to
receive either 0.5% methylcellulose vehicle control (once daily) or IACS-010759 (5 mg/kg once
daily) via oral gavage. Mice were weighed every two days and underwent BLI every week. Mice
that progressed to 20% weight loss were euthanized. Additionally, mice were euthanized once
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moribund or upon displaying neurological symptoms (ataxia, seizures, circling behavior,
paralysis, or cranial doming).
PGC1α knockdown studies. 1x104 A375P cells and 2x104 G361 cells stably transfected
with shRNA against PGC1α (shPGC1α) and their scrambled controls (shScr) suspended in HBSS
were directly implanted in the brain parenchyma of CD-1 nude mice (female, 8 weeks of age).
Mice were weighed every two days. Mice that progressed to 20% weight loss were euthanized.
Additionally, mice were euthanized once moribund or upon displaying neurological symptoms
(ataxia, seizures, circling behavior, paralysis, or cranial doming). In parallel, 3x106 shScr and
shPGC1α A375P and G361 cells were injected subcutaneously into mice from the same cohort.
Tumors were measured using a digital caliper every 3 days for a total of 28 days. The greatest
longitudinal diameter (length or “L”) and the greatest transverse diameter (width or “W”) were
recorded. Tumor volume was calculated as [(LxW2)/2].

2.19 - Efficacy Studies

IACS-010759 monotherapy. 1x103 luciferase-tagged A375-R1 cells and 2x104 SKMEL5
cells suspended in HBSS were directly implanted in the brain parenchyma of CD-1 nude mice
(female, 8 weeks of age). After 3 days (A375-R1) and 14 days (SKMEL5), mice were randomized
to receive either 0.5% methylcellulose vehicle control (once daily) or IACS-010759 (5 mg/kg
once daily) via oral gavage. Mice were weighed every two days. Mice with 15% weight loss were
provided with a single intraperitoneal injection of normal saline [mL = (0.06 x weight in g)/2] and
placed on a drug holiday. Mice that recovered to less than 10% weight loss restarted their
treatment regimen while those that progressed to 20% weight loss were euthanized. Additionally,
mice were euthanized once moribund or upon displaying neurological symptoms (ataxia, seizures,
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circling behavior, paralysis, or cranial doming). A375-R1 treatments were designed to end 42
days after randomization while SKMEL5 treatments ended 42 days or 80 days after
randomization.
IACS-010759+BRAFi. 1x103 luciferase-tagged A375 and A375-R1 cells and 2x104
SKMEL5 cells suspended in HBSS were directly implanted in the brain parenchyma of CD-1
nude mice (female, 8 weeks of age). After 3 days (A375-R1) and 14 days (A375 and SKMEL5),
mice were randomized into 4 treatment arms: vehicle, IACS-010759 (5 mg/kg p.o. once daily),
dabrafenib (30 mg/kg p.o. once daily), and IACS-010759 (5 mg/kg p.o. once daily) + dabrafenib
(30 mg/kg p.o. once daily). Mice were weighed every two days and were euthanized once
progressing to 20% weight loss. Additionally, mice were euthanized once moribund or upon
displaying neurological symptoms (ataxia, seizures, circling behavior, paralysis, or cranial
doming). Treatments ended 60 days after randomization. Brains were harvested from two A375
ICr mice progressing on vehicle treatments and two A375 ICr mice progressing on dabrafenib
treatments. Collagenase type I (200 units/ml) and DNase (270 units/ml) were used to form single
cell suspensions, as previously described (194). A purified population of cells was acquired via
treatment with 2 ug/ml puromycin (previously confirmed to kill all untransfected A375 cells after
72 hours).
Metformin+anti-PD1. 5x103 luciferase-tagged B16-F10 cells suspended in HBSS were
directly implanted in the brain parenchyma of C57BL/6 mice (female, 8 weeks of age). After 5
days, tumor uptake was confirmed via BLI and mice were randomized into 4 treatment arms:
isotype control (200 ug i.p. 3x/week) + PBS (10 ul/g body weight i.p. every other day), anti-PD1
(200 ug i.p. 3x/week) + PBS (10 ul/g body weight i.p. every other day), isotype control (200 ug
i.p. 3x/week) + metformin (50 mg/kg i.p. every other day), and anti-PD1 (200 ug i.p. 3x/week) +
metformin (50 mg/kg i.p. every other day). Mice were weighed every 2 days and were euthanized
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once progressing to 20% weight loss. Additionally, mice were euthanized once moribund or upon
displaying neurological symptoms (ataxia, seizures, circling behavior, paralysis, or cranial
doming). Treatments were designed to end 42 days after randomization.
CB839 monotherapy. Cell proliferation inhibition was determined using Cell Titer Blue
(Promega), as previously described (3). Subsequently, 1x103 luciferase-tagged A375-R1 and
1x104 MEL624 cells suspended in HBSS were directly implanted in the brain parenchyma of CD1 nude mice (female, 8 weeks of age). After 7 days, tumor uptake was confirmed via BLI, and
mice were randomized into 2 treatment arms: vehicle and CB839 (200 mg/kg p.o. twice daily).
Mice were weighed every 2 days and were euthanized once progressing to 20% weight loss.
Additionally, mice were euthanized once moribund or upon displaying neurological symptoms
(ataxia, seizures, circling behavior, paralysis, or cranial doming). Treatments were designed to
end 42 days after randomization.

2.20 - qRT-PCR Analysis

cDNA synthesis. 1000 ng of RNA was used to synthesize the first strand of cDNA using
the High Capacity cDNA Archive kit (Applied Biosystems) following standard ABI Protocol.
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qRT-PCR. Inventoried TaqMan assays were purchased from Life Technologies
[Mm00443258_m1

(Tnf),

Mm00812512_m1

Mm00442837_m1

(Gzmb),

Mm01182107_g1

Mm00434946_m1

(Cxcl9),

Mm00492586_m1

(Prf1),
(Cd8a),
(Ido1),

Mm01168134_m1
Mm00445235_m1
Mm00439531_m1

(Ifng),
(Cxcl10),
(Stat1),

Mm01208835_m1 (Ppargc1a), Mm00499674_m1 (Idh3a), Mm01250094_m1 (Cox4i1),
Mm05874166_g1 (Ldhb), and Mm01165335_m1 (Ndufa5)]. All qRT-PCR reactions were
performed using the 7900HT Fast Real-Time PCR system and Taqman gene expression master
mix (Applied Biosystems) with a standard cycling program of 40 cycles at 95 °C for 15 s and at
60 °C for 1 min. All reactions were run in duplicate and normalized to human 18S
(Hs99999901_s1). Data was analyzed using the 2-ΔΔCT method.

2.21 - Immunohistochemistry (IHC) of Clinical Samples

All IHC studies were performed on 5 µm FFPE sections using a Leica BOND RXm
autostainer. Slides were stained with antibodies targeting human P-S6 (Cell Signaling #4858,
1:100) and P-PRAS40 (Cell Signaling #13175, 1:200) using a modified version of either the
standard Leica Bond DAB “F” or red “J” IHC protocols. Slides were scored by a pathologist and
given an H-score based on percentage and intensity of positivity.

2.22 - Statistical Analyses

Overall survival analyses. Overall survival (OS) was defined as the time interval from
date of craniotomy (clinical samples) or treatment initiation (mouse studies) to date of death or
censoring from any cause. Survival duration was analyzed by the Kaplan-Meier method. Survival
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curves were drawn in Prism 7.0 (Graphpad). Hazard ratios and significance were calculated via
the Mantel-Haenszel test and log-rank test, respectively, in Prism 7.0 (Graphpad).
Additional analyses. Data analyses and representations were performed either with the R
(v3.3.3), Microsoft Excel 2013, or Prism 7.0 (GraphPad). Comparison of continuous variables
between two groups was performed by unpaired or paired Student’s t-test. The Perason correlation
coefficient was calculated to assess correlation between continuous variables. To control for
multiple hypothesis testing, we applied the Benjamini-Hochberg method. Lastly, all statistical
significance testing was two-sided at Type-I error rate of 0.05 except where specifically noted in
relevant figure legends.
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3.1 - INTRODUCTION

3.1.1 - Impact of the Tumor Microenvironment on Tumor Metabolism

While it is most convenient to classify melanomas as either glycolytic or oxidative, an
increasing body of evidence suggests that metabolic phenotypes of tumors are more accurately
viewed as dynamic in nature (11). While key oncogenic pathways implicated in melanomas
(RAS-RAF-MAPK and PI3K-AKT) typically promote glycolysis, this metabolic pathway
requires an extensive supply of glucose to fuel reactions. Tumor cells are not equally supplied
with oxygen and nutrients due to inadequate vascularization, and frequently they must adapt to
hypoxia and to glucose deprivation (11). In the presence of adequate glucose, hypoxic melanoma
cells almost completely decouple glycolysis from the tricarboxylic acid (TCA) cycle (10).
Glutamine then fuels the TCA cycle and provides citrate for fatty acid synthesis. Despite the
uncoupling of glycolysis and the TCA cycle, glutamine and glucose oxidation continue to produce
significant ATP for the cell because of the efficiency of oxidative phosphorylation (OXPHOS)
relative to glycolysis (10). Alternative pathways such as glutamine and fatty acid oxidation (FAO)
are essential in glucose-depleted conditions. For example, adipocytes in the tumor
microenvironment (TME) can communicate with melanoma cells via exosomes carrying proteins
involved in FAO (195). Upon uptake by melanoma cells, via an uncharacterized mechanism, these
exosomes force a metabolic reprogramming in melanoma cells characterized by high levels of
FAO and aggressiveness (195).
In recent years, the role of autophagy and macropinocytosis in promoting survival of
melanoma cells in hostile microenvironments has gained considerable interest. Autophagy is a
highly regulated process that involves the degradation of macromolecules and organelles into
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useful constituent components. In this manner, large proteins can be degraded to provide nitrogen
and carbon for bioenergetic maintenance. MEK/ERK signaling in melanoma upregulates phorbol12-myristate-13-acetate-induced protein 1 (NOXA), which promotes an increase in autophagy
through cAMP responsive element binding protein (CREB) (196, 197). NOXA-driven autophagy
delays the apoptosis of human melanoma cells in nutrient-depleted conditions (196). Furthermore,
autophagy provides a survival advantage to melanoma cells cultured in harsh, acidic conditions
(197, 198). In addition to autophagy, a variety of tumor types utilize macropinocytosis to scavenge
extracellular nutrients when grown in harsh conditions (12). Macropinocytosis can supply tumor
cells with necessary nitrogen and carbon (12, 199). In melanoma, hyperactive PI3K-AKT
pathway signaling drives macropinocytosis so efficiently that the cells require activation of Rasrelated protein Rab-7 (RAB7) to clear the vesicles taken into cells before a form of cell death
called methuosis occurs (200). In scenarios of widespread nutrient starvation, the ratio of ATP to
AMP declines, stimulating the LKB1-AMPK axis to suppress mTOR-mediated anabolic
processes and to stimulate autophagy and macropinocytosis (12).
Directly in contrast with the Warburg effect, the reverse Warburg effect was originally
proposed by Pavlides et al. in 2009. In this model, tumor cells and surrounding stromal cells
engage in a symbiotic relationship where tumor cells corrupt caveolin-1-deficient cancer
associated fibroblasts (CAFs) via secretion of hydrogen peroxide. Mitochondrial activity in the
CAFs is inhibited, forcing the cells to depend exclusively on glycolysis. These cells secrete lactate
into the TME via Monocarboxylate transporter 4 (MCT4), which tumor cells take up via
Monocarboxylate transporter 1 (MCT1) to fuel oxidative metabolism (201-203). While this
model originally was described in breast cancer, similar tumor-stroma interactions have been
demonstrated in a variety of other cancers, including oral squamous cell carcinoma and
osteosarcoma (204, 205). Though this model could offer novel therapeutic approaches via
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disruption of lactate shuttling, it remains to be investigated in melanoma, as does the concept of
metabolic symbiosis. Similar to the reverse Warburg effect, this version of lactate shuttling
involves hypoxic glycolytic tumor cells secreting lactate into the TME via MCT4, which oxidative
tumor cells uptake via MCT1 and utilize for energy. Interestingly, Ho et al. demonstrated that
increased expression of MCT1 and MCT4 correlate with melanoma progression (206). This
finding suggests that metabolic symbiosis could play a role in melanoma progression and
represents a potential therapeutic opportunity. For example, inhibition of MCT1 in a mouse model
of lung carcinoma resulted in oxygenated cells switching to glycolysis for ATP production. As a
result, hypoxic tumor cells died secondary to glucose starvation (207).
Studies in other cancer types have provided numerous insights into the role of the TME in
shaping tumor cell metabolism. For example, Smolkova et al. demonstrated that 4 days of glucose
deprivation completely reprogrammed HTB-126 breast cancer cells, significantly elevating
OXPHOS to compensate for aglycemia (208). Mitochondria are actually able to function at
oxygen concentrations as low as 0.5%, allowing this flexibility to occur even under hypoxic
conditions (12, 209, 210). The LKB1-AMPK-PGC1α signaling axis stimulates OXPHOS in these
scenarios (208). Redox balance is maintained through one-carbon metabolism, cytoplasmic malic
enzyme, and isocitrate dehydrogenase 1/2 (IDH1/2)-mediated production of NADPH (12).
Metabolic flexibility allows tumor cells to survive inhibition of a single metabolic pathway and
provides a survival advantage necessary for survival in harsh TMEs (211, 212). Furthermore, this
metabolic flexibility has complicated attempts to target single metabolic pathways as a therapeutic
strategy. However, targeting glycolysis and OXPHOS via simultaneous treatment with the
electron transport chain complex I inhibitor metformin and the lactate dehydrogenase (LDH)
inhibitor oxamate has produced promising results, significantly inhibiting B16-F10 tumor growth
in C57BL/6 mice (213).
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To date, no studies have attempted to understand the effect of the brain tumor
microenvironment on melanoma cell metabolism. Interestingly, Chen et al.’s breast cancer
metastasis study provides potential insights into this topic (211). The authors acquired circulating
tumor cells from a metastatic breast cancer patient and derived brain-metastatic and bonemetastatic variants of these cells via in vivo selection in immunodeficient mice. The brainmetastatic cells underwent significant adaptations to survive in the brain TME. Specifically, they
upregulated expression of enzymes involved in glycolysis, TCA cycle, and OXPHOS relative to
both parental cells and the bone-metastatic cells. Importantly, these cells maintained this
phenotype in vitro. These findings strongly suggest that the brain TME poses unique metabolic
challenges and selects metastatic cells inherently enriched in OXPHOS.

3.1.2 - Hypothesis Tested

Our recent RNA-seq analysis of 35 MBMs and 42 patient-matched ECMs identified 494
genes that were differentially expressed between the MBMs and ECMs (174). Focused pathway
analyses for the expression of 70 different metabolic gene networks demonstrated that OXPHOS
was the most significantly enriched metabolic pathway in MBMs. This expression profile could
be the result of the brain TME selecting cells inherently enriched in OXPHOS or from adaptation
of tumor cells to the brain TME. A previously published analysis of experimental breast cancer
brain metastasis indicated that the brain TME selects cells inherently enriched in OXPHOS for
colonization and outgrowth compared to melanoma cells that metastasize to other distant sites
(211). Thus, we tested the hypothesis that OXPHOS enrichment in MBMs results from
improved efficiency of melanoma cells with increased OXPHOS to form metastases at this
site in the body.
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3.2 – RESULTS

3.2.1 – Oxidative Phosphorylation Levels Do Not Predict Brain Tropism in Metastatic
Melanoma

We hypothesized that OXPHOS levels differ between primary melanomas that
metastasize to the brain compared to primary melanomas that metastasize exclusively to other
distant sites. To test this hypothesis, we performed RNA-seq analysis of primary melanomas from
patients that developed an MBM within 3-18 months of initial diagnosis (n=19) and patients that
developed metastases at sites other than the brain within 3-18 months of initial diagnosis (n=16).
We calculated OXPHOS-Indices (OP-Indices) for all samples and performed hierarchical
clustering to elucidate if samples would cluster by site of distant metastasis. However, we did
not observe any identifiable clustering pattern (Figure 6A). Significant heterogeneity was
observed in both groups of samples. To confirm these observations, we performed principal
components analysis (PCA) of the samples. Samples failed to cluster by site of distant
metastasis. Instead, groups significantly overlapped with each other (Figure 6B). Additionally,
we again observed marked variability within groups. Subsequent preranked gene set
enrichment (GSEA-P) analysis demonstrated no significant difference in KEGG OXPHOS gene
set expression between these two groups of samples (FDR q-val=0.516) (Figure 6C), and direct
comparison of OP-Indices failed to identify a significant difference between the groups
(p=0.5513) (Figure 6D). Finally, we pooled samples and divided them into tertiles based on OPIndices. Patients with high OP-Indices (highest tertile) had comparable brain metastasis-free
survival as patients with low OP-Indices (lowest tertile) (Figure 6E). Together, these results
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indicate that our observed OXPHOS enrichment in MBMs vs. ECMs was unlikely due to primary
tumors highly enriched for this metabolic program metastasizing to the brain more efficiently than
other primary tumors.
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Next, we evaluated publicly available Illumina microarray data (GSE60464) from
extracranial metastases of stage IV patients with cerebrotropism (developed brain metastases
within 6 months of initial stage IV disease diagnosis; n=17) and stage IV patients without
cerebrotropism (did not develop brain metastases within 18 months of initial stage IV diagnosis;
n=25) (129). GSEA determined that OXPHOS gene set expression was not significantly different
between groups (Figure 7A-B).
However, we recognized the possibility that bulk gene expression studies of primary
tumors and extracranial metastases might have failed to identify subclones highly enriched in
OXPHOS that efficiently metastasize to the brain but do not comprise the majority of cells in the
analyzed specimens. Thus, we downloaded publicly available Affymetrix microarray data
(GSE44660) for cell lines generated from surgically resected melanoma lymph node metastases
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(LNMs; n=12), and MBMs (n=7) (214). Lymph node specimens from patients with poor
prognosis (n=3) were excluded from this analysis to avoid the interference of gene expression

associated with distant organ metastasis – including undiagnosed MBMs - that may be present in
LNMs from patients with poor prognosis. We reasoned that if the brain TME selects for rare
subclones inherently more enriched in OXPHOS than cells that metastasize to other sites, cell
lines derived from brain metastases should express OXPHOS genes at significantly higher levels
than cell lines derived from LNMs. However, we observed no significant differences in OPIndices between the groups (p=0.5828) (Figure 8A). Additionally, GSEA of the KEGG OXPHOS
gene set demonstrated no significant enrichment of OXPHOS in MBM-derived cell lines vs.
LNM-derived cell lines (FDR q-val=0.738 ) (Figure 8B).
To confirm our findings, we downloaded publicly available Agilent microarray data from
a preclinical model of spontaneous melanoma brain metastasis (GSE23601) (116) and compared
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gene expression profiles from two variants of the human melanoma cell line WM239 (named
WM239_BM1 and WM239_BM2) which metastasize spontaneously to the brain after
implantation into the subcutaneous tissue and a variant that spreads to sites other than the brain
(WM239_ECM). GSEA-P demonstrated no significant enrichment of the KEGG OXPHOS gene
set in the brain-metastatic variants vs. the variant that metastasizes to non-CNS sites (Figure 9).

Cumulatively, these results disprove our initial hypothesis that OXPHOS enrichment in
MBMs vs. ECMs can be explained via selection of cells inherently more enriched in OXPHOS
genes than cells that metastasize to other sites. Instead, our findings suggest that the brain TME
facilitates OXPHOS gene expression to a significantly greater extent than other organs.
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3.2.2 - The Brain Tumor Microenvironment Induces Oxidative Phosphorylation in
Metastatic Melanomas

3.2.2a – Transcriptomics Studies Verify Increased Expression of Oxidative
Phosphorylation Genes in Melanoma Cells Growing in the Brain Compared to
Subcutaneous Tissue

To test the effect of the brain TME on OXPHOS gene expression, we implanted
A375

(BRAFV600E/wt),

(NRASQ61R/Q61R),

and

A375-R1
MEWO

(BRAFV600E/wt;MEKF129L/wt)

(BRAFwt/wt;NRASwt/wt)

human

(3),

WM1361A

melanoma

cells

intracranially (ICr) and subcutaneously (SQ) in CD-1 nude mice (Figure 10). Tumors
were harvested when mice became moribund or SQ tumors reached 250 mm 3. RNAseq was performed on RNA isolated from dissected tumor tissue, and Xenome (183)
was used to further discern gene expression signatures from the tumor (human) RNA .
Data was pooled following correction for cell line-intrinsic differences. GSEA-P of this
dataset identified OXPHOS as the most enriched KEGG metabolic pathway in the ICr
xenografts (Figure 11A). Additionally, anatomical locations were compared within
each model, and GSEA-P analysis established OXPHOS as the KEGG metabolism gene
network most enriched in the ICr xenografts from all of the models (Figure 11B-E).
Together, these results confirm that the brain TME is sufficient to induce transcription
of OXPHOS genes.
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3.2.2b - Metabolomics Analyses Confirm Increased Oxidative Phosphorylation in
Melanoma Cells Growing in the Brain Compared to Subcutaneous Tissue

To directly assess the metabolism of MBMs, Low-OXPHOS A375 and CHL1
(BRAFwt/wt;NRASwt/wt) human melanoma cells were implanted into the brains and SQ
tissue of CD-1 nude mice. Liquid chromatography-mass spectrometry (LC-MS) analysis
of metabolites collected from the ICr and SQ xenografts demonstrated significantly
higher concentrations of individual tricarboxylic acid (TCA) cycle metabolites in ICr
vs. SQ xenografts for both cell lines (Figure 12A-B). Metabolite set enrichment
analysis (MSEA) of differentially expressed metabolites (DEMs) (FDR q-val<0.25)
demonstrated significant enrichment (FDR q-val<0.05) of the TCA cycle pathway in ICr
vs. SQ xenografts for both lines (Figure 12C-D), supporting increased OXPHOS in
MBMs. To further support this finding, we implanted Low-OXPHOS A375 cells into the
brains and SQ tissue of CD-1 nude mice and performed in vivo [U-13C]-glucose tracing
studies (Figure 13A). Gas chromatography-mass spectrometry (GC-MS) analysis of the
xenografts demonstrated greater labeling of the TCA cycle metabolites fumarate (p<0.01),
malate (p<0.01), and citrate (p<0.001) in ICr vs. SQ tumors but no significant differences
in labeling patterns in glycolytic intermediates, indicating a specific increase in glucose
oxidation in ICr xenografts (Figure 13B).
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3.2.2c - Soluble Factors Secreted by the Brain Promote Oxidative Phosphorylation in
Melanoma Cells

Klein et al. isolated soluble factors from normal mouse brains and acquired
microarray data from cutaneous variants of YDFR melanoma cells (YDFR.C) grown in
vitro in the presence and absence of these brain-derived soluble factors (176). We
downloaded the microarray data (GSE34970) to further validate the role of the brain TME
in facilitating OXPHOS enrichment. Cumulative GSEA analysis of the 70 KEGG
metabolism gene sets determined that OXPHOS was the third most enriched pathway in
the YDFR.C cells grown in the presence of brain-derived soluble factors (Figure 14A).
Subsequent pathway analysis demonstrated that that the cells grown in the presence of
brain-derived soluble factors were significantly enriched in both the KEGG and MSigDB
Hallmarks OXPHOS gene set collections (FDR q-val = 0.005 and FDR q-val < 0.0001,
respectively) (Figure 14B-C). Together, these results confirm that factors present in the
brain TME are sufficient to induce significant upregulation of OXPHOS genes.
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3.2.2d - The Brain Tumor Microenvironment Activates Signaling Pathways Known to
Promote Oxidative Phosphorylation

Our lab and others have implicated mTOR signaling as a key mediator of tumor
cell oxidative metabolism (3, 40). A pooled GSEA-P analysis of the A375, A375-R1,
MEWO, and WM1361A ICr and SQ xenografts determined that OXPHOS was the most
enriched MSigDB Hallmarks pathway in ICr xenografts (Figure 15A). Interestingly,
genes regulated by mTORC1 signaling were identified as the third most enriched
MSigDB Hallmarks gene set in ICr xenografts (Figure 15A-B). Additionally, genes
induced by the PI3K-AKT-mTOR signaling axis were also significantly enriched in ICr
xenografts (Figure 15B).
To confirm these findings at the protein level, A375, A375-R1, and WM1361A
cells were implanted in the brains and SQ tissue of CD-1 nude mice. Tumors were
harvested when mice became moribund or SQ tumors reached 250 mm 3. Following
correction for intrinsic cell line differences, pooled analysis of reverse phase protein
array (RPPA) data from the samples demonstrated significant activation of the PI3KAKT and mTOR signaling pathways in ICr xenografts. Specifically, Figure 16 depicts
significant upregulation of insulin-like growth factor-1 receptor (IGF1R), P-AKT (S473
and T308), P-mTOR (S2448), P-4E-BP1 (S65), and P-70-S6K (T389).
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Additionally, compensatory upregulation of PTEN was observed. Interestingly, we
observed that the brain TME mediated profound metabolic effects at the protein level.
Significant upregulation of the succinate dehydrogenase complex flavoprotein subunit A
(SDHA) and downregulation of the glycolytic enzyme lactate dehydrogenase A (LDHA)
were observed in the ICr xenografts, indicating that these tumors increased their
mitochondrial biogenesis in lieu of producing enzymes involved in glycolysis. These
results suggest that the brain TME promotes OXPHOS in our ICr xenografts by activating
the PI3K-AKT-mTOR signaling pathway through RTKs such as IGF1R.
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To determine if PI3K-AKT-mTOR signaling associated with OXPHOS
discrepancy between surgically resected MBMs and ECMs, OP-Indices were first
compared between patient-matched, treatment (Tx)-naïve MBMs and ECMs (n=11). As
anticipated, mean OP-Index was significantly higher in the MBMs (p=0.0256) (Figure
17A). PGC1α expression correlated significantly with OP-Indices across the cohort of
samples (r2=0.45, p<0.0001) (Figure 17B). Together, these results established that
PGC1α-mediated OXPHOS was significantly enriched in the Tx-naïve MBMs vs.
patient-matched, Tx-naïve ECMs. Next, we performed immunohistochemistry to
demonstrate that P-PRAS40 and P-S6 stained significantly higher in Tx-naïve MBMs
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vs. patient-matched, Tx-naïve ECMs (p=0.0422 and p=0.015, respectively) (Figure
17C-D). However, we observed no significant difference in the incidence of complete
PTEN loss between groups (p=0.3665) (Figure 17E). Cumulatively, these results
establish a potentially meaningful association between hyperactive PI3K-AKT-mTOR
signaling and PGC1α-mediated OXPHOS enrichment in Tx-naive MBMs vs. patientmatched, Tx-naïve ECMs.

3.3 - DISCUSSION

In this study, we investigated why we previously observed significant enrichment of
OXPHOS genes in MBMs compared to patient-matched ECMs. This represents the first effort
to provide an explanation for that novel insight into the metabolism of MBMs. Based on a
previous study of experimental breast cancer brain metastasis (211), we hypothesized that
OXPHOS enrichment in MBMs resulted from improved efficiency of melanoma cells with
increased OXPHOS to form metastases at this site in the body.
Using bulk gene expression analysis methods, we compared primary tumors from patients
that developed brain metastases to primary tumors from patients that developed metastases at
other distant sites. We observed no significant differences in OXPHOS gene expression between
these groups, which strongly argues against the possibility of explaining differences in the
metabolism of MBMs and ECMs through differences in primary tumors. Likewise, OXPHOS
levels of ECMs did not associate with cerebrotropism in stage IV patients. Our subsequent
analysis of cell lines derived from surgically resected MBMs and lymph node metastases (LNMs)
demonstrated no differences in OXPHOS between groups, which excludes the possibility that the
brain TME selects subclones inherently enriched in OXPHOS compared to subclones that
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metastasize to LNs. We confirmed this finding by observing no differences in OXPHOS between
brain-metastatic WM239 variants and WM239 variants that metastasize exclusively to other
anatomical locations. Cumulatively, these studies prompted us to reject our initial hypothesis and
assess if differences between TMEs could sufficiently explain OXPHOS enrichment in MBMs.
Our initial preclinical studies sought to thoroughly characterize the effect of the TME on
the transcriptome of melanoma cells. We identified OXPHOS as the most enriched metabolic
pathway in brain xenografts from all 4 of our models and in our pooled analysis following
corrections for intrinsic cell line differences. We confirmed these observations through direct
metabolite analysis, which demonstrated significant enrichment of TCA cycle metabolites in brain
xenografts vs. subcutaneous xenografts, and via in vivo [U-13C]-glucose tracing studies, which
demonstrated that brain xenografts preferentially oxidized glucose compared to their
subcutaneous counterparts. Finally, we employed RPPA analysis to determine that the brain TME
activates the PI3K-AKT-mTOR pathway and promotes synthesis of mitochondrial proteins in lieu
of glycolytic enzymes. mTOR signaling has been implicated in mediating OXPHOS in non-CNS
melanoma metastases (3, 40). Thus, this finding provides potential mechanistic insight into how
the brain TME mediates OXPHOS enrichment compared to other anatomical sites. Of note, we
did not observe significant differences in PTEN levels between brain and subcutaneous
xenografts, despite previous studies demonstrating that the brain TME can activate the PI3KAKT-mTOR pathway via epigenetic silencing of PTEN (101). However, we observed
significantly increased levels of IGF1R in brain xenografts, which has been implicated in
mediating metastatic melanoma resistance to targeted therapies via activation of the PI3K-AKTmTOR pathway and OXPHOS (3, 215). We subsequently demonstrated PTEN-independent
activation of the PI3K-AKT-mTOR pathway in Tx-naïve MBMs vs. Tx-naïve, patient-matched
ECMs.
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This study is highly novel as it employs analysis of clinical samples and preclinical models
to provide the first detailed assessment of the brain TME’s effect on melanoma metabolism. We
ensured adequate representation of BRAF and NRAS-mutant and triple wild-type melanomas and
corrected for potential stromal contamination in our gene expression studies through our use of
the Xenome platform. Furthermore, we employed the highly novel technique of in vivo [U-13C]glucose tracing analysis to confirm our transcriptomic studies. Potential limitations of our study
include the absence of syngeneic models, which could more accurately model tumor cell/TME
interactions. Alternatively, patient-derived xenografts more accurately model tumor cell biology
in vivo and would represent a potential improvement over standard cell lines in our
immunodeficient models. Additionally, we did not analyze lesions grown in lungs and livers and
instead relied exclusively on analysis of subcutaneous tumors.
Our findings are highly clinically relevant. Previous analyses found that the brain was the
most common new site of disease progression in BRAF-mutant patients without CNS involvement
at baseline that were treated with the FDA-approved combination of dabrafenib (BRAFi) and
trametinib (MEKi) (216). Further, in the phase II COMBI-MB study of dabrafenib and trametinib
in MBM patients, 47% of patients progressed in the brain before progressing extracranially, and
the median duration of intracranial responses was ~50% shorter than that previously reported in
patients without CNS involvement (171). As our group and others have previously shown that
OXPHOS can mediate resistance to BRAFi and MEKi targeted therapies (3, 26), the finding of
increased OXPHOS in MBMs provides a potential explanation for these clinical observations.
This study provides insight into how OXPHOS becomes enriched in MBMs compared to other
sites and represents a critical step in overcoming the negative effects mediated by this metabolic
pathway.
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4.1 – INTRODUCTION

4.1.1 – Steps of the Brain Metastasis Cascade

Metastasis of cancer cells to the brain is a complex, multi-step process that involves
invasion of tissues surrounding the primary tumor; access to and survival in the lymphatic system
and bloodstream; arrest in brain capillaries and extravasation into the brain parenchyma; and
growth and survival in the brain (Table 4). Understanding the features that are critical to each of
these steps, and the drivers that support the maintenance and aggressive behavior of MBMs, will
facilitate the development of rational, more effective treatments for patients. Notably, many of
these studies suggest that MBMs have distinct characteristics that may contribute to the distinctly
poor outcomes associated with these tumors.

Table 4 - Key steps in melanoma brain metastasis formation and maintenance
Stage
Description
Growth of primary tumor

Migration/invasion of
surrounding tissues

Intravasation/spread to
regional lymph nodes
Survival in bloodstream
Arrest in brain capillary beds

Extravasation
Angiogenesis
Evasion of immune system

Genetic aberrations drive unregulated growth of transformed
melanocytes; accumulation of mutations results in creation of
subclones with increased metastatic propensity
Loss of adherence to cells in primary tumors; increased
communication with extracellular matrix and surrounding
stroma; digestion of extracellular matrix; increased cellular
motility
Acquisition of access to lymphatic vessels and growth in
regional lymph nodes, where melanoma cells typically spread
to initially
Survival in harsh environment and shear stress inherent to
circulatory system; ability to form emboli increases survival
Mechanical arrest in the capillary beds of brain; mediated by
interactions between adhesion molecules expressed on blood
vessels of brain capillaries and tumor cells
Exit from the circulatory system across the BBB; mediated by
factors able to digest tight junctions of the BBB
Acquisition of vital nutrients via formation of new blood
vessels or co-option of existing blood vessels in the brain
Evasion of immune attack facilitates tumor growth
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4.1.2 – Metabolic Pathways Implicated in Melanoma Metastasis

4.1.2a - Lactate/H+ Metabolism: A Major Contributor to Melanoma Metastasis

Produced at the end of glycolysis in order to maintain NAD+, lactate is
subsequently secreted into the tumor microenvironment (TME) via monocarboxylate
transporters (MCTs), with MCT4 as the most significant transporter (217). Pinheiro et al.
demonstrated that glucose transporter 1 (GLUT1) and MCT4 overexpression significantly
correlated with progression from primary tumor to lymph node metastasis in a cohort of
patient-derived melanoma samples, indicating that the Warburg phenotype and lactate
secretion cooperate to promote melanoma metastasis (218). In glycolytic tumor cells,
HIF1α and MYC upregulate MCT4 to promote the secretion of lactate into the TME (219,
220). Lactate drastically alters the TME, facilitating angiogenesis, promoting metastasis,
and suppressing the immune system (221). Once secreted, lactate is taken up by
surrounding endothelial cells via MCT1, where it facilitates nuclear factor kappa-lightchain-enhancer of activated B cells (NFκB), HIF1α, and interleukin-8 (IL-8) signaling,
resulting in upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and
basic fibroblast growth factor (bFGF) signaling (219, 222, 223) (Figure 18). Intracellular
protons produced via dissociation of lactic acid are secreted into the melanoma TME via
sodium-proton exchanger 1 (NHE1), lowering the pH of extracellular space (219, 224,
225). Additional membrane protein complexes, including carbonic anhydrase IX (CAIX),
sodium-bicarbonate transporter 1, and anion exchanger 2 (AE2) also contribute to
extracellular acidosis (218, 219, 226-228) (Figure 18).
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Acidification of the TME facilitates melanoma metastasis in several ways. First, a
low extracellular pH promotes the formation of collagen–integrin interactions in the
lamellipodia of melanoma cells, allowing focal adhesion complexes to form and
increasing migration of melanoma cells (219, 229). In addition, extracellular acidosis
disrupts cellular junctions through the induction of matrix metalloproteases (MMPs) 2 and
9 and cathepsins B and L, which are secreted into the TME as inactive zymogens and
require a low pH to be activated (230) (Figure 18). Rofstad et al. demonstrated that
melanoma cells grown in an acidic pH are significantly more metastatic than those grown
in normal pH and that treatment with MMP and cathepsin inhibitors prevented the
metastasis of the acid-treated cells following tail vein injection in immunodeficient mice
(230). As further evidence, inhibition of NHE1 in vitro prevented the invasive behaviors
of melanoma cells to a significantly greater extent than vehicle controls (224, 225).
Additionally, inhibitors of AE2 and CAIX block invasiveness of a variety of other tumor
cell types (219, 231-233).

4.1.2b - One-Carbon Metabolism: A Critical Deterrent of Oxidative Stress

Melanoma cells are subjected to oxidative stress, with reactive oxygen species
(ROS) formed secondary to oncogenic mutations, aberrant signaling pathways,
unregulated proliferation, and hypoxia (12). While minimal levels of ROS are actually
beneficial to these cells by stimulating proliferation and inducing mutations, excessive
ROS can induce damage and eventually apoptosis (12). As oxidative stress increases
during tumorigenesis progression and metastasis, melanoma cells must adjust and
strengthen their antioxidant defenses to survive (234). In addition to activating nuclear
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factor (erythroid-derived 2)–related factor-2 (NRF2) to drive the transcription of
antioxidant proteins, tumor cells increase their reliance on glutathione peroxidase to
manage oxidative stress (235). This protein utilizes reduced glutathione (GSH) to convert
peroxides to water. Glutathione reductase utilizes NADPH to restore GSH to its oxidized
state (GSSG), making NADPH a critical component of redox balance in melanoma cells.
Early in tumorigenesis, the PPP supplies the majority of the NADPH used by this enzyme.
Together with NRF2-regulated genes, the PPP is sufficient to manage the oxidative stress
secondary to intense proliferation. However, the role of one-carbon metabolism, mediated
by the folate cofactor, becomes increasingly important as tumorigenesis progresses,
glucose becomes scarce, and hypoxia becomes a more significant source of ROS (12). In
this

pathway,

serine

is

converted

to

glycine

via

serine

hydroxymethyltransferase (SHMT1) in a reaction that also converts tetrahydrofolate
(THF)

to

5,10-methylenetetrahydrofolate.

Methylenetetrahydrofolate

reductase

dehydrogenase 1 (MTHFD1) subsequently catalyzes a series of three reactions, the first
of which produces NADPH for use in redox reactions (7). One-carbon metabolism is
critical in the management of deleterious ROS during metastasis. Piskounova et al.
demonstrated that melanoma cells that successfully metastasized to distant sites in NSG
mice increase their dependence on one-carbon metabolism. Inhibition of one-carbon
metabolism prevented the formation of distant metastases without affecting subcutaneous
tumor growth (236).

4.1.2c - Lipid Metabolism: Synthesis and Degradation of Fatty Acids Promotes
Melanoma Metastasis
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Fatty acid synthase (FASN) catalyzes the rate-limiting step of the endogenous
synthesis of fatty acids (78). FASN expression levels correlate with tumor invasion and
poor prognosis in cutaneous melanoma (237, 238). Targeting FASN prevents the
proliferation of B16-F10 melanoma cells in vitro and activates the intrinsic apoptotic
pathway in melanoma cells (238). Furthermore, inhibiting the thioesterase domain of
FASN with orlistat, a drug originally approved by the FDA for the treatment of obesity,
prevented the metastasis of B16-F10 mouse melanoma cells following implantation in the
peritoneal cavity of C57BL/6 mice (239).
In addition to the synthesis of fatty acids, fatty acid oxidation (FAO) appears to
play an important role in promoting melanoma progression and metastasis. Rodrigues et
al. derived metastatic 4C11+ cells from melan-a melanocytes after sequential detachmentre-adhesion cycles, and FAO contributed significantly to the energy reserves of these
4C11+ cells, relative to nonmetastatic controls (85). How FAO promotes melanoma
metastasis remains unclear. Studies in other tumor types have demonstrated that fatty acids
can provide an ATP boost for tumor cells when necessary under nutrient-depleted
conditions (86-88). Indeed, the process of metastasis is a highly demanding process.
Highly efficient β-oxidation could provide a survival advantage for cells away from the
primary tumor site. Furthermore, fatty acids can serve as a valuable source of acetyl-CoA
that contributes to citrate formation after entering the tricarboxylic acid (TCA) cycle (87).
This citrate can enter metabolic reactions that produce NADPH via isocitrate
dehydrogenase 1 (IDH1), thereby contributing to redox balance in the tumor cells.
Additionally, fatty acid binding proteins, which are regulators of fatty acid uptake
and lipid trafficking, appear to play important roles in melanoma progression. Slipicevic
et al. demonstrated that fatty acid binding protein 7 (FABP7) is involved in proliferation
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and invasion of melanoma cells in vitro (Slipicevic et al., 2008) (240). siRNA-mediated
suppression of FABP7 inhibited invasion and proliferation of melanoma cells without
affecting apoptosis (240). However, the relevance of FABP7 in in vivo models of
metastasis remains to be validated.
Finally, Nath and Chan identified a crucial role for fatty acid metabolism in
melanoma progression while deriving a gene signature to detect activation of epithelialmesenchymal transition (EMT) programming across multiple cancers (241). TCGA
melanoma patients enriched in the authors’ 5-gene signature, which included the fatty acid
uptake genes caveolin-1 (CAV1) and cluster of differentiation 36 (CD36) and the fatty
acid oxidation gene carnitine palmitoyltransferase 1C (CPT1C), have significantly worse
overall survival than those whose melanomas are not enriched for the signature (241).
Additionally, CD36 amplifications significantly correlate with invasiveness in 501mel
melanoma cells (241, 242). In contrast, melanoma cells lacking CD36 fail to metastasize
in NOD scid gamma (NSG) mice following tail vein inoculation (242). These studies
further implicate lipid metabolism in the metastasis of human melanoma.

4.1.2d - Oxidative Phosphorylation (OXPHOS) – A Potential Driver of Melanoma
Metastasis

Peroxisome proliferator-activated receptor γ, coactivator 1α (PPARGC1A or
PGC1α) is a transcriptional co-factor that regulates multiple mitochondrial genes. PGC1α
overexpression promotes OXPHOS metabolism and significantly correlates with
decreased overall survival in patients with stage III melanoma (172). Additionally, basal
and compensatory upregulation of PGC1α expression also correlates with de novo and
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acquired resistance to MAPK pathway inhibitors (3, 35). PGC1α-high melanoma cells
tolerate oxidative stress to a significantly greater extent than PGC1α-low cells (172). As
tumor cells experience a great deal of oxidative stress, particularly during metastasis,
decreased sensitivity to ROS is beneficial for melanoma cells. Consistent with this notion,
shRNA knockdown of PGC1α in PGC1α-high melanoma cells inhibited expression of
numerous ROS-scavenging genes and sensitized these cells to ROS (172). Furthermore,
LeBleu et al. demonstrated that inhibition of PGC1α-mediated OXPHOS prevented
metastatic spread of B16-F10 melanoma cells in a murine model of melanoma metastasis
(243).

4.1.3 - Hypothesis Tested

To date, few studies have functionally validated metabolic pathways as mediators of brain
metastasis pathogenesis. Interestingly, reported analyses tend to indicate that the Warburg
phenotype does not sufficiently describe the metabolic dependencies of these lesions. For
example, MDA-MB-231 human breast cancer cells subjected to three rounds of in vivo selection
for brain-metastatic capacity survive in glucose-depleted conditions characteristic of the brain
microenvironment significantly better than parental cells by performing gluconeogenesis and
oxidizing glutamine and branched-chain amino acids. Silencing the expression of
gluconeogenesis enzymes inhibited development of breast cancer metastases within the brains of
mice (244). Sondstrom et al. showed that melanoma metastasis to the brain does not require
expression of lactate dehydrogenase A (LDHA), an enzyme implicated in aerobic glycolysis, and
that LDHA expression does not influence MBM progression (14). However, the authors did not
identify alternative metabolically active genes necessary for MBM formation and maintenance.
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Our recent RNA-seq analysis of 35 MBMs and 42 patient-matched ECMs identified 494
genes that were differentially expressed between the MBMs and ECMs (174). Focused pathway
analyses for the expression of 70 different metabolic gene networks demonstrated that OXPHOS
was the most significantly enriched metabolic pathway in MBMs. Thus, we hypothesized that
OXPHOS plays a critical role in the formation and maintenance of MBMs.

4.2 - RESULTS

4.2.1 - Molecular Profiling of Animal Models Implicates Oxidative Phosphorylation in
Melanoma Brain Metastasis Pathogenesis

Activation of the PI3K-AKT pathway promotes spontaneous metastasis to the lungs and
brain in an autochthonous RCAS-TVA mouse model of melanoma characterized by the
BRAFV600E mutation and loss of Cdkn2a (179). To determine if OXPHOS contributed to MBM
formation in this model, exploratory RNA-seq was performed on primary tumors, lung
metastases, and brain metastases. Enrichment of the KEGG OXPHOS gene set and OXPHOSIndex (OP-Index) was detected in the murine MBMs compared to both lung metastases (FDR qval<0.001 and p=0.0049, respectively) and primary tumors (FDR q-val<0.001 and p=0.0479,
respectively) (Figure 19A-D). Focused qRT-PCR on RNA from additional tumors confirmed
increased expression (p<0.0001-p<0.01) of several OXPHOS-related genes in the MBMs (Figure
19E).
Preranked Gene Set Enrichment Analysis (GSEA-P) identified significant enrichment
(FDR q-val=0.048) of KEGG OXPHOS gene set expression in primary melanomas of patients
that developed MBMs (n=19) vs. patients that developed no metastases with at least 5 years of
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follow-up (n=19) (Figure 20A) (148). Thus, we performed RNA-seq on 17 primary tumors from
the RCAS-TVA model with various genotypes and incidences of lung and brain metastasis
(Figure 20B). Consistent with our analysis of the clinical specimens, we observed enrichment of
the KEGG OXPHOS gene set and OP-Index in brain-metastatic primary tumors vs. nonmetastatic primary tumors, regardless of genotype (FDR q-val<0.001 and p<0.001, respectively)
(Figure 20C-F).
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Next, we acquired previously characterized brain-metastatic variants of A375P and
YDFR.C cells (A375-Br3 and YDFR.CB3, respectively) (109, 141). Bioenergetics stress testing
by Seahorse analyzer showed that the brain-metastatic variants were characterized by
significantly higher basal and maximum oxygen consumption rates (OCRs) (Figure 21A-D). We
then accessed publicly available Affymetrix microarray data (GSE34970) from YDFR.CB3 and
YDFR.C cells (176). GSEA analysis identified the KEGG OXPHOS gene set as the only KEGG
metabolism pathway enriched in the YDFR.CB3 cells (Figure 21E). Together, these analyses
strongly implicate OXPHOS in the pathogenesis of melanoma brain metastasis.
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4.2.2 - OXPHOS Inhibition Prevents the Growth But Not Formation of Melanoma Brain
Metastases

To functionally test the role of OXPHOS in MBM pathogenesis, newborn Dct::TVA;
BrafCA;Cdkn2alox/lox;Ptenlox/lox mice were injected subcutaneously with viruses encoding myrAkt1
and Cre to induce brain-metastatic BrafV600E;Cdkn2a-/-;Pten-/-;myrAkt1 primary tumors. Mice
with palpable primary tumors were randomized to receive IACS-010759 (7.5 mg/kg p.o. once
daily) or 0.5% methylcellulose treatment (Figure 22A). Treatment with IACS-010759 for 72
hours eliminated pimonidazole staining in primary tumors, confirming target inhibition (Figure
22B). Interestingly, IACS-010759 had no significant impact on Ki-67 staining in primary tumors
(p=0.4336) nor did the treatment affect primary tumor growth (rate-based T/C=0.7002; p=0.543)
(193) (Figure 22C-D). IACS-010759 also did not inhibit lung metastasis incidence (p=0.635),
but it significantly decreased the incidence of detectable brain metastases (incidence 4/10 vs. 0/11,
p=0.035) (Figure 22E).
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While highly novel, this model features two critical limitations. First, we did not know
when cells metastasized from the primary tumor. Second, we had to rely exclusively on necropsy
to identify MBMs. It is possible that OXPHOS inhibition primarily impeded the outgrowth of
micrometastases as opposed to preventing their initial formation. To further investigate this topic,
we established an immunocompetent experimental model of melanoma brain metastasis with duel
luciferase/GFP-tagged YUMM5.2 cells. To increase the brain‐seeking capacity of the brain‐
metastasizing variants, we used an approach undertaken previously (141). Cells were cycled
through the brain for three successive passages yielding brain metastatic variants (Br1, Br2, and
Br3—the numerals represent the number of selection cycles). Only the YUMM5.2-Br3 cells were
used for subsequent analyses.
Figure 23 illustrates our experimental metastasis model. YUMM5.2-Br3 cells were
treated in vitro with IACS-010759 (100 nM) or with vehicle control for 12 hours. This dose of
IACS-010759 significantly inhibited OCR (Figure 24A) without affecting cell viability (data not
shown). 2.5x106 cells were then injected into the left cardiac ventricles of C57BL/6 mice. Mice
injected with the cells treated in vitro with vehicle were randomized to receive either 0.5%
methylcellulose vehicle control (once daily) or the maximum tolerated dose of IACS-010759 (7.5
mg/kg once daily) via oral gavage. In parallel, mice injected with cells treated in vitro with IACS010759 were randomized to receive either 0.5% methylcellulose vehicle control (once daily) or
IACS-010759 (7.5 mg/kg once daily) via oral gavage. After 14 days, mice were euthanized and
ex vivo bioluminescence imaging (BLI) analysis was used to evaluate brain and lung involvement
(Figure 24B). Harvested brains underwent histological examination by a pathologist.
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Interestingly, ex vivo BLI and histological analyses determined that the incidence of brain
metastasis did not differ between any of the experimental groups (Figure 24C-E). However, in
vivo IACS-010759 treatment significantly decreased MBM tumor burden compared to vehicle
controls (p<0.01), regardless of whether or not the cells were previously treated with IACS010759 prior to injection (Figure 24F). In vitro OXPHOS inhibition alone failed to significantly
decrease MBM tumor burden compared to vehicle controls (Figure 24F). Together, these results
indicate that OXPHOS plays a critical role in the growth of MBMs without affecting their initial
formation. Finally, we observed no differences in lung metastasis incidence or tumor burden
between experimental arms (Figure 24G-H).
Subsequently, we acquired previously characterized A375P and G361 melanoma cells
stably transfected with shRNA targeting PGC1α (shPGC1α) and a scrambled control vector
(shScr). Bioenergetics stress testing by Seahorse analyzer showed that PGC1α silencing
significantly inhibited OXPHOS in both cell lines (Figure 25A-D). These cell lines were
implanted into the brains and SQ tissue of CD-1 nude mice. Interestingly, PGC1α knockdown
had no effect on the subcutaneous growth rates of either cell line compared to their scrambled
controls (Figure 25E-F). In contrast, silencing of PGC1α significantly extended survival of mice
bearing intracranial xenografts (Figure 25G-H).

119

120
Because PGC1α has been implicated in mediating cellular programming beyond
OXPHOS, we implanted A375-R1 cells into the brains of CD-1 nude mice and initiated treatment
immediately following tumor cell injection (Figure 26A). BLI of tumor-bearing mice indicated
that pharmacological inhibition of OXPHOS significantly lowered (p<0.001) total flux 14 days
following treatment initiation (Figure 26B). Furthermore, IACS-010759 treatment significantly
extended overall survival (Figure 26C). Together, these studies indicate that OXPHOS inhibition
prevented growth of cells injected into the brains of mice.
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4.3 - DISCUSSION

In this study, we sought to functionally validate OXPHOS as a mediator of MBM
pathogenesis. Based on our previous analysis of patient-matched MBMs and ECMs, we
hypothesized that OXPHOS promotes the formation and growth of MBMs.
Using bulk RNA-seq methods and qRT-PCR, we confirmed OXPHOS gene set
enrichment in MBMs formed in the RCAS-TVA mouse model compared to primary tumors and
lung metastases. To define determinants of metastatic growth of melanoma cells in the brain, we
compared primary tumors able to metastasize to the brain in this model with those unable to
metastasize and demonstrated significant enrichment of OXPHOS gene set expression in the
brain-metastatic primaries. Subsequently, we evaluated brain-metastatic variants of 2 different
melanoma cell lines. Our Seahorse bioenergetics analyses demonstrated significantly higher
basal/maximum OCR values in the brain-metastatic variants of both models. Additionally,
microarray analysis of the YDFR model confirmed OXPHOS gene set enrichment in the
YDFR.CB3 cells. Cumulatively, these studies characterize melanomas that metastasize to the
brain as significantly enriched in OXPHOS vs. non-metastatic controls.
To functionally validate OXPHOS as a mediator of MBM pathogenesis, we treated mice
bearing brain-metastatic primaries from the RCAS-TVA model with the novel OXPHOS inhibitor
IACS-010759. Treatments did not affect primary tumor growth or cellular proliferation and did
not significantly alter the incidence of lung metastasis. However, no mouse treated with IACS010759 developed a detectable brain metastasis. While encouraging, we recognized two critical
limitations of this model. First, we did not know when the primary tumors began to metastasize.
We initiated treatments upon identification of palpable tumors, but it is possible that cells had
already spread from the primary tumor site and seeded distant organs. In this case, we only
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succeeded in impeding the outgrowth of brain micrometastases as opposed to preventing their
initial formation. Second, this model relies exclusively on necropsy to identify distant metastases.
This method might have failed to identify micrometastases in the brains of mice treated with
IACS-010759 if the drug successfully prevented their outgrowth. To overcome these limitations,
we utilized an immunocompetent experimental model of MBM that features a cell line expressing
firefly luciferase. In this experiment, we pretreated cells with either vehicle or a concentration of
IACS-010759 that inhibited the pathway without killing the cells and then injected these cells into
the left cardiac ventricles of C57BL/6 mice, which then received either vehicle or IACS-010759
at a dose that potently inhibits the pathway in vivo (178). Lung metastases and brain metastases
developed at similar incidences across all experimental groups. Interestingly, in vivo IACS010759 treatment significantly decreased MBM tumor burden compared to vehicle controls,
regardless of whether or not the cells were previously treated with IACS-010759 prior to injection.
In vitro OXPHOS inhibition alone failed to significantly decrease MBM tumor burden compared
to vehicle controls. Together, these results indicate that OXPHOS plays a critical role in the
growth of MBMs without affecting their initial formation. Furthermore, the failure of the in
vitro/in vivo IACS-010759 combination to affect lung metastasis formation and tumor burden
indicates that OXPHOS plays no discernable role in the formation or growth of lung metastases.
This finding corroborates our observations in the RCAS-TVA model and remains highly
consistent with our previous profiling efforts that demonstrate OXPHOS enrichment in MBMs
compared to metastases at other tumor sites.
To further validate our findings, we acquired two previously characterized cell lines stably
transfected with shRNAs targeting PGC1α and a scrambled control. After confirming OXPHOS
inhibition in the knockdown cells, we implanted these cells into the brains and SQ tissue of nude
mice. Consistent with our experimental model of metastasis, we observed no differences in SQ
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tumor growth between the shPGC1α and shScr lines while mice injected intracranially with
shPGC1α cells lived significantly longer compared to shScr controls in both models. These results
further indicate that OXPHOS preferentially promotes melanoma growth in the brain without
affecting growth at other anatomical sites.
As a final means of validating the role of OXPHOS in MBM growth, we implanted
MAPKi-resistant A375-R1 cells into the brains of nude mice and immediately began to treat them
with either vehicle or IACS-010759 at a dose known to inhibit the pathway. We observed that
OXPHOS inhibition significantly decreased tumor burden after 14 days and significantly
extended the overall survival of the mice compared to vehicle controls.
This study is highly novel as it employed analysis of clinical samples and preclinical
models to provide the first detailed assessment of the role of OXPHOS metabolism in MBM
pathogenesis. We performed our functional studies in the first-ever RCAS-TVA model of
melanoma that forms brain metastases from cutaneous primary tumors. Furthermore, we
developed an experimental MBM model to validate our findings. Given the importance of
immunotherapies in metastatic melanoma patients, we ensured that we performed as many studies
as possible in models featuring functional immune systems.

We utilized genetic and

pharmacological approaches to achieve OXPHOS inhibition in our models. Our pharmacological
studies employed a potent OXPHOS inhibitor (IACS-010759) that is currently in phase I clinical
trials.
We could have made several improvements to the experiments in this study. First, we
could have used patient-derived xenografts (PDXs) or PDX-derived cell lines capable of
metastasizing to and/or growing in the brain. Compared to cell lines, PDXs more accurately
model tumor cell biology in vivo and represent a potential improvement over standard cell lines.
Ideally, we could have created a spontaneous or experimental metastasis model from PDXs or
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PDX-derived cell lines. Further, we could have been more consistent with our use of cells between
different experiments. For example, directly inhibiting OXPHOS in the RCAS-TVA via genetic
manipulation would have circumvented the need to inhibit the pathway via pharmacological
dosing and then confirm our findings in the unrelated YUMM5.2-Br3 model. Unfortunately,
logistical issues prevented us from making this possible. While these limitations should be noted,
they did not preclude us from making scientifically valid conclusions using the resources
available.
Findings from this study are highly clinically relevant. Our experiments suggest that the
use of IACS-010759 might impede brain metastasis development in metastatic melanoma
patients. While IACS-010759 did not prevent the formation of MBMs, this study presents
numerous lines of evidence that IACS-010759 treatment could keep lesions small and
asymptomatic. Indeed, the ability of IACS-010759 to prevent the formation of detectable MBMs
could significantly alter treatment options for metastatic melanoma patients. Other OXPHOS
inhibitors effectively synergize with and prevent resistance to MAPKi therapy (26, 245). Thus,
upfront treatment of BRAF-mutant melanoma patients with MAPKi therapy and IACS-010759
could effectively reduce tumor burden, prevent the onset of resistance, and decrease the incidence
of escape to the brain.
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5.1 - INTRODUCTION

5.1.1 - Immune Effects of Metabolic Reprogramming

As immune cells compose a critical component of the tumor microenvironment (TME),
there is an increasing interest in studying the metabolic interactions that occur between melanoma
cells and immune cells. To fully understand the complexity of these dynamic interactions, it is
necessary to review the typical metabolic statuses of the key immune cells present in the TME.
Neutrophils contain few mitochondria and therefore use glycolysis extensively to meet
their bioenergetic demands. Upon activation, these cells consume large quantities of glucose to
feed the pentose phosphate pathway (PPP) for production of NADPH, needed to activate NADPH
oxidase, which in turn produces hydrogen peroxide, a bactericidal byproduct (246). Unlike
neutrophils, dendritic cells are a highly complex group of cells responsible for connecting the
innate and adaptive arms of the immune system by responding to pathogen associated molecular
patterns (PAMPS) and subsequently controlling the fates of T cells. Naïve dendritic cells rely
extensively on oxidative phosphorylation (OXPHOS) to produce ATP. Activation of dendritic
cells stimulates the PI3K-AKT pathway and shifts the metabolic dependency to glycolysis (221).
The two categories (M1 and M2) of macrophages differ in their preferred bioenergetic pathways.
M1 macrophages, which have antimicrobial and antitumor functions, exhibit a glycolytic
phenotype. In contrast, M2 macrophages, which are critical regulators of wound healing with
minimal antitumor activity, utilize OXPHOS as their main source of ATP (246). T cells, the most
researched component of the adaptive immune system, utilize a spectrum of metabolic phenotypes
depending on their activation state and the subclass of T cells to which they belong. Activated
CD4+ and CD8+ effector T cells adopt a glycolytic phenotype, upregulating glucose transporters
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and glycolytic enzymes in the process (201). Unlike cells of the innate immune system, T cells
produce memory cells, which catabolize fatty acids and utilize OXPHOS to produce ATP (221).
Regulatory CD4+ T cells (Tregs) are highly oxidative cells while regulatory T helper-17 (Th17)
cells depend on glycolysis (246). While much work remains to full understand the metabolic
dependencies of B lymphocytes, these cells appear to utilize both OXPHOS and glycolysis (221).
Tumor metabolism can suppress the function of nearby immune cells (Figure 18). As
CD8+ T cells are glycolytic, they must compete with highly glycolytic tumor cells for access to
glucose (247). Without glucose, CD8+ T cell activity is inhibited.

Furthermore, high

concentrations of lactate in the TME prevent adequate secretion of lactate out of T cells, again
inhibiting their function (221, 248). By inducing P38 MAPK and c-Jun N-terminal kinase
(JNK)/c-JUN signaling pathways, lactate-based immunosuppression has been demonstrated in
numerous cancers, including melanoma (221, 249). Melanoma spheroids inhibit cytokine
secretion from T cells by secreting lactate into the TME (221, 250). However, T cells can recover
from this inhibition upon lactate clearance (248). Lactate can also suppress cells of the innate
immune system. It converts M1 macrophages to M2 macrophages, promoting tumor progression
(221). In addition, it prevents the maturation of dendritic cells, resulting in an increase in the
immunosuppressive IL-10 cytokine in the TME (221).
Tumor cell metabolism can also profoundly impact the immune system via tryptophan
metabolism. Once activated, effector T helper-1 (Th1) cells secrete interferon-γ (IFNγ), which
stimulates indoleamine 2,3-dioxygenase (IDO) in tumor cells. In turn, IDO metabolizes
tryptophan, producing kynurenine in the process. IDO promotes melanoma tumorigenesis and
diminishes survival through two mechanisms (251, 252). First, IDO starves effector T cells of
tryptophan, resulting in general control nonderepressible 2 (GCN2)-mediated suppression of
proliferation and promotion of apoptosis (252-255). While a minimum level of tryptophan for T
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cell maintenance has not been demonstrated, low serum tryptophan levels correlate with a poor
prognosis in melanoma patients (252, 256). In addition, kynurenine binds to the aryl hydrocarbon
receptor (AhR), inducing Treg differentiation and polarizing dendritic cells and macrophages to
immunosuppressive phenotypes (255, 257). Moreno et al. demonstrated that targeting IDO with
the competitive inhibitor 1-methyl-tryptophan (1-MT) retards the proliferation of melanoma cells
in vitro (258). Furthermore, 1-MT treatment delays the outgrowth of Lewis lung cancer cells in
syngeneic mice (259). Though monotherapy with 1-MT has little effect on the growth of
subcutaneous B16-F10 tumors, 1-MT sensitizes the tumors to chemotherapy and whole-body
radiation (260). While promising, additional exploration is required to further define how IDO
mediates immunosuppression in melanoma and whether or not 1-MT can be combined with
currently approved therapies.

5.1.2 - Therapeutic Implications of Melanoma Metabolism

The development of effective immune and targeted therapies has revolutionized the
management of patients with metastatic melanoma. However, these treatments have metabolic
implications that must be understood in order to identify potential mechanisms of resistance and
novel treatment combinations.

5.1.2a - Immunotherapy

Metabolic reprogramming of tumor cells has significant implications for
immunotherapy. Ipilimumab, an antibody that inhibits signaling by cytotoxic Tlymphocyte-associated protein (CTLA-4) on T cells, was approved by the US FDA in

130
2011 for the treatment of patients with metastatic melanoma. Three years later, the
programmed cell death protein-1 (PD-1) blocking antibodies pembrolizumab and
nivolumab were also approved. These three antibodies overcome inhibitory signals
encountered by T cells in their attempt to locate and destroy tumor cells. Specifically, the
expression of CTLA-4, also known as CD152, increases significantly following the
activation of CD4+ and CD8+ T cells (261). This T cell surface molecule subsequently
competes with CD28 for interactions with CD80 and CD86 (B7-1 and B7-2, respectively)
on the surface of antigen presenting cells, such as dendritic cells and macrophages. The
interactions between CTLA-4 and CD80 and CD86 are more favorable than those between
CD28 and CD80 and CD86, resulting in CTLA-4 binding with these molecules in place
of CD28. In response, inhibitory signals are transmitted to the effector CD8+ T cells,
resulting in suppression of the immune response (262, 263). Like CTLA-4, PD-1 is
expressed on the surface of T cells. Its ligand, PD-L1, is expressed on the surface of
dendritic cells, M2 macrophages, fibroblasts, and tumor cells (264). Activation of PD-1
following binding to PD-L1 inhibits effector CD8+ T cells, suppressing the antitumor
response (265). Mechanistically, CTLA-4 and PD-1 both inhibit the PI3K-AKT pathway
in distinct yet synergistic ways, with CTLA-4 signaling inhibiting AKT through protein
phosphatase 2A (PP2A) and PD-1 signaling inhibiting PI3K (266). Since this pathway
promotes glycolysis, CTLA-4 and PD-1 signaling promote OXPHOS at the expense of
glycolysis, and PD-1 signaling augments fatty acid oxidation (267). As activated effector
T cells utilize glycolysis, these metabolic alterations provide a metabolic explanation for
CTLA-4- and PD-1-mediated immunosuppression. Checkpoint inhibitors remove the
suppression of the PI3K-AKT in effector T cells, allowing them to become active once
again and adopt a glycolytic phenotype. Once this occurs, tumor cell death caused by
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the checkpoint inhibitors results in the release of glucose into the TME, promoting further
activation of effector CD8+ T cells (247).
While naïve CD4+ and CD8+ T cells rely exclusively on OXPHOS to meet their
bioenergetic demands, activation triggers a shift to a hypermetabolic phenotype
characterized by increased glycolysis and OXPHOS (268). Interestingly, pharmacological
suppression of OXPHOS does not appear to negatively impact effector T cell function.
Treatment with the OXPHOS inhibitors metformin and phenformin improves the response
of melanoma xenografts to anti-PD1 therapy (173, 269, 270). Metformin decreases
intratumoral hypoxia that is highly detrimental to effector CD8+ T cell function (173), and
phenformin facilitates an increased response by preventing the immunosuppressive effects
of myeloid derived suppressor cells (MDSCs) (270). Metformin monotherapy is sufficient
to significantly increase intratumoral CD8+ effector cells and protect them from apoptosis
in the TME (271).
In addition to central carbon metabolism, tryptophan metabolism also appears to
play a critical role in mediating response to immunotherapy. Holmgaard et al.
demonstrated that treatment of IDO-knockout mice with anti-CTLA-4 and anti-PD-1
inhibited the growth of B16-F10 melanoma tumors compared to wild-type mice.
Furthermore, IDO inhibitors synergized with anti-CTLA-4 treatment, promoting CD8+ T
cell recruitment and inhibiting tumor growth to a significantly greater extent than antiCTLA-4 treatment alone (272). When given to 19 treatment-naïve metastatic melanoma
patients participating in a phase I clinical trial (NCT02178722), the combination of
pembrolizumab and the IDO inhibitor Epacadostat achieved complete responses in 4
patients, partial responses in 7 patients, and stable disease in 3 patients (273). Furthermore,
the combination demonstrated an acceptable safety profile (273). Treatment-naive
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metastatic melanoma patients are currently being enrolled in phase II and III clinical trials
(NCT02752074) designed to evaluate this treatment strategy.

5.1.2b - Targeted Therapy

While the BRAF inhibitors dabrafenib and vemurafenib and the MEK inhibitors
trametinib and cobimetinib are highly effective in metastatic melanoma patients with
activating BRAF mutations, the depth and duration of clinical responses to these agents
are variable, and the majority of patients will eventually develop resistance to them (3).
As the MAPK pathway promotes aerobic glycolysis in tumor cells (Figure 1), inhibition
of the pathway results in significant reduction in glucose utilization and glycolytic flux.
This suppression results from modulation of the glycolytic regulators HIF1α and MYC
and is necessary to achieve clinical responses to BRAF inhibitors (20). Studies have shown
that glycolytic flux is restored in cells resistant to BRAF inhibition, and that combined
inhibition of BRAF and glycolysis could overcome targeted therapy resistance (20). While
those observations were based largely on experiments performed after 24-hour treatments,
Haq et al. demonstrated increased PGC1α-driven OXPHOS in response to longer (i.e., ≥
72 hours) treatments with MAPK inhibitors (26). Induction of OXPHOS has been
identified in 30-50% of BRAF-mutant melanomas with both de novo and acquired
resistance to MAPK pathway inhibitors (3). Enforced expression of PGC1α induces
resistance in cells previously sensitive to MAPK inhibitors (26), while genetic knockdown
of PGC1α results in synergistic growth inhibition and apoptosis induction with MAPK
pathway therapies in PGC1α-mediated High-OXPHOS cells (3). In addition, studies by
Herlyn and colleagues previously identified a population of slow-cycling, treatment-
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resistant cells characterized by expression of the histone 3 K4 demethylase JARID1B.
They further showed that these slow-cycling cells are characterized by High-OXPHOS.
Interestingly, Transcription factor A, mitochondrial (TFAM), not PGC1α, facilitates the
High-OXPHOS phenotype in these cells, indicating that some High-OXPHOS melanoma
cells adopt this metabolic phenotype independent of the MITF-PGC1α signaling axis, (35,
274, 275). Combination treatments with vemurafenib and mitochondrial inhibitors
overcame the multi-drug resistance of JARID1Bhigh cells in vitro (275). This strategy of
targeting both the MAPK pathway and OXPHOS has been highly effective in other studies
as well. For example, our lab determined that the High-OXPHOS phenotype predicts
sensitivity to combination treatment with MAPK pathway inhibitors and mTORC1/2
inhibitors (3). Mechanistically, mTORC1/2 inhibitors prevented the nuclear translocation
of MITF, thereby inhibiting PGC1α transcription (Figure 2) (3). Similarly, directly
targeting mitochondrial biogenesis with the mitochondria-targeted, small-molecule
HSP90 inhibitor gamitrinib, has also been shown to overcome MAPK pathway resistance
in melanomas with the High-OXPHOS phenotype (35).
Numerous studies have also examined the effects of the biguanide metformin as a
combinatorial strategy in melanoma. Commonly used for the treatment of diabetes
mellitus type 2, metformin became the subject of extensive oncological research after an
initial report indicated that diabetic patients treated with metformin had lower rates of
cancer (276). As an inhibitor of complex I of the mitochondrial electron transport chain,
metformin deprives cells of ATP, stimulating AMPK and resulting in mTOR inhibition,
p53 activation, and apoptosis (277). Furthermore, metformin independently inhibits
mTOR likely through a RAS-related GTPase and suppresses NFκB-STAT3 signaling
(277). Experiments testing metformin as a single-agent therapy have produced mixed
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results (277). While several studies demonstrated the anti-melanoma effect of metformin
therapy in vitro, Martin et al. found that metformin treatments promoted the growth of
BRAFV600E-mutated melanomas in vivo by inducing angiogenesis (278-281). Despite this
effect, metformin treatment also sensitized melanoma cells to treatment with angiogenesis
inhibitors (279). Other combination studies have been very promising, with Niehr et al.
demonstrating synergy between vemurafenib and metformin in BRAFV600E-mutated
melanomas (280).

Currently, two phase I/II trials are enrolling patients to test

combinations of vemurafenib and metformin (NCT01638676) and dabrafenib, trametinib,
and metformin (NCT02143050) in metastatic melanoma patients.
Recent work also supports that BRAF inhibitor-resistant, High-OXPHOS
melanomas prefer glutamine metabolism over glucose metabolism (282). This finding
suggests a new therapeutic opportunity, and experiments demonstrated that the
glutaminase inhibitor BPTES enhanced the antitumor effects of MAPK pathway inhibitors
in the treatment of these High-OXPHOS melanomas (282). While promising, additional
work remains to understand optimal dosing of treatment combinations with targeted
therapies and metabolic inhibitors.

5.1.3 - Hypothesis Tested

While the treatments and outcomes for patients with advanced melanoma have improved
dramatically over the last decade, MBMs remain a clinically significant challenge in this disease.
Improving our understanding of the features of MBMs is a critical first step to facilitate the
development of new, more effective therapeutic approaches to treat them. Our recent analysis of
gene expression in the largest cohort of MBMs analyzed by RNA-seq to date, and the largest
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cohort of patient-matched brain metastases and extracranial metastases from any tumor type,
provided key new insights into the pathogenesis of these tumors (174). A number of these novel
findings provide the rationale for the testing of new clinical strategies, including the targeting of
OXPHOS, to improve the outcomes of MBM patients. Importantly, our profiling efforts also
identified variability in OXPHOS levels between MBMs. Studies by our group and others
previously demonstrated that increased OXPHOS in melanoma (High-OXPHOS phenotype) is
associated with poor clinical outcomes, therapeutic resistance, oncogenic signaling pathways, and
therapeutic vulnerabilities (7-9) (173). Thus, melanomas with the High-OXPHOS phenotype
represent a clinically significant, metabolically-defined subgroup of this disease. Characterizing
this metabolic phenotype in MBMs could facilitate the development of new treatments for patients
with these tumors. We tested the hypothesis that OXPHOS associates with distinct molecular,
immunological, and metabolic features that, in addition to OXPHOS itself, could be
exploited therapeutically in High-OXPHOS MBMs.

5.2 - RESULTS

5.2.1

-

Molecular,

Immunological,

and

Metabolic

Associations

of

Oxidative

Phosphorylation in Melanoma Brain Metastases

5.2.1a - RNA-seq Identifies Clinically and Biologically Distinct Clusters of Melanoma
Brain Metastases Defined by Differential Enrichment of Oxidative Phosphorylation

We calculated OXPHOS-Indices (OP-Indices) for all 88 MBMs with available
RNA-seq data and performed hierarchical clustering to elucidate heterogeneity in
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OXPHOS gene expression amongst the tumors. Three large clusters were observed,
which we labeled as “High-OXPHOS,” “Intermediate-OXPHOS”, and “LowOXPHOS” (Figure 27A). To confirm that the High-OXPHOS MBMs differed
significantly from the other groups, we performed Preranked Gene Set Enrichment
Analysis (GSEA-P) and determined that the KEGG OXPHOS gene set was
significantly enriched in High- vs. Low-OXPHOS, High- vs. Intermediate-OXPHOS,
and High- vs. Low- and Intermediate-OXPHOS MBMs (Figure 27B-D). Supporting
the clinical significance of the observed heterogeneity of OXPHOS amongst MBMs,
Kaplan-Meier analysis identified a significant decrease in overall survival (OS) from
craniotomy for patients with High-OXPHOS MBMs vs. patients with Low-OXPHOS
MBMs (HR 0.393, 95% CI 0.187-0.830, p=0.014) (Figure 27E).
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5.2.1b - Molecular and Metabolic Associations of Oxidative Phosphorylation in
Melanoma Brain Metastases

As anticipated, High-OXPHOS MBMs express PGC1α and MITF - known
mediators of OXPHOS in melanoma - at significantly higher levels (FDR q-val<0.05) than
Low-OXPHOS MBMs (Figure 28A). Furthermore, GSEA-P analysis demonstrated
significant enrichment (FDR q-val<0.0001) of genes regulated by the mTORC1 signaling
pathway in High-OXPHOS MBMs (Figure 28B).

139
To confirm the association between mTORC1 signaling and OXPHOS status in
MBMs, we stained our High- and Low-OXPHOS MBMs for P-PRAS40 (marker of PI3KAKT pathway activity), PTEN (complete loss promotes PI3K-AKT pathway
hyperactivity), and P-S6 (marker of mTORC1 pathway activity). No significant difference
in P-PRAS40 staining was observed between High- and Low-OXPHOS MBMs
(p=0.4339) (Figure 29A). Additionally, prevalence of complete PTEN loss did not differ
significantly between High- and Low-OXPHOS MBMs (p=0.6844) (Figure 29B).
However, P-S6 stained significantly higher (p=0.0027) in High- vs. Low-OXPHOS
MBMs (Figure 29C). Together, these findings implicate mTORC1 signaling in High-
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OXPHOS MBMs and that mTORC1 activation in these lesions occurs independently of
input from the PI3K-AKT pathway.
We fully compared KEGG metabolism gene set enrichment between the High-and
Low-OXPHOS MBMs. As expected, the KEGG OXPHOS gene set was the most enriched
pathway in the High-OXPHOS MBMs (FDR q-val<0.0001) (Figure 30A). Interestingly,
the next most enriched pathways included purine synthesis, pyrimidine synthesis, and
aminoacyl tRNA biosynthesis (Figure 30A). Enrichment of these nucleic acid synthesis
and protein synthesis pathways suggests increased growth potential in High-OXPHOS
MBMs. Furthermore, all of these pathways require glutamine, which represents a potential
therapeutic target.
These clinical MBMs were uniformly FFPE samples and could not be reliably
subjected to direct metabolite analysis. To overcome this issue and further define the
metabolic dependencies of High- and Low-OXPHOS MBMs, we performed a focused
liquid chromatography-mass spectrometry (LC-MS) analysis of Low-OXPHOS A375 and
High-OXPHOS A375-R1 (3) intracranial xenografts to identify differentially expressed
glycolytic, tricarboxylic acid (TCA) cycle, and amino acid metabolites (FDR q-val<0.25).
As expected, A375-R1 xenografts were characterized by significantly lower
concentrations of the glycolytic metabolites pyruvate and 3-phosphoglycerate/2phosphoglycerate and higher concentrations of the TCA cycle metabolites malate and
fumarate (Figure 30B). Interestingly, we also observed evidence of increased
glutaminolysis. Specifically, A375-R1 xenografts featured significantly increased
concentrations of glutamic acid, threonine, and asparagine (Figure 30B). The presence of
these metabolites suggests that catabolized glutamine was feeding the TCA cycle, which
in turn produced the amino acids threonine and asparagine from oxaloacetate/aspartate.
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5.2.1c - Immunological Associations of Oxidative Phosphorylation in Melanoma
Brain Metastases

We assessed if High- and Low-OXPHOS MBMs differ in immune infiltrates.
Together, the ESTIMATE and MCP-Counter R packages identified significant decreases
in the ImmuneScore (p<0.0001), T cells (p<0.0001), CD8+ T cells (p<0.001), cytotoxic
lymphocytes (p<0.0001), monocytic lineage cells (p<0.0001), and myeloid dendritic cells
(p<0.01) in the High-OXPHOS MBMs (Figure 31A-B). Furthermore, High-OXPHOS
MBMs were characterized by significantly lower expression (p=0.0263) of a 6-gene IFNγ
mRNA signature previously demonstrated to correlate with response to anti-PD1
immunotherapy (283) (Figure 31C). Together, these findings indicate that OXPHOS
associates with significant immunosuppression in MBMs.
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5.2.1d - Clinical Correlates of Oxidative Phosphorylation in Melanoma Brain
Metastases

We accessed patient data archives maintained by the MD Anderson Cancer Center
MelCore to identify clinical factors that associate with OXPHOS in MBMs. Patient age
(p=0.0661), gender (p=0.1328), body mass index (BMI) (p=0.2347), serum lactate
dehydrogenase (LDH) status (p=0.1328), and history of prior radiation therapy (XRT)
(p=0.2122) do not significantly associate with MBM OXPHOS status (Figure 32A-F).
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5.2.2 - Overcoming Oxidative Phosphorylation in the Treatment of Melanoma Brain
Metastases

5.2.2a - Efficacy and Pharmacodynamic (PD) Effects of IACS-010759 in HighOXPHOS, MAPKi-Resistant Intracranial Human Melanoma Xenografts

We first evaluated the feasibility of indirectly targeting OXPHOS via mTORC1/2
inhibition in intracranial (ICr) xenografts of a human melanoma cell line with acquired
(A375-R1) resistance to BRAF and MEK inhibitors (3). Mice were randomized to
treatment with AZD2014 (20 mg/kg p.o. once daily) – an mTORC1/2 inhibitor previously
shown to synergize with MEKi in subcutaneous High-OXPHOS melanoma xenografts (3)
– or vehicle control. However, treatment for 7 days did not decrease P-S6 staining
(p=0.8623), indicating that the drug failed to sustainably inhibit its target (Figure 33AB). Thus, we focused our efforts on testing IACS-010759 (5 mg/kg p.o. once daily) – a
novel mitochondrial complex I inhibitor currently in phase I clinical trials (NCT02882321
and NCT03291938) – against its 0.5% methylcellulose vehicle control in mice with ICr
A375-R1 tumors (284). Treatment with IACS-010759 for 24 hours and 7 days eliminated
pimonidazole staining, confirming sustained intracranial target inhibition (Figure 33C-D)
(284). OXPHOS inhibition should silence mTORC1 pathway signaling by depriving cells
of ATP and subsequently inducing increased phosphorylation and activation of AMPK
(178). Consistent with this mechanism, IACS-010759 induced a significant decrease
(p=0.011) in P-S6 staining after 7 days of treatment and an observable though insignificant
decrease in P-S6 staining after only 24 hours of treatment (Figure 33E). Finally, IACS010759 caused a significant increase in cleaved caspase-3 staining after 7 days of
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treatment (p=0.0138), indicating that OXPHOS inhibition induced apoptosis in the
intracranial A375-R1 tumors (Figure 33F). Consistent with these PD studies, IACS010759 (5 mg/kg p.o. once daily) significantly decreased mean bioluminescence imaging
(BLI) signal after 14 days of treatment and ultimately improved survival of mice bearing
ICr A375-R1 tumors (HR 0.197, 95% CI 0.075 – 0.519, p=0.001) (Figure 34A-B).
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We confirmed these findings in a High-OXPHOS model characterized by de novo
resistance to MAPKi (SKMEL5). Single-agent IACS-010759 (5 mg/kg p.o. once daily)
significantly improved survival of mice with ICr xenografts of SKMEL5 cells (HR 0.072,
95% CI 0.024-0.214, p<0.0001) (Figure 34C). We stopped treatment after 42 days but
continued to monitor mice for an additional 18 days. While the majority of IACS-010759treated mice died immediately after cessation of treatment, 5 mice survived until the end
of the 18-day monitoring period without treatment (Figure 34C). This suggests that IACS010759 either cured these mice or ablated the tumor sufficiently to allow the mice to
survive for a period of time without treatment. To validate this finding, we treated mice
bearing ICr SKMEL5 tumors with IACS-010759 (5 mg/kg p.o. once daily) or vehicle
control for a total of 80 days. Again, we observed significant improvement in survival in
the IACS-010759-treated mice (HR 0.044, 95% CI 0.006-0.291, p=0.0012) (Figure 34D).
Further, 5/15 IACS-010759-treated mice survived long-term (40 days) following
cessation of treatment, confirming that the drug has a curative effect in approximately 33%
of mice bearing ICr SKMEL5 tumors (Figure 34D).

5.2.2b - MAPKi Does Not Improve the Efficacy of IACS-010759 in High-OXPHOS,
MAPKi-Resistant Intracranial Human Melanoma Xenografts

Previously, we and others have demonstrated that OXPHOS mediates resistance
to MAPK pathway inhibitors in non-CNS melanomas and cell lines, and that inhibiting
factors that promote this metabolic pathway sensitizes cell lines to MAPK pathway
inhibitors (3, 26). Thus, we evaluated whether or not direct OXPHOS inhibition sensitizes
A375-R1 and SKMEL5 intracranial xenografts to BRAF inhibition (3). In collaboration
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with the Center for Co-Clinical Trials (CCCT) at MD Anderson, we established that
IACS-010759 could be tolerated at doses of 5 mg/kg p.o. once daily in combination with
dabrafenib at its optimal dose of 30 mg/kg p.o. once daily. We then evaluated the
feasibility of targeting the MAPK pathway in ICr A375-R1 xenografts. Mice were
randomized to treatment with dabrafenib (30 mg/kg p.o. once daily) or vehicle control for
72 hours. Dabrafenib ablated P-ERK staining (Figure 35A), indicating intracranial target
inhibition. Mice with ICr xenografts of A375-R1 and SKMEL5 cells were then treated for
up to 60 days with vehicle, dabrafenib, IACS-010759, or the combination of dabrafenib +
IACS-010759. Both models demonstrated in vivo resistance to dabrafenib (Figure 35BC). As expected, single-agent IACS-010759 significantly improved the survival of mice
in both models (Figure 35B-C). However, combined treatment with dabrafenib did not
increase the efficacy of IACS-010759 in either model (Figure 35B-C).
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5.2.2c - The Combination of BRAFi + IACS-010759 Effectively Treats Intracranial
Low-OXPHOS Human Melanoma Xenografts

Notably, previous studies have demonstrated that A375 subcutaneous xenografts
respond to the BRAFi dabrafenib given orally at doses as low as 10 mg/kg once daily
(285). In contrast, ICr xenografts of luciferase-tagged A375 cells demonstrated resistance
to single-agent dabrafenib given at 30 mg/kg p.o. once daily (Figure 36A). Seahorse
Bioanalyzer analysis of cell lines derived from mice progressing on dabrafenib and vehicle
identified significantly greater basal and maximum oxygen consumption rates (OCRs) in
tumors following treatment with dabrafenib vs. vehicle (Figure 36B-C). To determine if
OXPHOS inhibition could overcome dabrafenib resistance in ICr A375 xenografts, we
implanted luciferase-tagged A375 cells in the brains of CD-1 nude mice. Tumor-bearing
mice did not respond to single-agent dabrafenib (30 mg/kg p.o. once daily) or IACS010759 (5 mg/kg p.o. once daily) (Figure 36D). However, the combination of IACS010759 and dabrafenib significantly improved survival of mice vs. vehicle controls
(p=0.0126) (Figure 36D).
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5.2.2d - OXPHOS Inhibition Improves Response of Intracranial B16-F10 Melanomas
to Anti-PD1 Immunotherapy

Recently, investigators have implicated OXPHOS in mediating resistance to antiPD1 immunotherapy in melanomas (173). Interestingly, low-dose treatment with
metformin inhibits OXPHOS exclusively in tumor cells and improves response to antiPD1 in subcutaneous xenografts of the High-OXPHOS B16-F10 melanoma cell line (173).
Our molecular profiling studies identified significant immunosuppression in HighOXPHOS MBMs and determined that these lesions were characterized by a gene signature
predictive of anti-PD1 treatment failure (Figure 31C). To determine if OXPHOS
inhibition could improve immunosuppression in High-OXPHOS MBMs, we implanted
luciferase-tagged B16-F10 melanoma cells intracranially in C57BL/6 mice. Mice with
10% weight loss were randomized to receive 3 treatments of metformin at a dose
previously shown to exclusively target tumor cells and promote immune cell function (50
mg/kg i.p. every other day) or PBS (10 ul/g body weight i.p. every other day) for 96 hours
(173). RNA isolated from the tumors was subjected to qRT-PCR analysis of 2 different
panels of genes: 1) a 5-gene signature indicative of activated CD8+ cytotoxic T cells and
2) 5 genes from the aforementioned 6-gene IFNγ mRNA signature known to correlate with
response to anti-PD1 (HLA-DRA from the original profile is only found in humans and
was therefore excluded from the panel) (283, 286). qRT-PCR analysis of the tumors
demonstrated significantly increased expression (p<0.05 – p<0.0001) of all genes in the
metformin-treated tumors, indicating that metformin treatment profoundly altered the
immune profile of the tumors (Figure 37A-B).
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To determine if the immunological effects of metformin would translate to
improved anti-PD1 response in High-OXPHOS MBMs, we implanted luciferase-tagged
B16-F10 melanoma cells intracranially in C57BL/6 mice. After 5 days, tumor uptake was
confirmed and mice were randomized into 4 treatment arms: isotype control (200 ug i.p.
3x/week) + PBS (10 ul/g body weight i.p. every other day), anti-PD1 (200 ug i.p. 3x/week)
+ PBS (10 ul/g body weight i.p. every other day), isotype control (200 ug i.p. 3x/week) +
metformin (50 mg/kg i.p. every other day), and anti-PD1 (200 ug i.p. 3x/week) +
metformin (50 mg/kg i.p. every other day). As expected, low-dose metformin
demonstrated no single-agent efficacy compared to vehicle control mice (p=0.4533)
(Figure 37C). Anti-PD1 monotherapy failed to improve survival compared to vehicle
control mice (p=0.4361) (Figure 37C). Interestingly, only the mice treated with both
metformin and anti-PD1 experienced a significant improvement in survival compared to
vehicle control mice (p=0.013) (Figure 37C). Further, the combination regimen
significantly improved survival vs. metformin monotherapy (p=0.0262). While the
combination failed to statistically increase survival vs. anti-PD1 monotherapy (p=0.1972),
a clear trend was observed and median survival improved from 11 days to 18 days.
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5.2.2e - The Glutaminase Inhibitor CB839 Improves Survival of Mice Bearing HighOXPHOS, MAPKi-Resistant Intracranial Human Melanoma Xenografts

Our IACS-010759 efficacy studies, gene expression studies, and LC-MS studies
supported the rationale to investigate the efficacy of other metabolic inhibitors to treat
High-OXPHOS, MAPKi-resistant MBMs. Specifically, our studies suggest that HighOXPHOS MBMs preferentially utilize pathways that require significant amounts of
glutamine. Consistent with this finding, our direct metabolite analyses identified increased
glutamine catabolism in High-OXPHOS brain xenografts. Based on these results, we
evaluated the efficacy of CB839 – a small molecule glutaminase inhibitor currently being
used in clinical trials (NCT02771626) – in vitro using Low-OXPHOS A375 and HighOXPHOS A375-R1 cells. As indicated in Figure 38A-B, CB839 significantly inhibited
OCR in A375-R1 cells without affecting this metric in A375 cells. As expected, CB839
inhibited proliferation of A375-R1 cells significantly more than the parental cells (Figure
38C). The IC50 of A375-R1 cells (182 nM) was less than half of the IC50 of A375 cells
(437 nM). Thus, we tested the response of mice bearing A375-R1 ICr xenografts to singleagent CB839. As anticipated, the drug significantly extended survival of these mice
relative to vehicle controls (p=0.0292) (Figure 38D). To further confirm CB839 as a
viable treatment for High-OXPHOS MBMs, we implanted luciferase-tagged HighOXPHOS, MAPKi-resistant MEL624 cells into the brains of mice. As observed in the
A375-R1 model, CB839 significantly improved survival relative to vehicle controls in the
MEL624 model (p=0.0266) (Figure 38E) and did so with minimal toxicity (Figure 38F).
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5.3 - DISCUSSION

A metabolic phenotype defined by elevated oxidative phosphorylation (High-OXPHOS)
has been identified in 30-50% of non-central nervous system (CNS) melanomas. This HighOXPHOS phenotype mediates de novo and acquired resistance to FDA-approved MAPK pathway
inhibitors and anti-PD1 immunotherapy (7-9) (173). Thus, melanomas with increased OXPHOS
represent a clinically significant subgroup of this disease. Prior to this study, we had observed
significant heterogeneity of OXPHOS gene expression between our surgically resected MBMs,
suggesting that these lesions could also be classified as “High-” or “Low-OXPHOS.” In this
study, we utilized our unique cohort of surgically resected tumors and preclinical models to
improve our understanding of the High-OXPHOS phenotype in MBMs. We tested the
hypothesis that OXPHOS associates with distinct molecular, immunological, and metabolic
features that, in addition to OXPHOS itself, could be exploited therapeutically in HighOXPHOS MBMs.
Using bulk RNA-seq methods, we applied an OXPHOS transcriptomic signature (Table
1) to 88 surgically resected MBMs. Clustering by this signature identified MBMs with significant
enrichment (High-OXPHOS) and depletion (Low-OXPHOS) of OXPHOS. Similar to non-CNS
metastases, OXPHOS enrichment in MBMs correlated with poor clinical outcomes.
We observed significantly higher mTORC1 pathway activation in High-OXPHOS
MBMs. However, OXPHOS did not associate with activation of the PI3K-AKT pathway. While
mTORC1 can be activated independently of PI3K-AKT pathway input, all known mechanisms of
mTORC1 activation require the small GTPase RAS homologue enriched in brain (RHEB) (287).
PI3K-AKT pathway activation suppresses the tuberous sclerosis complex (TSC), which keeps
RHEB in its active GTP-bound state and able to activate mTORC1 (287). Interestingly, the
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MAPK pathway can also suppress TSC through p90 ribosomal S6 kinase (RSK), which promotes
mTORC1 activation (288). The MAPK pathway is ubiquitously hyperactivated in cutaneous
melanomas (70). Further, our previous studies demonstrated that OXPHOS status does not
associate with BRAF/NRAS mutation status in cell lines or non-CNS metastases (3). Thus,
differential input from the MAPK pathway is unlikely to explain our observations. Alternatively,
exposure to amino acids can directly activate mTORC1 and is actually believed to be the most
important input for mTORC1 activation (287). To date, the specific amino acids required to
activate mTORC1 remain uncertain, though previous studies have implicated leucine, glutamine,
and arginine (287). Thus, it is possible that the High-OXPHOS MBMs have better access to these
amino acids compared to their Low-OXPHOS counterparts. Alternatively, increased P-AMPK
signaling could suppress mTORC1 signaling in Low-OXPHOS MBMs without affecting PPRAS40 staining (289).
Unfortunately, our attempts at directly targeting mTOR signaling failed due to AZD2014’s
inability to inhibit the pathway in High-OXPHOS MBMs, presumably due to poor penetration of
the blood-brain barrier (BBB). Our future studies will focus on elucidating the mechanism
underlying differential mTORC1 activation in High- and Low-OXPHOS MBMs. Further insights
into how mTORC1 mediates OXPHOS heterogeneity in MBMs could elucidate additional
pathways targetable via drugs known to pass the BBB. Additionally, we will continue to
investigate the BBB penetrance of alternative mTOR inhibitors to identify a more suitable
candidate for efficacy studies.
When our efforts to treat High-OXPHOS MBMs via the mTORC1/2 inhibitor failed, we
proceeded to collaborate with the MD Anderson Institute for Applied Cancer Science (IACS),
which recently developed and characterized a direct OXPHOS inhibitor (IACS-010759) able to
exert antitumor effects in a variety of cancer cell types at tolerable doses (178). Our findings
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demonstrate for the first time that single-agent OXPHOS inhibition with IACS-010759 can have
beneficial effects in High-OXPHOS, MAPKi-resistant intracranial melanomas.
Previous studies have shown that BRAF-mutant extracranial melanoma metastases treated
with BRAFi therapy can become addicted to OXPHOS and subsequently are highly sensitive to
direct OXPHOSi. In addition, phenformin, which inhibits OXPHOS, delays the development of
resistance to BRAFi treatment in human melanoma cell lines (26, 245). Thus, we reasoned that
adding IACS-010759 to BRAFi therapy at the initiation of treatment of BRAF-mutant MBMs
could increase the duration of tumor responses, which was the critical factor that limited the
clinical benefit of treatment with dabrafenib and trametinib in the COMBI-MB study (171).
Interestingly, we observed that the brain TME mediated resistance to dabrafenib treatment of
intracranial A375 xenografts. Despite being given at doses known to inhibit tumor growth
subcutaneously, single-agent dabrafenib failed to improve survival compared to vehicle controls.
Our PD studies confirmed that dabrafenib suppressed P-ERK staining at the dose tested, which
excludes the possibility that this observation occurred only because of dabrafenib’s failure to
achieve adequate on-target inhibition. Further, Seahorse Bioanalyzer analysis identified increased
OCR (OXPHOS) in cell lines derived from ICr A375 xenografts progressing on dabrafenib, as
compared to cell lines derived from ICr A375 xenografts progressing on vehicle. Excitingly, we
showed that while ICr xenografts of A375 demonstrated resistance to single-agent dabrafenib and
single-agent IACS-010759, the combination of these two treatments significantly improved
survival compared to vehicle controls.
Previous studies have suggested that the combination of MAPKi and IACS-010759 could
also yield synergistic effects in MBMs that have developed resistance to MAPKi therapies via
increased dependence on OXPHOS. Specifically, combined targeting of the MAPK and mTOR
pathways effectively treated MAPKi-resistant non-CNS melanomas dependent on OXPHOS (3).
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mTORC1/2 inhibition triggered apoptosis by preventing these tumors from utilizing OXPHOS to
meet their bioenergetic demands following MAPK pathway blockade (3). Interestingly, the
addition of dabrafenib to IACS-010759 failed to improve survival of mice bearing intracranial
A375-R1 and SKMEL5 xenografts compared to IACS-010759 monotherapy. While this
observation was primarily due to the impressive efficacy of single-agent IACS-010759 in the
treatment of these lesions, High-OXPHOS melanomas do not uniformly respond to single-agent
IACS-010759 (290). A subset of High-OXPHOS melanoma cells resistant to IACS-010759
treatment respond to the combination of IACS-010759 and MAPKi, indicating a potential use for
this combination in High-OXPHOS MBMs unresponsive to single-agent IACS-010759.
Our immunological analyses demonstrated that OXPHOS associates with features
consistent with immunosuppression in MBMs. Additional studies are warranted to further
characterize this apparent immunosuppressive factor in MBMs, but this finding is promising and
clinically significant. Most importantly, High-OXPHOS MBMs were characterized by
significantly lower expression of an IFN-γ gene signature known to predict response to anti-PD1
immunotherapy in non-CNS melanomas. These findings are consistent with previous studies that
have shown that OXPHOS inhibitors can enhance response to anti-PD1 immunotherapy (291,
292), but to our knowledge this data is the first to implicate OXPHOS as a potential mediator of
immunosuppression in MBMs. Notably, OXPHOS associated with decreased B cell infiltration,
but not CD8+ T cell density, in the MBMs. Numerous recent studies have highlighted the antitumor role of intratumoral B cells, and a potential link between baseline B cell infiltration and
ipilimumab efficacy has been proposed (293-295). Recent data also implicate a possible important
role for B cells in response to anti-PD1 (296) and thus our results support the rationale for
investigating combinatorial approaches with these immunotherapies and OXPHOS inhibitors in
MBM patients. As a first step in this effort, we demonstrated that low-dose metformin sensitized
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intracranial High-OXPHOS B16-F10 melanoma xenografts to anti-PD1 treatment. Molecular
studies demonstrated that metformin increased intratumoral expression of markers known to
predict response to anti-PD1.
Our analysis of clinical and preclinical samples highlighted High-OXPHOS MBMs’
dependence on glutamine metabolism. Profiling studies demonstrated increased activity of
multiple glutamine-dependent metabolic pathways in these lesions. Direct metabolite analysis of
High- and Low-OXPHOS intracranial xenografts confirmed increased glutamine metabolism in
High-OXPHOS MBMs. Based on these results, we performed a pilot study to evaluate the safety
and efficacy of CB839, a novel small molecule glutaminase inhibitor currently being used in
clinical trials (NCT02771626), in mice with High-OXPHOS, MAPKi-resistant intracranial
xenografts of A375-R1 and MEL624 cells. Excitingly, glutaminase inhibition significantly
improved survival in both models.
This study is highly novel as it employed the largest available cohort of surgically resected
MBMs with RNA-seq data and preclinical models to fully characterize the molecular,
immunological, and metabolic associations of OXPHOS in MBMs. These analyses directly
informed preclinical studies, which featured innovative strategies that overcame limitations in the
treatment of High-OXPHOS MBMs. Further, this study extensively utilized novel metabolic
inhibitors currently in clinical trials. Cumulatively, we verified our initial hypothesis and
supported the rationale to improve our understanding of OXPHOS heterogeneity in MBMs.
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CHAPTER 6: DISCUSSION

6.1 - SUMMARY / CONCLUSIONS

Melanoma is the cause of >80% of skin cancer-related deaths (1). Many of these deaths
result from brain metastases, a devastating complication of melanoma that is diagnosed in up to
60% of patients with distant metastases (167). Surgery and radiation have historically been the
predominant therapeutic modalities used to treat melanoma brain metastases (MBMs), but they
have minimal impact on the long-term survival of patients (167). Targeted and immune therapies
have activity for patients with MBMs but also significant shortcomings (154, 168-171). As
patients with MBMs have a median survival of ~4 months, there is a critical unmet need to develop
new, more effective therapeutic strategies for this disease. The development of such treatments
will be facilitated by improving our understanding of the features, heterogeneity, and functional
drivers of MBMs.
Prior to this dissertation research, I performed gene expression profiling which showed
that OXPHOS was the most enriched metabolic pathway in MBMs compared to extracranial
metastases (ECMs) from the same patients. Based on this preliminary data and previous studies,
the central hypothesis of this dissertation is that OXPHOS plays a critical role in the
pathogenesis of MBMs.
In this dissertation, I addressed the current gap in knowledge about the role of OXPHOS
in MBM pathogenesis through the analysis of unique clinical specimens and functional testing of
clinically relevant preclinical models. I showed that the experimental strategy of applying the
Xenome pipeline to RNA-seq data from xenografts grown in distinct anatomical locations could
characterize the gene expression profiles of melanoma cells in different metastatic sites by

166
discriminating signatures of cancer cells from stromal cells. This approach allowed me to
demonstrate that the brain tumor microenvironment (TME) induces significant enrichment of
OXPHOS gene set expression compared to subcutaneous (SQ) tissue. My analyses of brain and
SQ xenografts via direct metabolite profiling and in vivo [U-13C]-glucose tracing confirmed these
findings. Interestingly, treating cutaneous variants of melanoma cells with brain-derived soluble
factors significantly induced OXPHOS compared to untreated cells. RPPA analysis of brain and
SQ xenografts demonstrated that the brain TME induced PI3K-AKT-mTOR signaling compared
to the SQ tissue. Additionally, the brain TME upregulated mitochondrial biogenesis and
downregulated production of glycolytic enzymes compared to the SQ tissue. I confirmed
increased PI3K-AKT-mTOR signaling and OXPHOS enrichment in Tx-naïve MBMs vs. Txnaïve, patient-matched ECMs. Importantly, I utilized multiple publicly available gene expression
datasets to exclude the possibility that increased OXPHOS in MBMs results from increased
efficiency of melanoma cells enriched in OXPHOS to form metastases at this site.
Next, I functionally validated OXPHOS as a mediator of MBM pathogenesis. Experiments
in the RCAS-TVA model of spontaneous MBM and lung metastasis determined that
pharmacological suppression of OXPHOS decreased the incidence of detectable MBMs without
affecting the incidence of lung metastases or primary tumor growth. To clarify if OXPHOS
promotes the formation of MBMs or the growth of established micrometastases, I used an
imageable experimental model of MBM to determine that OXPHOS promotes the growth of
MBMs without influencing their initial formation or the formation and growth of lung metastases.
Knockdown of PGC1α/OXPHOS significantly extended the survival of mice challenged by
intracranial (ICr) injection of melanoma cell lines but had no effect on subcutaneous tumor
growth. Together these studies indicate that while OXPHOS does not affect the incidence of
melanoma brain metastasis, it plays a crucial role in intracranial tumor growth.
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Interestingly, molecular analyses identified a subset of MBMs particularly enriched for
OXPHOS. These “High-OXPHOS” MBMs were characterized by the following: increased
mTORC1 pathway activation independent of PI3K-AKT pathway input, overexpression of known
mediators of OXPHOS in melanoma including MITF and PGC1α, enrichment of pathways known
to consume glutamine, and significant immunosuppression. Analysis of High- and LowOXPHOS brain xenografts confirmed increased glutamine metabolism in High-OXPHOS
MBMs. Together, these observations determined that High-OXPHOS MBMs have unique and
potentially targetable molecular, immunological, and metabolic features. Additionally, the
identification of significant associations provided new insights into MBM biology and the
interplay between prominent signaling and metabolic pathways. I utilized these insights to
prioritize evaluation of novel metabolic inhibitors alone and in combination with approved
therapies for metastatic melanoma. Single-agent treatment with IACS-010759 – a potent
OXPHOS inhibitor currently in phase I clinical trials – significantly extended survival of mice
bearing High-OXPHOS intracranial melanoma xenografts with acquired and de novo resistance
to MAPKi. Importantly, I showed that the brain TME mediated resistance to MAPKi in a
previously sensitive cell line via induction of OXPHOS and that the combination of IACS-010759
and dabrafenib significantly improved survival in mice bearing intracranial xenografts of this cell
line. Additionally, I showed that OXPHOS inhibition overcame resistance to anti-PD1
immunotherapy in a High-OXPHOS syngeneic model of MBM. Finally, the novel glutaminase
inhibitor CB839 induced significant responses in two High-OXPHOS, MAPKi-resistant models
of MBM.

6.2 - NOVELTY
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These studies employed the largest cohort of MBMs analyzed by RNA-seq to date, and
the largest cohort of patient-matched brain metastases and extracranial metastases from any tumor
type, to provide key new insights into the metabolic features and dependencies of MBMs.
Analysis of these clinically-annotated, data-rich samples identified associations between
OXPHOS and molecular, immune, and metabolic features. These findings supported the rationale
for in-depth evaluation of novel therapeutic strategies designed to exploit these features in
validated preclinical models. These novel therapeutic approaches included a potent OXPHOS
inhibitor (IACS-010759) and glutaminase inhibitor (CB839) that are currently in clinical trials.
Additionally, I integrated gene expression data and metabolomics data to determine that
OXPHOS enrichment in MBMs vs. patient-matched ECMs occurred because the brain TME
mediated significantly different metabolic reprogramming compared to the subcutaneous tissue
and not because metastatic cells enriched in OXPHOS are inherently more capable of
metastasizing to the brain. I utilized the first-ever RCAS-TVA model of melanoma that forms
brain metastases from cutaneous primary tumors and numerous experimental models of
metastasis and tumor growth to determine that OXPHOS plays a critical role in the growth of
MBMs but not their initial formation.

6.3 - SIGNIFICANCE

My findings suggest that OXPHOSi may work better in MBMs than in metastases at other
sites. This would be a revolutionary paradigm, as generally patients with MBMs have been
excluded from clinical trials due to concerns about lack of efficacy in these lesions. My results
not only have implications for the development of inhibitors that target OXPHOS, but for the
design of future clinical trials and the preclinical evaluation of investigational agents.
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The findings here support the rationale to see if there are unique dependencies of
melanoma cells that have metastasized to organs besides the brain, particularly those associated
with poor outcomes (i.e. the liver and bones). My data strongly supports that analyses should
encompass immune, molecular, and metabolic features.
An obvious question is whether or not OXPHOS is only important for MBMs, or for brain
metastases from other cancer types as well. Metabolic profiling of brain metastases from other
cancer types remains limited to experimental models and small cohorts of clinical samples (211,
297). While these studies have implicated OXPHOS metabolism in brain metastasis pathogenesis,
the results should be further validated in larger cohorts of patient-matched samples.

6.4 - FUTURE DIRECTIONS

6.4.1 - Providing Mechanistic Insight Into How the Brain Microenvironment Promotes
Oxidative Phosphorylation Compared to Other Anatomical Locations

Despite the immense amount of molecular and metabolic profiling presented in this
dissertation, the precise mechanism by which OXPHOS becomes preferentially activated in
MBMs remains unclear. Given the role of this pathway in supporting MBM growth, providing
mechanistic insight into how the brain TME promotes OXPHOS enrichment should be prioritized
in future studies.
All cells respond to oxygen deprivation by inhibiting OXPHOS (298). Consequently, it
might be tempting to blame the differential expression of OXPHOS genes on differences in
oxygen tension between the brain and other anatomical sites. However, the oxygen concentration
in the brain (0.5-8%) is comparable to the oxygen concentration in the lungs (4-14%), liver (4-

170
14%), and adipose tissue (2-8%) (299). Of course, it is possible that intratumoral oxygen tension
differs significantly between MBMs and ECMs. However, my global analysis of brain and
subcutaneous xenografts determined that hypoxia-associated gene sets were enriched in the brain
xenografts (Figure 15A). Together, these findings exclude the possibility that ECMs inhibit
OXPHOS in response to growing in a more hypoxic TME than the MBMs.
These studies identified enrichment of genes regulated by the mTORC1 and PI3K-AKTmTOR signaling pathways in the brain xenografts. In addition, RPPA analysis identified increased
concentrations of numerous proteins indicative of PI3K-AKT and mTORC1 pathway activation
in the brain xenografts. I confirmed increased staining of activation markers for these pathways
in surgically resected Tx-naive MBMs vs. Tx-naïve ECMs from the same patients. Importantly, I
ruled out the possibility that the PI3K-AKT pathway was activated due to loss of PTEN. Instead,
I demonstrated overexpression of IGF1R in brain xenografts. Previous studies have demonstrated
that signaling through IGF1R drives the activation of mTOR and the High-OXPHOS phenotype
in non-CNS melanomas (3, 215). Interestingly, specific factors within cerebrospinal fluid (CSF)
activate the PI3K-AKT-mTOR signaling cascade in melanoma cells (105). High levels of IGF‐1
have been reported in CSF (300). Thus, IGF-1 in the CSF could be mediating OXPHOS
enrichment in MBMs by engaging IGF1R and activating the PI3K-AKT-mTOR pathway. Testing
this hypothesis must be prioritized in the future.
Alternative hypotheses could be tested if future experiments exclude IGF-1/IGF1R
signaling as a key mediator of MBM OXPHOS enrichment. First, additional brain-derived soluble
factors could be responsible for activating the PI3K-AKT-mTOR signaling pathway.
Alternatively, intercellular communication between tumor cells and surrounding stroma might be
responsible for mediating the OXPHOS enrichment. The ability of astrocytes to alter tumor cell
signaling has been extensively studied (101, 145). While none of these studies implicated
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OXPHOS, it is possible that astrocytes somehow reprogram the tumor cells to increase
mitochondrial biogenesis and utilize OXPHOS at significantly higher levels than cells
metastasizing to other sites of the body.
Finally, it is worth noting that OXPHOS heterogeneity across the surgically resected
MBMs associated significantly with mTORC1 signaling. These findings implicate mTORC1 as a
critical mediator of OXPHOS in MBMs. As detailed in Chapter 5, PI3K-AKT pathwayindependent activation of mTORC1 could occur via differential access to critical amino acids
(287). In turn, mTORC1 could have then promoted MYC signaling, which also associated
strongly with OXPHOS enrichment in MBMs in these studies and has been strongly implicated
in OXPHOS signaling in independent studies (301).
Based on my findings, I now propose a schema in which melanoma cells growing in the
brain parenchyma overexpress IGF1R, which ensures frequent engagement with IGF-1 that is
present in high concentrations in the brain TME. This interaction hyperactivates the PI3K-AKTmTOR signaling pathway, which induces mitochondrial biogenesis and OXPHOS. In parallel,
MBMs from different patients differ in their access to critical amino acids and thus experience
different degrees of mTORC1 signaling and OXPHOS enrichment.

6.4.2 - Understanding How Oxidative Phosphorylation Promotes the Growth of Melanoma
Brain Metastases

6.4.2a - Metabolic Flexibility

The increased ability to perform OXPHOS could benefit melanoma cells growing
in the brain parenchyma in a variety of ways. First, this pathway is able to metabolize
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more than glucose. The brain utilizes over half of the glucose available in the body (302).
For this reason, it appears as a saturated mass on whole body positron emission
tomography-computed tomography (PET–CT) scans. However, competition for glucose
in the brain is intense. Astrocytes in the brain avidly consume glucose and secrete lactate,
which is consumed by neurons for OXPHOS. This “lactate shuttle” causes the levels of
glucose available for MBMs to be highly variable (303, 304). OXPHOS would allow
brain-metastatic cells to efficiently utilize glutamine and branch-chain amino acids richly
available in the brain interstitium (244). Alternatively, OXPHOS would allow MBMs to
scavenge acetate through its direct incorporation into the TCA cycle (297). This metabolic
flexibility could provide a marked survival advantage for melanoma cells attempting to
grow in the brain parenchyma. Testing this hypothesis could identify additional
therapeutic targets. In addition, it could provide meaningful insights into a topic on the
minds of many cancer patients – the effect of their diets on tumor growth. In general, the
potential benefits of the ketogenic diet in metastatic melanoma remain unclear. For
example, Xia et al. demonstrated that ketone bodies actually promoted the growth of
BRAF-mutant xenografts and had no effect on NRAS-mutant and triple wild-type mutant
melanoma xenografts (305). In contrast, several patients with metastatic melanoma
appeared to benefit from the diet in a feasibility trial of multiple metastatic diseases (306).
Regardless, this diet would significantly increase the circulating levels of acetate, which
could feed MBMs attempting to survive in the hostile brain TME.

6.4.2b - Immune Evasion
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Previously, I observed both enrichment of OXPHOS and depletion of immune
cells in MBMs vs. patient-matched ECMs (174). This result suggests that OXPHOS
enrichment in MBMs could mediate their immunosuppression. Consistent with this
finding, I observed a significant association between OXPHOS and immunosuppression
in MBMs. In addition to significant differences in B cell density between High- and LowOXPHOS MBMs, I also observed significant alterations in IFNγ signaling. I demonstrated
that High-OXPHOS MBMs were characterized by a signature previously shown to predict
failure to anti-PD1 immunotherapy. OXPHOS could impact immune cell function in
several ways. First, memory T cells rely significantly on OXPHOS to meet their
bioenergetic needs (307). Intratumoral memory T cells have been identified in melanomas
(308). Tumor cell OXPHOS could directly impede the ability of these cells to function
and proliferate through direct competition for resources. Alternatively, OXPHOS
facilitates intratumoral hypoxia. Hypoxia can negatively affect effector T cells by inducing
detrimental epigenetic changes (309). In addition, effector T cells preferentially utilize
glycolysis to meet their bioenergetic demands (307). As such, they rely significantly on
glutamine to replenish their TCA cycles for production of biosynthetic precursors.
Without oxygen available to act as an electron acceptor, the cycle ceases to operate
efficiently and prevents the synthesis of intermediates. OXPHOS correlates significantly
with glutamine consumption in melanomas (282). Thus, OXPHOS induction in MBMs
might result in an intratumoral competition for glutamine that could be highly detrimental
for effector T cells.
My findings pose many exciting questions. Future studies should assess if
OXPHOS in MBMs inhibits the proliferation of immune cells after they successfully reach
the tumor and/or if it somehow prevents their trafficking into the tumor. Second, it is
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imperative to further investigate OXPHOS-mediated resistance to immunotherapies in
MBMs and how we can overcome this resistance through combinations of
immunotherapies and metabolic inhibitors such as IACS-010759, metformin, and CB839.
The dosing and sequence of these combinations will certainly require an extensive amount
of troubleshooting to ensure optimal response. Most importantly, we need to consider how
to implement treatments in patients with metastases at multiple anatomical sites. A patient
with a lung metastasis might require a combinatorial regimen that negatively affects MBM
treatment or vice versa. Addressing these difficult issues must be a priority in the future
to move the treatment of this deadly disease forward.

6.4.2c - Mitochondrial Signaling

Mitochondria are important stress sensors, and signaling by mitochondria allows
the cell to adapt to its environment. For example, citrate produced in the TCA cycle can
be transported to the cytosol, where ATP citrate lyase (ACL) cleaves it into acetyl-CoA
and oxaloacetate. Acetyl-CoA can fuel acetylation of histones in epigenetic regulation
reactions that could affect signaling pathways required for MBM growth (301). Likewise,
α-ketoglutarate supports a range of chromatin-modifying reactions (301). Thus, TCA
cycle function supported by mitochondrial biogenesis/OXPHOS enrichment could
facilitate a range of beneficial intracellular epigenetic changes in MBMs.

6.4.2d - Mitigating Oxidative Stress
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Studies have identified a subset of melanoma cell lines and surgically resected
ECMs characterized by high expression of PGC1α and OXPHOS enrichment that are able
to withstand significantly higher levels of oxidative stress (172). I analyzed the growth of
two cell lines from this paper and found that silencing PGC1α inhibited the growth of
these cells in the brains but not subcutaneous tissue of mice. This suggests that the brain
TME induces particularly high levels of oxidative stress and that the knockdown cells
could not detoxify reactive oxygen species (ROS) efficiently enough to survive. Further
analyses should be prioritized to confirm this possibility.

6.4.3 - Translating Findings Into Novel Therapeutic Strategies

Treatment with the novel OXPHOS inhibitor IACS-010759 prolonged survival in mice
with intracranial High-OXPHOS, MAPKi-resistant melanoma xenografts. While my results
demonstrate that single-agent OXPHOS inhibition with IACS-010759 can have beneficial effects,
the models I employed were selected due to their previously established in vitro sensitivity to the
drug (290). Not all High-OXPHOS, MAPKi-resistant melanomas respond uniformly to this
treatment (290). Furthermore, acquired resistance will likely be a barrier to overcome. Thus, it
will be imperative to characterize predictive and prognostic markers of MBM response and to
develop strategies to prevent and overcome resistance to feasibly utilize this drug in the treatment
of MBMs.
One challenge in treating and studying brain metastases is the difficulty in routinely
acquiring tissue. While these studies indicated that target inhibition by IACS-010759 significantly
decreased pimonidazole and P-S6 staining, routinely acquiring biopsies of MBM patients treated
with this drug would not be feasible. To benefit patients, we need a non-invasive way to assess
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the extent of OXPHOS inhibition in MBMs following treatment. FAZA-PET analysis is a novel
imaging technique that uses [18F]-labeled FAZA (fluoroazomycin arabinoside) to assess OXPHOS
inhibition following treatment with IACS-010759 (310). As this technique has been validated in
orthotopic glioblastoma models, it could be used to confirm OXPHOS suppression in MBM
patients treated with IACS-010759. Excitingly, CB839 inhibited OXPHOS in A375-R1 cells,
indicating that this imaging modality could also be used to assess target inhibition in MBM
patients treated with CB839. Future studies should assess the utility of this imaging modality in
clinically relevant models of MBM treated with these inhibitors.
Ideally, we would want to be able to noninvasively identify High-OXPHOS MBMs as
these lesions would be least likely to respond to MAPKi and anti-PD1 therapy and require
alternative therapies such as IACS-010759 or CB839. Future studies should focus on establishing
radiomic correlates for this metabolic phenotype in MBMs (311). My unique cohort of surgically
resected High- and Low-OXPHOS MBMs with archived imaging makes this highly feasible.
Preclinical models with pre-and post-treatment imaging could be used in parallel to validate
radiomic markers predictive of response to IACS-010759 or CB839 and to identify prognostic
radiomic markers for these treatments. Ultimately, these markers would need to be validated in
patients.

6.4.4 - Obstacles to Translating Findings Into Novel Therapeutic Strategies

Resistance and/or toxicity will likely be critical challenges in the use of metabolic
inhibitors in MBMs and will complicate efforts to move molecules such as IACS-010759 and
CB839 into the clinic as single-agent therapies for MBMs. I observed significant survival benefit
in mice treated with these two molecules. However, all mice eventually progressed on CB839
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treatment, and the majority of mice eventually progressed on IACS-010759 treatment. Since these
mice were injected with cells selected because of their in vitro sensitivities to these inhibitors,
response rates could be worse in xenografts of other cell lines. IACS-010759 resistance would
likely result from a switch from dependence on OXPHOS to glycolysis. Alternative mechanisms
might include selection of rare subclones with mutated binding sites at complex I of the electron
transport chain (ETC), which would inhibit the drug from effectively suppressing OXPHOS.
Resistance to CB839 is well-documented in other cancer types and involves multiple
compensatory pathways that alleviate cellular stress induced by disruption of glutamine
metabolism (312).
I anticipate that metabolic inhibitors such as IACS-010759 and CB839 will be most useful
in the treatment of MBMs by augmenting available targeted and immune therapies. IACS-010759
and dabrafenib provided a significant survival benefit in mice bearing intracranial A375
xenografts compared to either of these therapies alone. This finding is consistent with previous
studies that have shown that BRAF-mutant extracranial melanoma metastases treated with BRAFi
therapy can become addicted to OXPHOS and subsequently are highly sensitive to direct
OXPHOSi. Phenformin, which inhibits OXPHOS, delays the development of resistance to BRAFi
in human melanoma cell lines (26, 245). Thus, adding IACS-010759 to MAPKi therapies at the
initiation of treatment of BRAF-mutant MBMs could increase the duration of tumor responses,
which was the critical factor that limited the clinical benefit of treatment with dabrafenib and
trametinib in the COMBI-MB study (171). Future studies should prioritize confirming these
findings using relevant preclinical models. The combination of MAPKi and IACS-010759 could
also yield synergistic effects in some MBMs that have already developed resistance to MAPKi
therapies via increased dependence on OXPHOS. While my combination studies showed no
benefit in the A375-R1 and SKMEL5 models, these observations were primarily due to the
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impressive efficacy of single-agent IACS-010759 in the treatment of these lesions. Intracranial
xenografts of other High-OXPHOS cell lines might not respond as well to single-agent IACS010759, and the combination of MAPKi and IACS-010759 could be beneficial in this subset of
tumors.
Immune therapies represent the other main category of front-line therapies for metastatic
melanoma. Intracranial response rates (ICRR) observed with anti-PD1 (~20%) (153) (154) are
significantly lower than response rates of ECMs, and promising results of combined
immunotherapy with anti-CTLA4 and anti-PD1 have only been reported for patients with small,
asymptomatic MBMs (155). Identifying ways to overcome MBM resistance to immune therapies
remains a critical challenge. My findings demonstrated that OXPHOS inhibition can improve the
response of MBMs to anti-PD1. I utilized metformin in these studies, but the effects of IACS010759 on the immune system must be investigated. Also, future studies should investigate
whether or not OXPHOS inhibition can improve MBM response to other single-agent immune
therapies and if it can be added to the combination of anti-CTLA4 and anti-PD1 in the treatment
of MBMs. Despite promising preclinical results, CB839 induced a response rate of only 19% in
a cohort of 16 metastatic melanoma patients progressing on anti-PD1 therapy (313). However,
this trial excluded patients with MBMs. My data identified enriched glutamine metabolism in
MBMs compared to ECMs. Thus, MBMs might respond better to the combination of CB839 and
anti-PD1 than ECMs. Future preclinical studies should prioritize testing this combination in
immunocompetent models of MBM.
Finally, my data suggests that inhibition of OXPHOS could form part of a preventative
strategy in the treatment of metastatic melanoma patients. OXPHOS inhibition significantly
slowed the growth of MBMs in our experimental model and significantly decreased the incidence
of detectable MBMs in the RCAS-TVA model. The ability of IACS-010759 to potentially keep
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MBMs small and asymptomatic could significantly alter treatment options for metastatic
melanoma patients. Excitingly, IACS-010759 could work regardless of tumor genotype, as my
RNA-seq and LC-MS findings demonstrated enrichment of the OXPHOS pathway in ICr tumors,
regardless of genotype. However, my findings suggest that OXPHOSi appears to be more
important for inhibiting MBM growth than the growth of metastases at other sites. Thus, IACS010759 would need to be combined with additional agents to form a comprehensive strategy able
to prevent metastatic outgrowth at all sites of the body.

6.5 - CLOSING REMARKS

These studies represent a small fraction of my lab’s efforts to perform the most
comprehensive molecular profiling of patient-matched MBMs and ECMs reported to date. For
the first time ever, I provide insights into the role of OXPHOS in MBM pathogenesis. Importantly,
these studies suggest rational strategies to improve outcomes in patients. Together, the findings
add to our understanding of the pathogenesis of MBMs, support the rationale for further dedicated
analyses of these tumors, and provide new directions for interrogation in other diseases in which
brain metastases remain a critical challenge.
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